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Abstract 
 
 
Plasma cells are the terminally differentiated effector cells of the humoral 
immune system. The majority of plasma cells are short-lived and undergo 
programmed cell death in the form of apoptosis after few days of intensive 
immunoglobulin secretion. Despite potentially wide-ranging implications for 
infection control, auto-immunity, and plasma cell dyscrasias, the mechanisms 
that govern the initiation and execution of plasma cell apoptosis are poorly 
understood. In this study, it was found that a sharp increase in endoplasmic 
reticulum (ER) stress and a substantially decreased tolerance to survive ER 
stress occur in plasma cells that have completed differentiation and begin to 
undergo apoptosis. Caspase-12, which has been linked specifically to ER stress-
induced apoptosis, is activated during programmed plasma cell death and 
mediates apoptotic DNA fragmentation and chromatin condensation. In contrast, 
the major apoptotic effector caspases downstream of the mitochondria become 
resistant to activation during terminal plasma cell differentiation and are not 
activated during plasma cell apoptosis. Caspase-3, which acts as the major 
executioner of apoptosis in most cells, becomes stabilized in its inactive form in 
plasma cells and human myeloma cell lines. Immunohistochemistry of human 
lymphoid tissue sections demonstrated that primary plasma cells and myeloma 
cells undergo spontaneous apoptosis in vivo without activation of caspase-3.  
Using mouse embryonic fibroblasts double-deficient in caspase-3 and caspase-7, 
it was found that lack of active executioner caspases substantially delays but 
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does not prevent ER stress-induced apoptosis. These observations suggest that 
developmentally regulated inhibition of key apoptotic caspases has evolved in 
plasma cells as a means to delay apoptosis under conditions of ER stress that is 
linked to immunoglobulin secretion. Overwhelming ER stress ultimately limits the 
life-span of short-lived plasma cells by inducing apoptosis using alternative 
mechanism involving caspase-12, which mediates nuclear apoptotic events.  
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1      Introduction 
 
Plasma cells are the terminally differentiated effector cells of the humoral 
immune system that provide the organism with specific antibodies 
(immunoglobulins), thereby playing an indispensable role in the protection 
against infections. The plasma cells that are formed during an acute immune 
response are mostly short-lived and die after a few days of immunoglobulin 
production, but a small number of plasma cells survive for prolonged periods and 
form the basis of immunological memory. The factors that regulate the life-span 
of plasma cells are largely unknown. 
    Plasma cells are characterised by their ability to produce and secrete vast 
amounts of antibodies, which is inevitably accompanied by the production of 
faulty proteins that are dysfunctional. The post-translational modifications that are 
needed to make a protein “fit” for secretion, and the associated quality control 
mechanisms, largely take place in the endoplasmic reticulum (ER). When the 
secretory capacity of a cell cannot match the secretory demand, faulty proteins 
accumulate and cause ER stress. ER stress results in the activation of a cellular 
programme termed the unfolded protein response (UPR) that aims to rectify the 
defect. If the UPR is insufficient to rectify the problem, overwhelming ER stress 
leads to programmed cell death.  
    Programmed cell death usually occurs in the form of apoptosis, a tightly 
regulated sequence of cellular events that results in the immunologically inert 
disposal of a cell. In most cells, apoptosis is executed by the concerted activation 
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of cysteine proteases, the caspases. Although caspase-independent 
programmed cell death can occur under certain circumstances, the existence of 
physiological caspase-independent apoptosis is debated. 
    In this study, the role of ER stress and inhibition of effector caspases in the 
regulation of the life-span of short-lived plasma cells was investigated. 
 
1.1 Plasma cells 
Apart from B1 cells, which produce so-called “natural” antibodies, plasma cells 
are the exclusive and prolific purveyors of antibodies, which are secreted at rates 
of up to 10.000 molecules per second (Hibi and Dosch, 1986). Plasma cells 
provide antibodies for both primary and secondary immune reactions and are 
therefore critically involved both in the immediate response to infections and in 
the maintenance of protective humoral immune memory. Hence, plasma cells 
play an integral part in the control of infections, which is most dramatically 
illustrated by the frequent occurrence of infections in patients with defects in 
antibody production (Wood et al., 2007).  
    While earlier stages of B cell differentiation have been investigated 
extensively, plasma cell biology is considerably less well understood, which is in 
part due to their relative scarcity in lymphoid tissue and the lack of plasma cell 
lines. Many investigations into plasma cell biology have therefore used myeloma 
cell lines, whose transformed phenotype impairs conclusions for physiological 
plasma cells. Another difficulty in the study of plasma cells is their very limited life 
span in culture, which applies to primary cells as well as plasmacytic cells 
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generated by antigenic stimulation of B lymphoid cell lines. In this respect it is 
notable that plasma cells exist in two forms. The vast majority of plasma cells are 
short-lived and produce low-affinity IgM during the immediate immune response, 
while a relatively small number of immunoglobulin class-switched plasma cells 
are long-lived. Despite identical morphology and relatively small differences in 
their molecular profile, short-lived plasma cells undergo programmed cell death 
within several days (Smith et al., 1996), whereas long-lived plasma cells can 
survive for prolonged periods, possibly up to the life-time of an organism (Slifka 
et al., 1998). Although some evidence links the prolonged life-span of long-lived 
plasma cells to the presence of survival factors in anatomical niches (Moser et 
al., 2006), this huge difference in life-expectancy between “cellular siblings” is 
poorly understood. 
     Autoimmune diseases are characterised by the presence of pathological auto-
antibodies, which contribute to disease manifestations in various organs, and 
several lines of evidence underline the involvement of plasma cells in the 
pathophysiological process. It has been shown recently in a mouse model of 
systemic lupus erythematosus (SLE) that both short-lived and long-lived plasma 
cells contribute to the production of autoantibodies (Hoyer et al., 2004). Mice that 
lack the pro-apoptotic molecule Bim accumulate plasma cells and are susceptible 
to autoimmune disease (Bouillet et al., 1999). Mice that are prone to SLE do not 
express the surface receptor, FcgammaRIIb, whose cross-linking induced 
plasma cell apoptosis (Xiang et al., 2007). Furthermore, increased numbers of 
plasma cell precursors have been found in the blood of children with SLE (Arce 
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et al., 2001). In addition, the persistence of autoantibody levels after 
immunosuppressive therapy for many autoimmune diseases indicates that long-
lived plasma cells, which do not require continuous antigenic stimulation, provide 
the pathological antibodies (Arce et al., 2002; Manz et al., 2005). 
    Malignant transformation of plasma cells results in a group of clonal diseases 
that are termed plasma cell dyscrasias. The most frequent of these disorders, 
which are generally incurable, is multiple myeloma, which accounts for 
approximately 10% of all haematological cancers (Kyle and Rajkumar, 2007, 
2008). In the United Kingdom, approximately 3,800 new cases were diagnosed in 
2004 (www.cancerresearchuk.org, 25 August 2008). Around half of the cases of 
multiple myeloma carry one of five recurrent chromosomal translocations that 
lead to the overexpression of a putative oncogene, whereas the other half has 
one or more of a number of numerical chromosome aberrations. Nearly all cases 
of multiple myeloma show overexpression of cyclin D1, D2, or D3 (Bergsagel and 
Kuehl, 2005). Despite recent advances in treatment, the median survival from 
diagnosis is still only 4-5 years.  
    Plasma cells are also of considerable general scientific interest regarding their 
value as a model system for studies on terminal differentiation and entry into a 
post-mitotic state (Sabbattini et al., 2007).  
    More detailed insights into the regulation of plasma cell survival are of 
considerable importance, since they may have clinical implications for the 
development of therapeutic strategies in plasma cell-related diseases and 
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infection control. In addition, they can provide a better understanding of how 
life/death decisions are made in cells in general. 
 
1.1.1 The humoral immune response 
The primary role of the humoral immune response is to produce antibodies, or 
immunoglobulins, which play an integral part in the elimination of antigen. 
Antibodies (which are also called immunoglobulins) are produced by 
differentiated specialised B lymphocytes and are involved in both the recognition 
and effector phase of the humoral immune response. The membrane bound 
forms of antibodies are expressed at various intermediate stages of B 
lymphocyte development and act as antigen receptors on the B cells. The 
secreted forms of antibodies are mainly produced by plasmablasts and plasma 
cells, the differentiated effector cells of the adapted humoral immune response 
that are found in secondary lymphoid organs and the bone marrow . The 
important role of a serum component in infection control (later to be identified as 
antibodies) was first described in the late 19th, and plasma cells were found to be 
the major source of antibodies in the 1950s (Fagraeus, 1981). Antibodies are 
also secreted by cells derived from B1 cells, which contribute to innate immunity. 
Antibodies promote various effector mechanisms which eliminate the antigen. 
These include binding-mediated neutralisation of antigen, facilitation of 
phagocytosis (opsonisation), activation of the complement system, antibody-
dependent cell-mediated cytotoxicity which involves antigen lysis by 
macrophages, and hypersensitivity during which antibodies activate mast cells. In 
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addition to these contributions to the actual elimination of antigen, the 
predominant role of antibodies is to guarantee the specificity of the humoral 
response. 
 
1.1.2 Early stages of B cell development 
The early stages of B lymphocyte development involve differentiation from the 
haematopoietic stem cell to the pre-B cell and take place in the bone marrow in 
an antigen-independent way (Figure 1.1.2).  
   Immature B cells in the bone marrow already express low-levels of IgM on their 
surface. They do not proliferate or differentiate in response to antigen, but 
undergo programmed cell death upon encounter with self-antigen. At the next 
stage of B cell differentiation, immature B cells leave the bone marrow and 
differentiate into the B1 and B2 cell subsets (Hardy and Hayakawa, 2001; Hardy 
et al., 2000; Kantor and Herzenberg, 1993). B1 cells reside predominantly in the 
pleural and peritoneal cavities and the lamina propria of the intestinal tract and 
express high levels of IgM but low levels of IgD on their cell surface. They are 
maintained by self-renewal and are important for the formation of IgA-secreting 
plasma cells and secrete so-called natural IgM antibodies. They recognise 
antigens that are often shared between microorganisms, have a limited antigenic 
repertoire and persist in the absence of infection. B2 cells are constantly 
replenished from bone marrow progenitors and continue their development to 
become mature B cells, which express IgM and IgD on their cell surface 
(Hayakawa and Hardy, 2000; Hayakawa et al., 1997). Some mature B cells 
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home to the marginal zone of the spleen, an area that is localised at the border of 
the white pulp that favours the early recognition of antigens, and are therefore 
called marginal-zone cells. Most mature B cells are follicular cells, which circulate 
through the follicles of lymph nodes and spleen until they encounter antigen or 
die (Shapiro-Shelef and Calame, 2005). These antigen-naïve follicular B cells 
also represent the majority of B lymphocytes found in the peripheral blood of 
healthy individuals. 
 
Figure 1.1.2 B cell differentiation. B cells develop from pluripotent stem cells in 
the bone marrow. Naive B cells that exit the bone marrow continue to undergo 
maturation in the spleen to form long-lived naive follicular B cells and, to a lesser 
extent, naive marginal-zone B cells. Different stages of B cells and characteristic 
surface molecules are shown. BCR, B-cell receptor; HSC, haematopoietic stem 
cell; pre-B cell, precursor B cell; T1, transitional stage 1; T2, transitional stage 2. 
Reproduced, with permission, from Shapiro-Shelef and Calame, Nature Reviews 
Immunology (2005) © 2005 by Nature Publishing Group. 
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1.1.3 B cell activation  
The process of B cell activation and antibody-generation is initiated when mature 
B cells in the secondary lymphoid organs encounter antigen that binds 
specifically to the Ig expressed on the cell surface. Binding of antigen results in 
both internalisation of the antigen and the induction of signalling cascades within 
the B cell (Figure S1, p.214). Internalised antigen is processed and different 
peptide epitopes of the antigen are then expressed in conjunction with major 
histocompatibility complex (MHC) class II molecules on the cell surface. Thereby, 
the B cells become antigen-presenting cells and stimulate nearby T cells. The 
signalling cascades that are triggered within the B cell upon antigen binding drive 
further B cell differentiation and are transduced by Igα and Igß, transmembrane 
molecules that make up the B lymphocyte receptor complex with surface Ig (Gold 
and DeFranco, 1994). These signals can be considerably enhanced by activation 
of the B cell co-receptor complex, which consists of cluster of differentiation (CD) 
CD19, CD 81, and CR2. CR2 is the type 2 complement receptor that binds C3d, 
a proteolytic product of C3 that is generated during activation of the complement 
system by antigen-antibody complexes (classical pathway) or microbial 
components (alternative pathway). The signals generated by the B cell receptor 
and co-receptor complex have a wide range of impact on the B cell. The resting 
cells enter the cell cycle and begin to proliferate rapidly, increase in size to 
accommodate the expansion of biosynthetic organelles, and express anti-
apoptotic molecules such as Bcl-XL to promote survival. Furthermore, MHC class 
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II molecules and co-stimulators such as CD86 and CD80 are up-regulated on the 
B cell surface to re-enforce interaction with helper T cells (Buhl et al., 2000).  
 
1.1.4 B cell response to T-independent and T-dependent antigen 
Antibody responses to protein antigens require T cell help and result in the 
production of high-affinity antibodies that are generated through class-switch 
recombination in the germinal centre reaction (discussed in more detail below). 
Non-protein antigens, however, can stimulate the production of antibodies in the 
absence of T cells. The most important T-independent antigens are 
polysaccharides, glycolipids, and nucleic acids. They cannot be processed and 
presented with MHC class II molecules by antigen-presenting cells and therefore 
are not recognised by T cells, but activate B cells by binding to membrane-bound 
immunoglobulins and activation of the complement system. Marginal-zone B 
cells, which express high levels of IgM but low levels of IgD on their surface, 
have an antibody repertoire that is skewed towards T-independent antigens 
(Fagarasan and Honjo, 2000). Although T-independent antibody responses result 
predominantly in the production of low-affinity IgM, limited class-switching does 
occur. Some polysacchardides appear to require the presence of a small number 
of T cells in order to raise an antibody response, and those antigens are termed 
T-independent (TI)-2 antigens (Vos et al., 2000). In contrast, TI-1 antigens do not 
need any other cell type to induce an antibody response. The proteotypical TI-1 
antigen is lipopolysaccharide (LPS), which is found in the walls of many gram-
negative bacteria. LPS can stimulate immunoglobulin secretion at low doses and 
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induces polyclonal B cell proliferation without binding to membrane-bound 
immunoglobulin on B cells at high doses, although the latter function is largely 
restricted to mice and not found in humans. LPS also increases the expression of 
MHC class II on the B cell surface, thereby enhancing the B cell’s function as 
APCs (Tobias et al., 1997; Ulevitch and Tobias, 1999). The B cell responses to 
LPS are mediated by the transmembrane receptors Toll-like receptor 4 and 
CD180 (also known as RP105) and ultimately result in the activation of 
transcription factors involved in B cell activation, such as nuclear-factor kappaB  
(NF-κB) (Chow et al., 1999; Ogata et al., 2000).  
    T-dependent antibody responses lead to the secretion of class-switched high-
affinity antibodies and induce competent immunological memory. T helper cells, 
which are the predominant T cell type involved in T-dependent immune 
responses, are typically CD4+CD8- and require antigen to be presented to them 
in conjunction with MHC class II molecules. T cell help to antigen-activated B 
cells requires close contact between cells with a certain antigen-specificity, which 
is achieved by concentration of antigen, antigen-presenting cells (APCs), B and T 
cells in secondary lymphoid organs, such as lymph nodes and spleen. In the 
secondary lymphoid organs, antigen-naïve mature B cells reside predominantly 
in lymphoid follicles, where they are called follicular B cells (Clark and Ledbetter, 
1994). By comparison with marginal-zone B cells, follicular B cells express higher 
levels of IgD and lower levels of IgM on their surface. In the lymphoid follicles, 
they encounter and bind antigen, which induces their migration to the periphery 
of the follicles. At the same time, helper T cells that have been presented antigen 
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by antigen-presenting cells in T cell-rich zones migrate towards the follicle. This 
leads to close physical proximity between antigen-specific activated B and T cells 
at the edge of the follicle, which contributes to the specificity of the antibody 
response since the antigen-specific B cells become the preferential recipients of 
T cell help that comes predominantly in the form of cytokines (Przylepa et al., 
1998). Cytokines are polypeptides that are secreted by activated T helper cells 
and APCs and exert their function on B cells in two major ways: stimulation of B 
cell proliferation and differentiation, and contribution to the choice of 
immunoglobulin class. T-cell cytokines such as interleukin (IL)-5, IL-6, and IL-10 
are recognised as important promoters of terminal B cell differentiation and have 
various effects such as the promotion of antibody secretion (Kawano et al., 1995; 
MacLennan, 1994; Morse et al., 1997; Moser et al., 2006; Tangye et al., 2003; 
Zhang et al., 2001). They have differential effects on class-switching, thereby 
modulating the preferential secretion of IgM that is caused by B cell activation 
with LPS alone. For example, IL-5 promotes secretion of IgA, which is supported 
by another T-cell cytokine, transforming growth factor (TGF)-ß (Bao et al., 1998; 
Sonoda et al., 2009). Since these cytokines are also produced by and have 
differential effects on other cells participating in the immune response, the type 
and location of B cell activation is critical for the choice of the preferential 
antibody subclass that will be secreted by the B cell.  
   Another important pathway of B and T cell interaction is mediated by CD40, 
which is constitutively expressed on B cells, and CD40L (CD154). CD40L 
becomes expressed on T cells after activation by antigen presented in 
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conjunction with MHC class II molecules. CD40L induces oligomerisation of 
CD40 on neighbouring B cells, which activates signalling cascades that result in 
the activation of transcription factors relevant for further B cell differentiation, 
such as NF-κB (Laman et al., 1996).  
 
1.1.5 The germinal-centre reaction 
Activated follicular B cells can either become Ig-secreting plasmablasts, which 
undergo apoptosis after a few days, or migrate back into the centres of lymphoid 
follicles where they begin to proliferate rapidly, dividing every 6-12 hours. A 
single activated B cell, which is classically termed centroblast at this 
developmental stage, can thereby generate a progeny of up to several thousand 
cells to form the so-called germinal centre (GC) (Liu and Arpin, 1997; 
MacLennan, 1994). Centroblasts make up the dark zone of the GC (named after 
its strong histological staining) and show a high rate of spontaneous point 
mutations in the genes coding for the antigen-binding variable regions of the 
antibodies, which is estimated to be as high as 1 in 1000 base pairs per cell 
division (which is more than 1000 times the rate of spontaneous mutations in 
other genes). This so-called somatic hypermutation causes a variability of up to 
ten amino acids between antibodies derived from a single B cell clone, which will 
increase the affinity of antigen-binding in some cells, and decrease it in others 
(Berek et al., 1991; Klein et al., 1998). The progeny of centroblasts that have 
undergone somatic hypermutation are smaller cells that are called centrocytes 
and migrate to the light zone of the GC, where they are in close contact with the 
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cytoplasmic protrusions of follicular dendritic cells (FDCs). FDCs are only found 
in lymphoid follicles and germinal centres and differ from dendritic cells, which 
present processed antigen together with MHC class II molecules to T cells. FDCs 
can bind antigen-antibody complexes and antigen bound to complement, which 
they display to centrocytes. Only centrocytes that express antibodies with high-
affinity to the antigen will then bind to the antigen presented by FDCs, resulting in 
the upregulation of anti-apoptotic proteins and survival. Centrocytes with less 
specific antibodies will bind antigen insufficiently to be rescued from cell death, 
which is induced as a default mechanism in these cells. This process of B cell 
selection in the GC is termed affinity maturation and is critical for the efficiency of 
the immune response (Batista and Harwood, 2009; MacLennan, 1994).  
 
1.1.6 Memory B cells 
The majority of antigen-activated B cell that have survived affinity maturation 
become antibody-secreting plasmablasts and plasma cells. Some GC cells 
develop into memory cells, which can persist in the lymph node or other lymphoid 
tissues in the absence of antigen (Maruyama et al., 2000). The mechanisms that 
regulate this developmental decision between plasma cell and memory cell fate 
are only partly understood. There is evidence that the expression of high affinity 
immunoglobulin favours plasma cell development (Smith et al., 1997; Smith et 
al., 2000), whereas signalling via CD40 promotes memory cell formation (Arpin et 
al., 1995). In addition, cytokines play important roles, with IL-4 favouring memory 
cell development, and IL-6 and IL-10 promoting plasma cell formation (Kawano 
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et al., 1995; Zhang et al., 2001). Memory cells do not secrete antibody but 
express high-affinity immunoglobulin on the cell surface. Upon secondary 
encounter with the same antigen, memory cells are biased to rapidly differentiate 
into plasma cells. Compared with naïve B cells, memory cells show an enhanced 
proliferative response to activation and give rise to five to eight fold more plasma 
cells, resulting in four to five times more secreted immunoglobulin (Arpin et al., 
1997; Tangye et al., 2003). This intrinsic readiness and propensity of memory 
cells to differentiate into plasma cells is thought to be a major reason for the rapid 
production of antigen-specific antibodies during a secondary immune response. It 
has been suggested that a subset of memory cells that are found in the bone 
marrow can differentiate into plasma cells even faster than the bulk of splenic 
memory cells, but the existence of these memory cells is still controversial (Bell 
and Gray, 2003; McHeyzer-Williams et al., 2000).  
 
1.1.7 Terminal B cell differentiation into plasma cells 
Plasma cells can develop from marginal-zone, follicular, activated GC, and 
memory B cells, depending on the circumstances of antigen encounter (Figure 
1.1.7). The first B cells to begin differentiation into plasma cells after antigen 
encounter are marginal-zone cells, owing to their location in the lymphoid organs 
and their antibody repertoire, which is skewed towards TI antigens (Pillai et al., 
2005). Therefore, antigen-activated marginal-zone cells begin to proliferate within 
hours of immunisation. Their proliferative potential in response to LPS has been 
shown to be greater than that of follicular B cells, which has been partly attributed 
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to the higher expression of co-stimulatory surface molecules, such as CD80 and 
CD86 (Martin et al., 2001; Oliver et al., 1997a; Oliver et al., 1999). Activated 
marginal-zone cells typically proliferate in the red pulp of the spleen, where they 
concomitantly differentiate to form extrafollicular foci of plasmablasts, which 
secrete IgM but are not fully differentiated plasma cells in that they do not exit the 
cell cycle (Pillai et al., 2005). Antigen-activated follicular B cells that do not 
become GC cells can also form extrafollicular foci of plasmablasts and plasma 
cells (Jacob et al., 1991a). Since both marginal-zone and follicular B cell-derived 
plasmablasts and plasma cells do not undergo affinity-maturation in the GC, they 
secrete IgM with lower antigen-affinity than their class-switched counterparts that 
are derived from GC cells and memory cells (Jacob et al., 1991b). These plasma 
cells begin to appear two days after immunisation in periarteriolar lymphoid 
sheaths, reach a maximum density after eight days when they represent 1% of 
the splenic volume, and disappear by day 14 (Jacob et al., 1991a). 
    Activated B cells that have survived the selection process of the GC reaction 
can differentiate into memory cells, which may ultimately develop into plasma 
cells upon secondary encounter with antigen, or directly into plasma cells. The 
plasma cells that are formed via this route express class-switched 
immunoglobulins whose genes have undergone somatic hypermutation, have 
therefore higher antigen affinity, and largely migrate to the bone marrow, where 
they can persist for prolonged periods in the absence of infection (Manz et al., 
2005). 
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Figure 1.1.7 Terminal B cell differentiation into plasma cells. Antibody-
secreting cells (ASCs) generated from B1 cells secrete natural antibody in the 
absence of external antigen and IgA in the gut. On encounter with foreign 
antigen, marginal-zone B cells differentiate into plasma cells, and subsequently, 
naive follicular B cells also differentiate into plasma cells. Most of the 
extrafollicular plasma cells that are formed in this early response are short-lived. 
Some activated follicular B cells form a germinal centre. Post-germinal-centre 
plasma cells might progress through a memory B-cell stage in the primary 
response or might develop directly from germinal-centre B cells. Plasma cells 
that result from a germinal-centre reaction might become long-lived if they find 
survival niches, which are mainly located in the bone marrow. CSR, class-switch 
recombination. Reproduced, with permission, from Shapiro-Shelef and Calame, 
Nature Reviews Immunology (2005) © 2005 by Nature Publishing Group. 
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1.1.8 Cellular and molecular characteristics of plasma cells 
Independent of the route of differentiation, plasma cells share a variety of cellular 
and molecular characteristics that distinguish them from activated B cells. These 
include (1) changes in the expression of cell surface molecules, (2) a switch in 
expression from membrane-bound to secreted antibodies, (3) terminal exit from 
the cell cycle, (4) a substantial and characteristic change in the transcriptional 
program, and (5) expansion of the secretory apparatus and activation of the ER 
stress response (Shapiro-Shelef and Calame, 2005). 
 
1.1.8.1 Cell surface molecules  
A number of cell surface molecules undergo changes in expression during 
plasma cell differentiation. CD138 (Syndecan-1) generally serves as the major 
marker for plasma cells and is a member of the syndecan family of 
proteoglycans, which promote cell adhesion to extracellular matrix and 
neighbouring cells (Bernfield and Sanderson, 1990). CD138 is predominantly 
expressed on mature epithelial cells, but is also found on pre-B cells and 
particularly on plasma cells (Sanderson and Borset, 2002; Sanderson et al., 
1989). CD38, another adhesion molecule, is expressed on human but not on 
mouse plasma cells (Oliver et al., 1997b). Very late antigen (VLA)-4 is the 
predominant member of the integrin family of adhesion molecules expressed on 
plasma cells and mediates contacts between plasma cells and bone marrow 
stroma cells (Drew et al., 1996). The chemokine receptor C-X-C motif receptor 
(CXCR)-4 is present on plasma cells and mediates migration to the splenic red 
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pulp and the bone marrow, where its ligand C-X-C motif ligand (CXCL) 12 is 
expressed at high levels (Hargreaves et al., 2001). In contrast, expression of 
CXCR5 and C-C motif ligand (CCL) 7 is down-regulated in plasma cells, which 
decreases retention in lymphoid follicles, where levels of the respective ligands 
CXCL13, CCL19, and CCL21 are high (Hargreaves et al., 2001). Class II MHC is 
not expressed on plasma cells since plasma cells do not act as APCs (Silacci et 
al., 1994). The decrease of CD19, CD21, CD22 and B220 on plasma cells is in 
line with the lack of B cell receptor signalling, for which these molecules act as 
modifiers  (Calame et al., 2003). B220 is a 220kD isoforms of CD45 that is 
expressed on all mouse B cells and down-regulated only in terminally 
differentiated plasma cells, whereas its expression is also reduced in human B 
cells that acquire the memory cell marker CD27 (Bleesing and Fleisher, 2003). 
 
1.1.8.2 Expression of secretory immunoglobulins 
Terminal plasma cell differentiation leads to a switch in the expression from 
membrane-bound to secreted immunoglobulins. This is due to a substantial 
increase in the ratio of membrane-bound to secreted heavy chain mRNA, which 
is determined by the use of a different polyadenylation site in plasma cells 
compared to mature B cells (Galli et al., 1988; Galli et al., 1987). As a 
consequence, membrane-bound immunoglobulin and the B cell receptor are 
virtually absent on fully differentiated plasma cells.  
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1.1.8.3 Exit from the cell cycle  
Activation of B cells leads to a proliferative burst, and it has been shown that 
each cell division during the proliferative burst increases commitment to the 
plasma cell fate, providing evidence for a stochastical component in the 
regulation of plasma cell formation (Hasbold et al., 2004). While plasmablasts, 
which may be considered an intermediate stage between activated B cells and 
plasma cells, still proliferate (Jego et al., 1999), cessation of the cell cycle is a 
prerequisite for terminal plasma cell differentiation (Lin et al., 2000). Exit from the 
cell cycle is induced by transcriptional repression of the proto-oncogene c-myc by 
B-lymphocyte-induced maturation protein 1 (BLIMP1), the major regulator of 
plasma cell development, and is required but not sufficient for terminal plasma 
cell differentiation (Lin et al., 2000). Cell cycle arrest during plasma cell 
differentiation is also mediated by suppression of pRb phosphorylation, which 
depends on IL-6-induced activation of the cyclin-dependent kinase (CDK) 
inhibitor p18INK4c (Morse et al., 1997). The functional importance of cell cycle 
cessation for terminal plasma cell differentiation has been demonstrated in mice 
lacking p18INK4c, which have hyper-proliferative GCs and form plasmacytoid cells, 
but have severely impaired serum antibody titers (Tourigny et al., 2002). 
 
1.1.8.4 Gene expression pattern 
The substantial changes in the gene expression pattern that not only accompany 
but govern terminal differentiation of activated B cells into plasma cells have 
been extensively studied over the last decade. It has been become clear that the 
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major transcriptional regulators whose activity is critical for terminal plasma cells 
differentiation repress genes that are required during earlier stages of B cell 
development, and vice versa. This mechanism serves to establish a mutually 
exclusive gene expression program in plasma cells and mature B cells, which is 
believed to prevent premature terminal differentiation (Fillatreau and Radbruch, 
2006; Shapiro-Shelef and Calame, 2005). The transcription factors that play key 
roles in resting and activated B cells, in which they also act to  suppress plasma 
cell formation, are BTB and CNC homology 1-basic leucine zipper transcription 
factor 2 (BACH2), B-cell lymphoma-6 (BCL-6), Microphthalmia-associated 
transcription factor (MITF), and paired box protein 5 (PAX5). In contrast, 
interferon-regulatory factor 4 (IRF4), X-box binding protein 1 (XBP1), and 
BLIMP1 are major promoters of plasma cell formation. BLIMP1 has been 
described as the “master regulator” of plasma cell formation that is also critically 
involved in the repression of transcription factors required for earlier B cell stages 
(Kallies and Nutt, 2007). 
    PAX5 (also called B-cell lineage-specific activator protein), which can act as a 
transcriptional activator or repressor, is required for the progression of B 
lymphopoiesis beyond the pro-B cell stage and for the maintenance of B cell 
identity until the onset of plasma cell differentiation, since it induces expression of 
a large number of genes that have various roles in B cell function (Mikkola et al., 
2002; Nutt et al., 2001; Schebesta et al., 2007). Notably, PAX5 induces 
expression of activation-induced cytidine deaminase (AID) in germinal centre B 
cells, which is critical for both somatic hypermutation and class-switch 
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recombination (Gonda et al., 2003; Shinkura et al., 2004). Importantly, PAX5 
blocks plasma cell formation by repressing expression of IgH, IgL, J chain and 
XBP1 (Reimold et al., 1996; Rinkenberger et al., 1996; Shaffer et al., 1997; Singh 
and Birshtein, 1993). This transcriptional repression is relieved when PAX5 
expression is directly down-regulated by BLIMP1 during plasma cell 
differentiation (Lin et al., 2002), and loss of PAX5 has been shown to promote 
plasmacytic differentiation in the chicken B cell line, DT40 (Nera et al., 2006).  
    BCL-6 protein levels are present ubiquitously at low levels, but are 
substantially up-regulated in GC cells (Allman et al., 1996), and mice lacking 
BCL-6 have a defective GC reaction (Dent et al., 1997). BCL-6 has been shown 
to suppress expression of positive-regulatory-domain containing 1 (Prdm1), the 
genes that encodes for BLIMP1, and Bcl-6-/- mice  form more plasma cells in T-
dependent immune responses and produce higher levels of antibodies after 
immunisation with LPS (Shaffer et al., 2000; Tunyaplin et al., 2004). Furthermore, 
overexpression of BCL-6 inhibits plasma cell formation (Reljic et al., 2000). In the 
GC, B cells constantly receive signals via the B cell receptor. Since BCL-6 
expression is repressed in cells expressing BLIMP1, it has been suggested that 
the reciprocal regulation of these two proteins has a major role in determining 
terminal B cell fate and ensuring that plasmacytic differentiation is irreversible 
(Shaffer et al., 2002). 
    BACH2 is required for GC formation, up-regulation of AID, and somatic 
hypermutation and class-switch recombination of immunoglobulin genes in both 
T-dependent and TI immune responses (Muto et al., 2004). Observations that 
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LPS-stimulated B cells from Bach2-/- mice express higher levels of BLIMP1 and 
XBP1 than their wild-type counterparts (Muto et al., 2004), and that 
overexpression of BACH2 in B cell lines represses Prdm1 (Ochiai et al., 2006), 
suggest that BACH2 has a role in repressing terminal plasma cell differentiation . 
    The transcription factor MITF is highly expressed in naïve B cells where it 
inhibits plasmacytic differentiation by repressing IRF4. This has been shown in 
mice that have a mutation in the DNA-binding domain of MITF, which results in 
dysfunctional MITF activity, leading to spontaneous plasma cell formation and 
auto-antibody production. Furthermore, ectopic expression of MITF in activated B 
cells suppressed plasma cell formation and immunoglobulin secretion (Lin et al., 
2004).  
    IRF4 is a transcriptional activator that has a role in the progression of B cell 
differentiation beyond the pre-B cell stage (Lu et al., 2003). Later in development, 
IRF4 is involved in inducing expression of AID in GC cells and thereby 
contributes to CSR and somatic hypermutation (Klein et al., 2006). Transgenic 
mice with a conditional deletion of Irf4 in GC cells fail to form post-GC plasma 
cells and to differentiate plasma cells from memory B cells (Lu et al., 2003). The 
same study also suggested a requirement for IRF4 in addition to BLIMP1 for 
plasma cell differentiation. It has also been demonstrated that Irf4-deficient LPS-
activated B cells fail to up-regulate expression of Prdm1 and to establish the 
plasma cell-specific gene expression program (Sciammas et al., 2006). 
Expression of IRF4 gradually increases during plasmacytic differentiation of 
activated B cells, and transduction of the human GC-derived lymphoma cell line 
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Oci-Ly7 with IRF4 retroviruses results in increased expression of CD38, BLIMP1, 
XBP1, and many of their target genes, suggesting that high levels of IRF4 
promote the developmental progression from GC cells to plasma cells 
(Sciammas et al., 2006). The involvement of IRF4 in both GC reaction and 
plasma cell formation also indicates some molecular overlap between the GC 
and plasma cell stage, which are otherwise regarded as incompatible 
differentiation steps (Fillatreau and Radbruch, 2006). 
    XBP1 is a transcriptional activator that plays an integral part in the ER stress 
response. The roles of XBP-1 during plasma cell differentiation are outlined in 
detail in chapter 1.1.8.5. 
     BLIMP1 is a transcriptional repressor that contains five zinc finger motifs that 
confer its ability to bind to DNA (Keller and Maniatis, 1992). Its role in plasma cell 
formation was first noted when upregulation of BLIMP1 transcripts was found in 
lymphoma cell lines undergoing induced plasmacytic differentiation, and when 
overexpression of BLIMP1 in lymphoma cell lines induced typical features of 
plasma cells, such as immunoglobulin secretion, increased size and granularity, 
and expression of Syndecan-1 (Turner et al., 1994). Although mice deficient in 
BLMIP1 are not viable due to the roles of BLIMP1 in embryogenesis (Robertson 
et al., 2007), a number of subsequent studies firmly established BLIMP1 as the 
major regulator of plasma cell differentiation: BLIMP1 was found to be expressed 
in vivo in plasma cells that are derived from both TI and T-dependent immune 
responses, in plasma cells formed during a secondary immune response, and in 
plasma cells that reside in secondary lymphoid organs as well as in the bone 
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marrow (Angelin-Duclos et al., 2000). LPS-stimulated B cells lacking BLIMP1 
proliferate, but fail to up-regulate CD138 and to secrete immunoglobulin, which is 
due to a deficient switch from membrane-bound to secreted heavy chains 
(Shapiro-Shelef et al., 2003).  
    BLIMP1 is also expressed in a subset of GC B cells in human tonsils and 
murine spleen that show a phenotype that is intermediate between GC B cells 
and plasma cells (Angelin-Duclos et al., 2000). BLIMP1 has also been shown to 
be required for the formation of CD79+B220- pre-plasma memory B cells 
(Shapiro-Shelef et al., 2003), a subset of memory cells that reside mainly in the 
bone marrow and differentiate more efficiently into plasma cells upon antigen 
recall than their B220+ counterparts (McHeyzer-Williams et al., 2000). B1 cells 
require BLIMP1 for immunoglobulin secretion, but not for self-renewal (Savitsky 
and Calame, 2006). BLIMP1 acts to directly repress c-myc (Lin et al., 1997), and 
Pax5 (Lin et al., 2002). BLIMP1 also acts to down-regulate the anti-apoptotic 
molecule A1 (Knodel et al., 1999). Gene expression microarray analyses of 
various B cell lines induced to express BLIMP1 revealed that more than 225 
genes that are down-regulated by BLIMP1, in contrast to more than 30 genes 
being up-regulated (Shaffer et al., 2002). Predominantly, the genes that were 
down-regulated by BLIMP1 belonged to two classes. One class was associated 
with the gene expression signature of proliferation and growth and includes 
genes involved in cell cycle progression such as c-myc and cdk2 as well as DNA 
synthesis and repair. The other class was linked to mature B cell function and 
included genes such as CD19, MHCII, Pax5 and Bcl6. Among the genes induced 
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in the presence of BLIMP1 were those required for plasma cell function such as 
Xbp1, J-chain, and light chain (Shaffer et al., 2002). It is of note that a recent 
study which also used gene expression microarray analysis found that 
expression of BLIMP1 in the mature B cell lymphoma line M12 led to the 
induction of 158 known and 152 unknown genes and to the repression of 49 
known and 50 unknown genes (Sciammas and Davis, 2004). Although there was 
some overlap between the results of these two studies in that they both found 
that BLIMP1 induced genes involved in plasma cell differentiation and repressed 
genes that are actively transcribed in mature B cells, it is not clear why one study 
found that BLIMP1 represses the majority of differentially regulated genes 
(Shaffer et al., 2002), while the other one found that BLIMP1 induced a 
considerably larger fraction of these (Sciammas and Davis, 2004). It has been 
suggested that, apart from intrinsic differences in the cell models used in the two 
studies, different modes of plasma cell differentiation could account for 
differential effects of BLIMP1 on the transcriptome (Sciammas and Davis, 2004). 
      By generating a mouse model where the nucleotide sequence coding for 
green fluorescent protein (GFP) was introduced into the Blimp1 locus, it could be 
shown that all antibody-secreting cells in vivo and in vitro express BLIMP1 
(Kallies et al., 2004). The same study also demonstrated that expression levels 
of BLIMP1 were higher in bone marrow than in splenic antibody-secreting cells, 
that BLIMP1 levels in these subsets were inversely correlated with the 
expression of B cell markers (B220, MHCII, CD19), and that high levels of 
BLIMP1 were associated with post-mitotic plasma cells in the spleen and bone 
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marrow. These observations led the authors to propose a model of cellular 
ontogeny where increasing BLIMP1 levels result in progressive maturation from 
antibody-secreting plasmablasts in the spleen to post-mitotic plasma cells in the 
spleen and bone marrow. Consistent with this model, the same group has 
recently demonstrated that the very early stages of plasma cell differentiation do 
not require BLIMP1 and are represented by a pre-plamablast stage, which is 
characterised by BLIMP1-independent repression of PAX5, increasing 
expression of XBP1 and J-chain, and low immunoglobulin secretion (Kallies et 
al., 2007). This pre-plasmablast stage is followed by up-regulation of BLIMP1 
and IRF4 in plasmablasts and subsequent terminal plasma cell differentiation, 
indicating that full differentiation but not commitment to the plasma cell fate 
depend on BLIMP1 (Klein and Dalla-Favera, 2007).  
     A number of other factors have been demonstrated to have a role in plasma 
cell differentiation. Conditional deletion of Signal transducer and activator of 
transcription (STAT) 3 in the B lineage showed that STAT3 is specifically 
required for T-dependent IgG responses (Fornek et al., 2006). However, another 
study suggested a more general role for STAT3 in plasma cell differentiation, 
with STAT3 inducing immunoglobulin secretion and upregulation of BLIMP1 
(Diehl et al., 2008). In contrast, STAT5 has been suggested to inhibit plasma cell 
differentiation by direct up-regulation of BCL6 (Scheeren et al., 2005). Mice 
deficient in all three members of the Vav family of proteins, which are believed to 
mediate a variety of signals downstream of surface receptors, have normal 
mature B cells but exhibit severe defects in plasma cell formation and 
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immunoglobulin secretion. Vav-deficient B cells induced to undergo plasmacytic 
differentiation up-regulate IRF4 normally but fail to induce BLIMP1 and XBP1 
(Stephenson et al., 2006). A novel level of gene regulation that has been 
identified over the last years involves microRNAs (miRNAs), which inhibit target 
genes by sequence-specific base pairing that initiates inhibition of translation or 
degradation of the mRNA (Bartel, 2004). Expression of miRNA155 is induced 
upon antigenic stimulation in B and T cells, regulates a wide spectrum of genes 
including chemokines, cytokines and transcription factors, and is required for 
normal immune function (Rodriguez et al., 2007). Mice lacking miRNA155 in their 
B cells show a reduced formation of extrafollicular and GC responses and fail to 
produce high-affinity IgG1 (Vigorito et al., 2007).  
    These studies demonstrate the complexity of the signalling networks that 
regulate the transition from activated B cells to plasma cells. 
 
1.1.8.5 Expansion of the secretory apparatus and the ER stress response 
The steady state levels of both heavy and light chain mRNA increase to very high 
levels during terminal plasma cell differentiation. This is due to both increased 
transcription and increased mRNA stability (Calame et al., 2003), resulting in the 
secretion of up to 10,000 molecules of immunoglobulin per second per cell (Hibi 
and Dosch, 1986). Proteins destined for the endo- or exocytic pathway, such as 
immunoglobulins, must first traverse the ER lumen to undergo folding and 
assembly of nascent polypeptides into functional proteins (Cenci and Sitia, 
2007). In order to cope with such a massive secretory challenge, plasma cells 
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must undergo considerable structural reorganization. Using electron microscopy 
of CH12 cells, murine B cells that undergo plasmacytic differentiation upon 
stimulation with LPS, it was shown that both the ER and the Golgi complex 
expand substantially during terminal plasma cell differentiation (Wiest et al., 
1990). The area and volume of the rough ER was found to increase 3.3 and 3.7 
fold, respectively, while the area and volume of the Golgi apparatus was 
measured to increase 3.3 and 4.1 fold, respectively. Due to this considerable 
expansion of the secretory apparatus, the concentration of IgM within the ER 
increased only twofold, despite a 12fold overall increase in IgM production (Wiest 
et al., 1990).  
     A proteomics analysis of LPS-stimulated I.29µ+ cells revealed that ER 
resident proteins increase about 6fold during plasmacytic differentiation (van 
Anken et al., 2003). The same study showed that the up-regulation of ER 
proteins precedes the increase in immunoglobulin secretion. IgM subunits remain 
stable during early phases of plasmacytic differentiation from B cells, until ER 
residents have increased around 3fold, and rapidly increase approximately 20fold 
thereafter (van Anken et al., 2003). Thus, B cells undergoing terminal plasma cell 
differentiation appear to “anticipate” the secretory challenge that awaits them and 
prepare for it by up-regulating the required “paraphernalia” (Figure 1.1.8.5).      
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Figure 1.1.8.5 Expanded endoplasmatic reticulum in a plasma cell. During 
terminal plasma cell differentiation, the area and volume of the endoplasmatic 
reticulum increase around 3.5fold to occupy a large part of the cytosol. ER, 
endoplasmatic reticulum; N, nucleus. Electron microscopic image adapted from  
www.missinglink.ucsf.edu, accessed 28 July 2008 (Multimedia Learning 
Modules, University of California San Francisco). 
    
 The transcription factor XBP1 is preferentially expressed in several foetal 
tissues, and mouse embryos lacking XBP1 die in utero (Clauss et al., 1993; 
Reimold et al., 2000). XBP1 plays an integral part in the UPR in response to 
secretory stress in the ER (Ron and Walter, 2007).The mechanisms of activation 
of XBP1 during the UPR are discussed in detail in chapter 1.2.6 and involve 
alternative splicing of Xbp1, which creates a potent transcription factor that 
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activates a number of downstream targets that participate in the restoration of ER 
homeostasis (Ron and Walter, 2007). In order to investigate the role of XBP1 in 
late B cell development, reconstitution of recombination-activating gene-2 (RAG-
2) deficient blastocysts, which develop into mice that do not have mature T and B 
cells due to the inability to initiate VDJ recombination (Chen et al., 1993), with 
XBP1-/- embryonic stem cells was performed (Reimold et al., 2001). The resulting 
chimeric mice had normal numbers of mature B and T cells that were derived 
from the XBP1-/- embryonic stem cells, but substantially reduced serum levels of 
IgM, IgA, and IgG subclasses (Reimold et al., 2001). B cells from these mice that 
were stimulated ex vivo to undergo plasmacytic differentiation secreted 
significantly lower amounts of immunoglobulins, and retroviral transduction of 
XBP1 into XBP1 deficient B cells restored immunoglobulin secretion. The XBP1 
deficient chimeras had very low numbers of plasma cells, which lacked the 
characteristic perinuclear huff upon microscopy that indicates the Golgi 
apparatus, and failed to mount an adequate humoral immune response to 
antigen in vivo (Reimold et al., 2001). Thus, this study demonstrated that plasma 
cell differentiation requires XBP1. Another investigation then showed that IL-4 
rapidly increases the expression of Xbp1 but not its splicing, which is induced by 
LPS (Iwakoshi et al., 2003a). The same study also found that splicing of Xbp1 
greatly enhances immunoglobulin secretion but also largely depends on the 
production of IgM, indicating a reciprocal function between XBP1-mediated 
plasma cell differentiation and secretory stress in the ER. This was further 
confirmed by the observation that Inositol-requiring enzyme (IRE) 1α, one of the 
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major “sensors” of ER stress (discussed in detail in chapter 1.2.6), is required for 
splicing of Xbp1 and plasma cell differentiation (Zhang et al., 2005). Gene 
expression profiling of B cells deficient in Xbp1 or prdm1, the gene coding for 
BLIMP1, revealed that XBP1 acts downstream of BLIMP1 (Shaffer et al., 2004). 
It was also shown that XBP1 up-regulates a considerable number of genes that 
code for proteins involved in the secretory pathway, with diverse functions such 
as protein transport into the ER, protein folding and glycosilation, protein 
trafficking, and ER associated degradation. By over-expressing the spliced form 
of Xbp1 in mature B cell lines, it was also demonstrated that XBP1 substantially 
increases cell size, overall protein content, mitochondrial mass, ribosome 
number, lysosome content, and ER volume (Shaffer et al., 2004). Analyses of 
XBP1-/- primary B cells stimulated to undergo plasmacytic differentiation 
demonstrated that XBP1 is required for high-level synthesis and secretion of IgM, 
but not other glycoproteins and immunoglobulin light chains or for ER-associated 
degradation of proteins, including µ chains (Tirosh et al., 2005). 
    The second major arm of the ER stress response generally involves inhibition 
of translation. This is mediated by (PKR)-like ER kinase (PERK), which 
phosphorylates and inhibits the alpha subunit of eukaryotic translation initiation 
fator-2α (eIF2α), thereby reducing overall protein production (Ron and Walter, 
2007). This protective pathway is not activated during plasma cell differentiation, 
presumably to facilitate the secretion of huge amounts of immunoglobulins (Gass 
et al., 2008; Zhang et al., 2005).  
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    The third arm of the ER stress response involves activating transcription 
factor-6 (ATF6), which targets a subset of genes involved in the UPR (Ron and 
Walter, 2007). Enforced expression of a dominant-negative ATF6 mutant by 
retroviral transduction of primary B cells undergoing plasmacytic differentiation 
demonstrated that ATF6 is not required for the formation of plasma cells. 
However, plasmacytic cells expressing the ATF6 mutant secreted lower amounts 
of IgM and released higher amounts of incompletely assembled IgM, indicating a 
role for ATF6 in quality control of immunoglobulin secretion (Gunn et al., 2004). 
 
1.1.9  Plasma cell life-span 
The majority of plasma cells that are formed during the humoral immune 
response are short-lived and undergo apoptosis in the secondary organs within 
several days (Smith et al., 1996). However, a proportion of plasma cells, most of 
which are found in the bone marrow, can survive for most of the life-time of an 
organism (Manz et al., 1998; Manz and Radbruch, 2002).  
 
1.1.9.1 Short-lived plasma cells 
The first product of the humoral immune response to antigen is un-switched low-
affinity immunoglobulin (IgM) produced by plasma cells that are formed in 
extrafollicular foci of the spleen and lymph nodes, from where they disappear 
within 2 weeks of immunisation (Jacob et al., 1991a). It was shown that the 
decline of antigen-specific plasma cells in the extrafollicular foci is not paralleled 
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by an increase in antigen-specific plasma cells in the bone marrow, indicating 
that the disappearance from lymph node and spleen is not due to migration 
(Smith et al., 1996). The same study also demonstrated that plasma cells in the 
extrafollicular foci are lost by apoptosis at a rate of approximately 20% of the 
plasma cell population per day. Another study found that that the number of 
plasma cells in the spleens reaches a peak at 8 days after viral infection with 
approximately 6x104 antibody-secreting cells per spleen,  which is then reduced 
by 95% within three weeks (Slifka et al., 1998). Thus, the majority of plasma cells 
rapidly undergo programmed cell death by apoptosis at the site of their formation 
(Smith et al., 1996). However, a subset of plasma cells formed in the secondary 
lymphoid organs become long-lived and play a key role in maintaining 
immunological memory that provides protection against re-infection (Manz and 
Radbruch, 2002). Although these observations have been made in murine 
systems, it is generally assumed that they also apply to human short-lived 
plasma cells. 
 
1.1.9.2 Long-lived plasma cells 
Recovery of acute viral or microbial infections often results in long-term or even 
life-long immunity (Ahmed and Gray, 1996). A recent study has shown that the 
half-lives of antigen-specific antibodies in the serum of humans range from an 
estimated 11-19 years for bacterial vaccine antigens to a calculated 50-200 years 
for common viral antigens such as varicella zoster or measles (Amanna et al., 
2007). Until the late 1990s, it was generally assumed that long-term humoral 
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immunity is provided by the continuous generation of plasma cell, which were 
then deemed to be short-lived, from memory cells (Zinkernagel et al., 1996). 
However, after it had been demonstrated that plasma cells can persist in the 
bone marrow of mice for more than 90 days without turnover (Manz et al., 1997), 
a seminal investigation documented that plasma cells can survive for most of the 
life-time of an organism to provide humoral immunity (Slifka et al., 1998). In this 
study, which used the mouse model of infection with lymphocytic 
choriomeningitis virus (LCMV), it was observed that from 30 days post-infection 
for the rest of the life of the mouse, the bone marrow contained 2-3x104 virus-
specific plasma cells. Total body irradiation of LCMV-infected mice was then 
used to deplete memory B cells (but not plasma cells, which are relatively 
resistant to irradiation), which demonstrated that in the absence of memory B 
cells, both antigen-specific serum immunoglobulin levels and plasma cells were 
maintained, with bone marrow and splenic plasma cell half-lives of 3 and 6 
months, respectively, and approximately 90% of the antigen-specific plasma cells 
being found in the bone marrow. Another investigation then provided evidence 
that long-lived plasma cells are maintained in the absence of antigen (Manz et 
al., 1998).  
    The majority of long-lived plasma cells are found in the bone marrow, although 
a small proportion can survive in the spleen of humans and mice for prolonged 
periods (Ellyard et al., 2004; Slifka et al., 1998). Plasmablasts can also migrate to 
the primary site of the immune activation, where they become plasma cells and 
survive for as long as the inflammatory reaction persists (Moser et al., 2006). The 
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exit of plasma cell precursors from lymph nodes and spleen and migration to the 
site of inflammation is largely governed by the expression of chemokine 
receptors on the plasmablasts and the production of chemokines by inflammatory 
tissue (Radbruch et al., 2006). Interferon-gamma (IFNγ) is present at high 
concentrations in inflamed tissue and increases the expression of CXCR3 on 
plasmablasts and of CXCR3 ligands by inflammatory cells (Muehlinghaus et al., 
2005), which indicates an important role for IFNγ in attracting plasmablasts to 
inflammatory tissue. In mucosal immune reactions, the expression of CCR9 and 
CCR10 on plasmablasts and of their ligands CCL25 and CCL28 by mucosal cells 
is believed to play major roles in the homing of plasma cell precursors to sites of 
inflammation (Moser et al., 2006; Radbruch et al., 2006). This mechanism is also 
likely to be important in the accumulation of plasma cells in inflammatory tissue, 
such as the synovia of patients with rheumatoid arthritis (Tsubaki et al., 2005). 
Increased numbers of plasma cells are also found in the spleens of mice that are 
prone to the auto-immune disease SLE, and approximately 40% of these splenic 
plasma cells have a half-life of >6 months and produce auto-antibodies (Hoyer et 
al., 2004). It is assumed that the presence of chemokines and cytokines is critical 
for plasma cell survival in the inflamed tissue, and that the termination of the 
inflammatory process results in plasma cell death (Radbruch et al., 2006). 
    A number of survival factors for long-lived plasma cells have been identified 
largely by isolating plasma cells from the bone marrow and testing the effect of 
candidate molecules on their survival in vitro. The presence of bone marrow-
derived stroma cells extends plasma cell survival in vitro substantially, and this is 
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likely to be largely mediated by IL-6 (Minges Wols et al., 2002). IL-6 alone can 
decrease the decline in plasma cells in culture, and its production is induced in 
stroma cells when they are co-cultured with plasma cells (Minges Wols et al., 
2002).  However, although the early phases of antigen-specific humoral immune 
responses are impaired in IL-6 deficient mice, maintenance of bone marrow 
plasma cell does not require IL-6 in vivo (Cassese et al., 2003). Other factors that 
were found by the same group to support plasma cell survival in vitro are IL-5, 
tumor necrosis factor (TNF)-alpha, stromal cell-derived factor-1 alpha, and CD44 
ligands (Cassese et al., 2003). B cell activating factor of the TNF family (BAFF, 
also called BlyS) has been observed to prevent apoptosis of plasma cells, but is 
not required for memory B cell survival (Avery et al., 2003; Benson et al., 2008). 
A proliferation-inducing ligand (APRIL), which is secreted by neutrophils and 
macrophages, promotes plasma cell survival both in the bone marrow and in the 
mucosa-associated lymphoid tissue probably by up-regulating anti-apoptotic 
proteins such as bcl-2, bcl-x(L), and mcl-1 (Belnoue et al., 2008; Huard et al., 
2008). Like BAFF, APRIL appears not to be required for memory B cell survival 
(Benson et al., 2008). Both BAFF and APRIL are ligands for B cell maturation 
antigen (BCMA), whose expression is up-regulated in plasma cells, and mice 
deficient in BCMA have a substantially reduced number of bone marrow plasma 
cells (O'Connor et al., 2004). These observations have led to the proposal that 
the combination of specific signals provided by anatomical niches is critical for 
the longevity of bone marrow plasma cells. Expression of the inhibitory Fc 
receptor, FcγRIIb, is higher in fully differentiated splenic and bone marrow 
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plasma cells than in less differentiated plasma cells and mature B cells, and 
cross-linking of FcγRIIb induces plasma cell apoptosis (Xiang et al., 2007).  
1.1.9.3 Plasma cell survival and the changing repertoire of humoral memory 
The total number of long-lived bone marrow plasma cells, which normally 
represent around 1% of all bone marrow cells in a healthy individual, is estimated 
to be around 106 in mice and 109 in humans (Radbruch et al., 2006). Based on 
measured serum concentrations of immunoglobulins for specific antigens and 
assuming that mouse and human plasma cells secrete similar amounts of 
antibodies, human adults are estimated to contain around 1x106 vaccine-specific 
long-lived plasma cells. Thus, the repertoire of the human plasma cell “memory” 
compartment may comprise of up to 1,000 specificities (Radbruch et al., 2006). 
Secondary immunisation in the mouse leads to approximately 5x104 antigen-
specific bone marrow plasma cells after 40 days, which is a higher proportion of 
total plasma cells than in humans and most likely results from housing in 
pathogen-reduced conditions and the relatively young age of laboratory mice 
when they are used for experiments (Manz et al., 1998; Manz et al., 1997; 
Radbruch et al., 2006). The latter of these two possible explanations is supported 
by the observation that human adolescents have a 2-fold higher level of tetanus-
specific serum IgG than adults (Schauer et al., 2003). The fact that each new 
immunisation leads to the recruitment of around 1x106 new plasma cells to the 
pool of long-lived plasma cells with its limited overall capacity has lead to 
suggestions that newly generated plasma cells compete with resident plasma 
cells that have been formed in previous immune responses for space in survival 
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niches (Manz et al., 2005; Radbruch et al., 2006). According to this model, every 
new plasma cell population that is recruited to the bone marrow subsequent to 
immunisation would displace a small fraction of plasma cells with older 
specificities. Such a concept would also provide an explanation for the slow 
decline in antigen-specific immunoglobulin levels with time (Odendahl et al., 
2005; Radbruch et al., 2006).  
1.1.10 Plasma cell apoptosis 
The observations discussed above provide some explanation regarding the 
factors that are required for prolonged plasma cell survival in the bone marrow 
and indicate that a small proportion of long-lived plasma cells is repeatedly lost 
because they are displaced by newly generated plasma cells and thus deprived 
of their survival signals. As discussed in the previous sections, the vast majority 
of plasma cells that are generated in the spleen or lymph nodes do not exit the 
site of their formation but undergo apoptosis in situ within a few days of 
immunoglobulin secretion. The major concepts that have been proposed 
regarding the causes of this rapid death of most plasma cells suggest extrinsic 
and intrinsic constraints on survival, respectively. One investigation found that 
mouse spleens can sustain the survival of 20-100 plasma cells/mm2, but that the 
generation of a higher density of plasma cells resulted in the loss of excess cells 
within 2-3 days (Sze et al., 2000). The authors of that study concluded that a high 
numbers of plasma cells would “overshoot” the capacity of the splenic stroma to 
support their survival and therefore proposed that plasma cell survival is limited 
by extrinsic factors. Another study which used IL-6 to differentiate CESS human 
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lymphoma cells and murine B cells into plasmacytic cells found that plasma cell 
apoptosis is induced by both intrinsic and extrinsic TNF-related apoptosis-
inducing ligand (TRAIL), suggesting that TRAIL-induced apoptosis may 
contribute to programmed plasma cell death partly in a cell autonomous manner 
(Ursini-Siegel et al., 2002). Other recent investigations have proposed a role for 
the protein secretion machinery in plasma cell apoptosis: using the murine B 
lymphoma line, I.29µ+, that undergoes plasmacytic differentiation upon 
stimulation with LPS, and primary in vitro differentiated mouse plasmablasts, 
Sitia and co-workers found that terminal differentiation into plasma cells leads to 
proteasomal deficiency (Cascio et al., 2008; Cenci et al., 2006). The proteasome 
is a multi-enzyme complex that is critical for the degradation of misfolded and 
unfolded proteins from the ER (Werner et al., 1996). The decreasing capacity of 
the proteasome coupled with an increased susceptibility to apoptosis after 
treatment with proteasome inhibitors led to the proposal that an intrinsic 
imbalance between proteasome load and capacity contributes to the termination 
of plasma cell life (Cenci et al., 2008). Using ex-vivo polyclonal mouse plasma 
cells and human plasma cells differentiated in vitro from tonsillar GCs, DeFrance 
and co-workers found that the pro-apoptotic molecule Bax becomes activated at 
the ER in apoptotic plasma cells, indicating an involvement of the ER in the 
termination of plasma cell life (Pelletier et al., 2006). In the same investigation, it 
was found that plasma cells express two out of six known death receptors, DR3 
and CD95, but that blocking these receptors does not reduce plasma cell death, 
arguing against a role for death receptors in plasma cell apoptosis (Pelletier et 
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al., 2006). In summary, these studies provide some evidence for a role of various 
intrinsic and extrinsic signals in plasma cell death but have not yielded a 
comprehensive view of the mechanisms involved in plasma cell apoptosis.  
 
 
1.2     Protein secretion and the ER 
Secretory proteins such as immunoglobulins undergo a number of post-
translational modifications before they can be secreted. Most of these 
modifications, and various quality control procedures, take place in the ER. When 
the amount of proteins that need to pass through the ER surpasses an 
(unknown) threshold, an adaptive programme termed the “unfolded protein 
response” (UPR) is activated to adapt to the secretory challenge. If the UPR is 
inadequate to cope with the demands for protein processing, the accumulation of 
faulty proteins causes ER stress, which can eventually lead to cell death. 
 
1.2.1 Immunoglobulin structure  
All antibodies share the same basic structural features, which have been known 
for several decades now (Franklin, 1975). Each antibody consists of two identical 
light chains of approximately 24kd each and two identical heavy chains of 55 or 
70kD each (Figure 1.2.1). Disulfide bonds between cysteines serve to attach 
each light chain to one heavy chain and the two heavy chains to each other. 
Light chains are distinguished by two different types of C regions (Cκ and Cλ), 
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and each antibody contains either Cκ or Cλ. Both the light and heavy chains 
contain N-terminal variable (V) and C-terminal constant (C) regions, and the 
heavy and light chain V regions (VH and VL) are juxtaposed to form the antigen-
binding fragment (Fab) of the antibody. The V regions are characterised by 
extensive sequence variability, which result in the capacity of different antibodies 
to recognise a large number of antigens, with an estimated 107-109 different 
antibodies estimated to be present in one individual (Abbas et al, 2000). The C 
regions do not participate in antigen binding, but interact with other effector 
molecules such as complement. The C regions of heavy chains (CH) serve to 
anchor membrane bound antibodies in the B cell membrane (Harris et al., 1999). 
   Based on amino acid sequence differences in CH regions, antibodies are 
subdivided into isotypes named IgA, IgD, IgE, IgG, and IgM. IgA is further 
subdivided into IgA1 and IgA2, and IgG consists of the subclasses IgG1, IgG2, 
IgG3 and IgG4 (in mice this corresponds to IgG1, IgG2a, IgG2b and IgG3). 
Greek letters corresponding to the isotype of the antibody are used to designate 
the heavy chain, e.g. α1 for IgA1 or µ for IgM. The differences between the CH 
regions are largely responsible for the differences in effector functions that are 
exerted by the antibody isotypes (Spiegelberg, 1989). Differences in the function 
of antibodies are also conferred by the variability in immunoglobulin glycosilation 
(Burton and Dwek, 2006). 
    Depending on the length of CH, antibodies are membrane-bound or secreted. 
While the latter terminate with hydrophilic amino acids, the former are larger and 
contain hydrophobic sequences typical of transmembrane proteins. Membrane-
 56
bound and secreted heavy chains are designated with an M or S, e.g. µS for the 
heavy chain that forms part of secreted IgM (Peterson, 2007).  
    While IgD, IgE, and IgG are always produced as monomers, IgA can also be 
secreted as a dimer or larger polymer, and IgM is assembled as a pentamer or 
hexamer. The multimeric immunoglobulins (except for hexameric IgM) are linked 
at the C-terminus by small peptides called J-chains via disulfide bonds (Brewer 
and Corley, 1997; Johansen et al., 2000; Niles et al., 1995; Sorensen et al., 
2000).  
    Covalent modifications, folding, and oligomerisation of immunglobulins largely 
take place in the ER, where quality control mechanisms – which have been 
elucidated by the studies not only of immunoglobulins but a variety of secretory 
and membrane-bound proteins - ensure that only functional antibodies are 
secreted, whereas misfolded proteins are destined for degradation (Anelli and 
Sitia, 2008). 
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Figure 1.2.1 Immunoglobulin structure. Schematic 3D-immunoglobulin 
structure. LC, light chain; HC, heavy chain; yellow balls, disulfide bonds; red 
network, glycosilation (adapted from www.sci.sdsu.edu, San Diego State 
University College of Sciences, accessed 26 August 2008). 
 
 
1.2.2 Quality control in the ER 
Newly translated proteins are in a “nascent” state that is energetically 
unfavourable, and must undergo a number of post-translational modifications to 
acquire a “native” conformation that is energetically advantageous. The 
modifications, which lead to correct “folding” of the protein, include disulfide bond 
formation, glycosilation, and oligomeric assembly (Dobson, 2004). Most of these 
maturation steps take place in the ER, which provides a unique environment with 
respect to ion composition, redox balance, and presence of molecular 
chaperones, and cannot be achieved in other cellular compartments (Figure 
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1.2.2). This implies that stringent quality control mechanism are in place to 
prevent proteins from leaving the ER prematurely, which would result in the 
secretion of non-functional or even toxic proteins. The quality control 
mechanisms regulate whether a protein is passed on from the ER along the 
secretory pathway, retained for further modifications, or returned to the cytosol 
for ER-associated degradation (ERAD) (Anelli and Sitia, 2008). Molecular 
chaperones, which act as folding sensors and assist proteins in acquiring their 
native configuration, recognise misfolded proteins and unassembled oligomers. 
Quality control by chaperones is a retention-based system, in which proteins with 
even minor aberrations from the native state are detected and retained in the ER, 
whereas properly folded proteins escape detection and can therefore leave the 
ER along the secretory route (Ellgaard and Helenius, 2003). 
    Newly synthesised polypeptides that are still bound to the ribosome are co-
translationally translocated into the ER through a cylindrical transmembrane 
channel whose major component is the heterotrimeric Sec61 complex, which is 
composed of an α, ß, and γ subunit (Beckmann et al., 1997; Song et al., 2000). 
The inner diameter of this aqueous pore, which is termed translocon, extends up 
to 60Å and thus requires sealing mechanisms to prevent passive ion exchanges 
between the ER and cytosol (Wirth et al., 2003). This is achieved by the 
ribosome and dynamic conformational changes of the translocon itself on the 
cytosolic side and the major ER chaperone BiP on the ER luminal side (Crowley 
et al., 1994; Hamman et al., 1998; Woolhead et al., 2004). The enzyme 
oligosaccharyltransferase (OST), which is associated with the translocon on the 
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ER luminal side, catalyses the transfer of a preassembled oligosaccharide 
(i.e.Glc3Man9GlcNAc, where Glc stands for glucose, Man for mannose, and 
GlcNac for N-Acetylglucosamine) onto selected asparagine residues of the newly 
assembled polypeptide (Wang and Dobberstein, 1999). Two glucose residues 
are then removed by ER glucosidases I and II (Malhotra and Kaufman, 2007). 
The mono-glycosilated glycan can now be recognised by calnexin (Cnx) and 
calreticulin (Crt) (Williams, 2006). Cnx and Crt are ER lectins (lectins are proteins 
that bind carbohydrates) that associate with Erp57, an oxidoreductase that 
catalyses the formation of disulfide bonds (Frickel et al., 2004; Frickel et al., 
2002). Due to their specificity to bind monoglycosilated glycans, Cnx and Crt 
probably associate with most of all glycoproteins that enter the ER and are at the 
heart of a well characterised and elegant quality control system: when 
glucosidase II removes the glucose from the core glycan, the polypeptide is 
released from Cnx and Crt and can undergo further folding (Malhotra and 
Kaufman, 2007). In the subsequent quality control step, UDP-
glucose:glycoprotein glycosyltransferase 1 (UGT1) recognises localised folding 
defects, which are characterised by the exposure of hydrophobic amino acid 
clusters, and preferentially re-glucosylates glycans in these misfolded regions of 
the protein (Taylor et al., 2004; Taylor et al., 2003). Consequently, the re-
glucosylated protein can be bound again by Cnx and Crt and is therefore 
retained in the ER for further maturation, such as disulfide bond formation by the 
associated Erp57. These rounds of binding to and release from Cnx and Crt are 
repeated until the protein is folded correctly so that it is not re-glucosylated by 
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UGT1. Instead, the native protein becomes a substrate for mannosidases such 
as ER Man I and II, which remove mannose residues to inhibit re-glucosylation, 
and may move on along the secretory pathway (Anelli and Sitia, 2008). 
  Another quality control mechanism is based on Binding Protein (BiP), which 
was first isolated on the basis of its binding to unassembled H chain. The 
association of the C-terminal domain of BiP with many, but not all, nascent 
proteins in the ER is likely to be linked to the recognition of hydrophobic 
sequences but is still not fully understood. The N-terminal ATPase domain of BiP 
catalyses the hydrolysis of ATP to ADP, which leads to a conformational change 
that results in the release of the bound substrate. Owing to the weak ATPase 
activity of BiP, this reaction is assisted by the ERdj family of co-chaperones, and 
the oxidoreductase activity of its member ERdj5 has been proposed to provide a 
link between binding of unfolded proteins by BiP and disulfide bond formation. 
BiP has been shown to promote protein folding, and although the exact 
mechanisms are unknown, it is assumed that cycles of binding to and release 
from BiP are involved. Since glycoproteins usually do not bind to BiP and Cnx/Crt 
simultaneously, it has been suggested that nascent proteins may preferentially 
associate with one of these two quality control systems and possibly with the 
other if the first one fails. 
   The formation of disulfide bonds between the thiol (-SH) groups of cysteines 
enhances the stability of the native protein and is thus critical for protein 
maturation in the ER. Protein disulfide isomerise (PDI) is the best characterised 
member of a family of oxidoreductases that catalyse the formation of disulfide 
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bonds in the ER (Ellgaard and Helenius, 2003). In terms of quality control, it is of 
note that the presence of certain cysteines that are not part of a disulfide bond 
and therefore exposed on the molecule is sufficient to cause retention or 
degradation of an otherwise correctly matured protein. This process may be 
mediated by the formation of disulfide bonds between the exposed thiol in the 
misfolded secretory protein and proteins of the ER matrix (Fra et al., 1993; 
Reddy et al., 1996).  
    Another mechanism by which quality control is exerted relies on oligopeptide 
motifs. As long as the RKR (arginine, lysine, arginine) sequence motif is exposed 
on unassembled protein subunits,  e.g. the alpha and beta subunits of the 
K(ATP) complex, they are retained in the ER, from which the correctly assembled 
polymer is released due to masking of the retention signal (Zerangue et al., 
1999). Retention signals also serve to retain ER resident proteins in the ER, or to 
retrieve them from the Golgi apparatus. An example of such an ER retention 
signal is provided by the KDEL (lysine, aspartate, glutamate, leucine) motif, 
which is present in many ER chaperones (Munro and Pelham, 1987; Sonnichsen 
et al., 1994). 
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Figure 1.2.2 Quality control in the ER. Nascent polypeptides are translocated 
in to the ER through the Sec61 channel, which is assisted by the ER chaperone 
BiP. A pre-assembled oligosaccharide (i.e. N-acetylglucosamine2 mannose9 
glucose3) is attached by oligosaccharyltransferase (OST). Removal of glucose 
residues by glucosidases I and II (GlcI/II) allows recognition and retention of the 
glycoprotein by calnexin (Cnx) and calreticulin (Crt). Cnx/Crt associate with 
Erp57, an oxidoreductase that catalyzes the formation of disulfide bonds. Glc II 
removes the innermost glucose residue so that the glycoprotein can detach from 
Cnx/Crt. UDP-glucose:glycoprotein glycosyltransferase (UGT1) recognises 
localised folding defects and preferentially re-glucosylates glycans in these 
misfolded regions so that the protein is retained in the ER by Cnx/Crt. 
Alternatively, misfolded proteins are bound by BiP to assist further maturation. 
Correctly folded proteins undergo deglucosylation by Glc II and have mannose 
residues trimmed away by mannosidases (ER Man I), are packed into vesicles at 
ER exit sites, and transported into the ERGIC and Golgi apparatus in COP II 
vesicles. This process is assisted by lectins such as ERGIC-53. Terminally 
misfolded proteins undergo substantial mannose removal mediated by members 
of the ER degradation enhancing α-mannosidase-like (EDEM) protein family and 
are retro-translocated into the cytosol (largely through Sec61 channels but 
probably other means as well) for proteasomal ER associated degradation 
(ERAD). Red triangles, glucose; green circles, mannose; black squares, N-
acetylglucosamine). Reproduced, with permission, from Malhotra and Kaufman, 
Seminars in Cell & Developmental Biology 18 (2007) © 2007 by Elsevier.  
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1.2.3 Quality control beyond the ER 
Once proteins have been selected to be eligible for further transport along the 
secretory pathway, they leave the ER at ER exit sites (ERES), from which 
misfolded proteins can be excluded. At the ERES, proteins are packed into 
vesicles that are coated with the coat protein II (COPII) complex. When COPII 
proteins are assembled on the ER membrane, they recruit both proteins destined 
for export (cargo) and cargo receptors, and polymerisation of the COPII coat on 
the budding membrane is then thought to drive the formation of the vesicle 
(Mancias and Goldberg, 2005). The next compartment that is reached on the 
secretory pathway is the ER-Golgi intermediate compartment (ERGIC), a 
membrane system between the ER and the Golgi apparatus that has recently 
been suggested to play a role in the quality control of IgM assembly. Plasma 
cells secrete IgM only in polymeric form [(µ2-L2)5-J pentamers or (µ2-L2)6 
hexamers], with the subunits being linked by disulfide bonds at Cys575 at the C-
terminus of the secretory heavy chain µS. While assembly of IgM monomers (µ2-
L2) is largely checked by BiP in the ER (Hendershot et al., 1987; Hendershot et 
al., 1996; Hendershot and Kearney, 1988; Lee et al., 1999), quality control of IgM 
polymerisation occurs to a substantial extent in the ERGIC. The retention of 
unassembled IgM polymers that have passed quality control by BiP was found to 
be mediated by ERp44, a protein that accumulates at the ERGIC. ERp44 
interacts with ERGIC-53, a major component of the ERGIC that shuttles between 
the ER and the Golgi apparatus and preferentially binds partially assembled IgM 
subunits (Anelli et al., 2003; Anelli et al., 2007). Retrieval of misfolded or 
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misassembled proteins as well as ER resident proteins to the ER from the Golgi 
apparatus involves transport in coat proteins (COP I) complex coated vesicles 
and uses retrieval/retention motifs such as the KDEL sequence described above 
(Ellgaard and Helenius, 2003). 
 
1.2.4 ER-associated degradation  
Terminally misfolded proteins have to be disposed of in an orderly way. Although 
some misfolded proteins are transported to and degraded in the lysosome (Hong 
et al., 1996), the bulk of protein degradation is executed in the cytosol by the 
proteasome, a process that is referred to as ER-associated degradation (ERAD). 
The close link between proteasomal ERAD and quality control in the ER has 
been demonstrated by several studies showing that inhibition of the proteasome 
leads to accumulation of misfolded proteins and secretory incapacity (Anelli and 
Sitia, 2008; Cenci et al., 2008).  
    In a first step, terminally misfolded proteins must be distinguished from 
proteins that are still undergoing maturation. Although the exact mechanisms of 
this process are not fully understood, mannose trimming is thought to be 
involved. As described above, a protein that has passed quality control by 
Cnx/Crt becomes a substrate for mannosidases such as ER Man I and II, which 
remove mannose residues to inhibit re-glucosylation and therefore recognition by 
Cnx/Crt. However, further removal of mannose residues increases ERAD (Anelli 
and Sitia, 2008). The most prominent enzymes involved in ERAD are members 
of the ER degradation enhancing α-mannosidase-like (EDEM) protein family. 
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EDEM1, 2 and 3 are major targets of the IRE1α/XBP1 pathway (Yoshida et al., 
2003) that is activated upon ER stress and during plasma cell differentiation. 
Genetic targeting and overexpression of EDEM family members has 
demonstrated that EDEM proteins play important roles in the degradation of 
misfolded proteins and maintenance of secretory capacity (Eriksson et al., 2004; 
Molinari et al., 2003; Olivari et al., 2006). Another group of proteins involved in 
ERAD are Derlins, which are induced by the mammalian ER stress response. 
Overexpression and knock-down of  members of the Derlin family results in the 
enhanced and decreased degradation of misfolded glycoproteins, respectively 
(Oda et al., 2006; Olivari et al., 2005). 
    Once terminally misfolded proteins have been identified they undergo at least 
partial unfolding and reduction, a process in which both BiP and PDI have been 
implicated. Subsequently, they are retro-translocated into the cytosol largely 
through the Sec61 channel that is also used for translocation of newly 
synthesised polypeptides in to the ER. Once in the cytosol, proteins receive a 
ubiquitin “tag” by the E2-E3 complexes that are associated with the ER 
membrane and undergo degradation by the proteasome (Meusser et al., 2005).  
 
1.2.5 ER stress  
When the load of nascent polypeptides that enter the ER for folding and 
assembly into native proteins surpasses the processing and quality control 
capacity of the ER, misfolded proteins accumulate and cause a disequilibrium in 
the ER that is named ER stress. ER stress activates a complex cellular reaction, 
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the unfolded protein response (UPR) that aims to restore homeostasis in the 
secretory pathway. ER stress also induces autophagy, a cellular response to 
various types of stress that recycles damaged organelles and macromolecules.  
If these mechanisms fail, ER stress causes programmed cell death in order to 
prevent the organism from the potentially disadvantageous effects of faulty 
protein assembly.  
 
1.2.6 The unfolded protein response 
The UPR provides a variety of mechanisms that allow cells to rapidly adapt to 
secretory challenge. In metazoan cells, three ER transmembrane signal 
transducers (IRE1, ATF6, and PERK) sense secretory overload in the ER and 
induce three distinct arms of the UPR (Figure 1.2.6). While activation of IRE1 and 
ATF6 results in the upregulation of various components of the protein secretion 
pathway and thus increased folding capacity, activation of PERK largely serves 
to attenuate overall protein translation in order to reduce the secretory burden 
(Ron and Walter, 2007).  
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Figure 1.2.6 The unfolded protein response. ATF6, IRE1, and PERK all 
associate with BiP in their inactivate state. Upon accumulation of misfolded 
proteins in the ER lumen, these sensors are released and activated. ATF6 
transits to the Golgi where it is cleaved by S1P/S2P and the cytosolic fragment of 
ATF6 migrates to the nucleus. Both IRE1 and PERK are oligomerized and 
autophosphorylated. Phosphorylated IRE1 catalyzes the splicing of XBP1 mRNA, 
which generates a more potent transcription factor. Activated PERK 
phosphorylates eIF2α, which attenuates the general translation rate while 
inducing the translation of selective mRNAs. The downstream effectors of these 
three subpathways combinatorially induce the expression of the genes encoding 
proteins that function to augment the ER protein-folding capacity. Meanwhile, 
ERAD is accelerated to remove terminally misfolded proteins. Reproduced, with 
permission, from Wu and Kaufman, Cell Death and Differentiation (2006) © 2006 
by Nature Publishing Group. 
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1.2.6.1 IRE1 
The first signal transducer of the UPR to be identified was Ire1p in yeast, a so-
called bifunctional protein owing to its kinase and endoribonuclease activity (Cox 
et al., 1993; Mori et al., 1993). In mammals, two homologues of the yeast protein 
have been identified: IRE1α, which is expressed in most tissues, and IRE1ß, 
which is only expressed in intestinal epithelial cells (Tirasophon et al., 1998; 
Wang et al., 1998). It was found that IRE1, an ER transmembrane protein, 
associates with the major ER chaperone BiP in unstressed cells, and that the 
accumulation of unfolded proteins in the ER results in dissociation of BiP from 
the ER luminal side of IRE1, which allows for IRE1 to oligomerize (Bertolotti et 
al., 2000). Oligomerization can also be triggered by direct binding of unfolded 
proteins to the ER luminal domain of IRE1 (Credle et al., 2005; Zhou et al., 2006) 
and leads to trans-autophosphorylation of juxtaposed IRE1 kinase domains on 
the cytoplasmic domain of IRE1 (Shamu and Walter, 1996). Surprisingly, it was 
found that the only substrate for the IRE1 kinase is IRE1 itself. Consequently, no 
other kinase signalling cascades are activated by IRE1 trans-
autophosphorylation (Ron and Walter, 2007). However, phosphorylation of its 
kinase domain results in the activation of the endoribonuclease activity of IRE1, 
which mediates splicing of its only known target, the precursor mRNA for the 
transcription factor HAC1 (in yeast) and XBP1 (in metazoans). In yeast, the 
splicing event removes a 252 base pair intron from the mRNA that suppresses 
translation (Cox and Walter, 1996; Mori et al., 2000). In metazoans, splicing 
removes a 26 nucleotide intron from the XBP1 mRNA (Calfon et al., 2002). 
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Although both the spliced and unspliced mRNAs are translated into proteins, the 
uspliced mRNA is labile and encodes a protein that represses transcription of 
UPR genes, whereas the spliced form is more stable and encodes a protein that 
is a potent activator of many genes involved in the ER stress response 
(Ruegsegger et al., 2001; Yoshida et al., 2001; Yoshida et al., 2006). These UPR 
target genes, such as the chaperones BiP and GRP94, contain an ER stress 
response element (ERSE, CCAAT(N9)CCACG) that is required for transcriptional 
activation, and XBP1 is one of the transcriptional activators that bind to this 
ERSE. Consistent with the activation of the UPR during terminal differentiation of 
plasma cells, which is thought to be related to the secretory challenge caused by 
antibody secretion, signalling through IRE1 and XBP1 is critical for plasma cell 
formation, expansion of the secretory machinery in stimulated B cells, and 
secretion of IgM (Iwakoshi et al., 2003b; Reimold et al., 2001; Shaffer et al., 
2004; Tirosh et al., 2005; Zhang et al., 2005). In I.29µ+ cells, which undergo 
plasmacytic differentiation upon stimulation with LPS, the spliced form of XBP1 
becomes prominent during the first days of differentiation but decreases at later 
stages when spontaneous apoptosis of the plasmacytic I.29µ+ cells begins to 
take place (Cenci et al., 2006), suggesting that a reduction in XBP1-mediated 
UPR signalling might be involved in the termination of plasma cell life. IRE1 can 
also activate signalling by tumour necrosis factor receptor-associated factor-2 
(TRAF2), which is activated following recruitment to phosphorylated IRE1. 
Downstream signalling from the IRE1-TRAF2 complex includes activation of Jun 
N-terminal kinase (JNK) and possibly caspase-12, the ER initiator caspase, 
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which has been suggested to be involved in ER stress-induced apoptosis. In 
addition, IRE1-mediated degradation of ribosome-associated mRNAs has been 
proposed as a means by which the UPR reduces protein load. Activation of the 
IRE1/XBP1 pathway also enhances ERAD by inducing members of the EDEM 
am Derlin family of proteins (Oda et al., 2006) 
 
1.2.6.2 ATF6 
ATF6 is a transcription factor that was identified based on its ability to bind to the 
ERSE in UPR genes. ATF6 contains a transmembrane domain that anchors it in 
the ER membrane, from which it protrudes into the ER lumen with a domain that 
binds BiP. Binding to BiP appears to retain ATF6 in the ER, since dissociation of 
BiP during ER stress results in trafficking of ATF6 to the Golgi, where it is 
cleaved by two resident proteases, site 1 protease (S1P) and S2P in its luminal 
domain and N-terminal portion, respectively (Malhotra et  al, 2007). This releases 
the N-terminal DNA-binding fragment of ATF6, ATF6f, which translocates to the 
nucleus, where it binds to the ERSE and other regulatory elements of UPR target 
genes such as BiP. The two isoforms of ATF6, ATF6α and ATF6ß, are 
expressed in all cell types and undergo cleavage by S1P and S2P followed by 
nuclear translocation. They have the same DNA-binding domain but differ in their 
transcription activation domains. Overexpression and gene-specific knockdown 
of the N-terminal fragments of the two isforms have shown that ATF6α is a strong 
transcriptional activator of UPR genes, whereas ATF6ß attenuates the activating 
effect of  ATF6α on UPR targets. This opposing effect of the two ATF6 isoforms 
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has been interpreted as a regulatory mechanism to modulate the strength or 
duration of the UPR (Thuerauf et al., 2007; Thuerauf et al., 2004). In addition to 
its roles in the activation of the UPR, ATF6 has also been suggested to mediate 
ER stress-induced apoptosis (Nakanishi et al., 2005). Although ATF6 has been 
shown to be activated and cleaved during terminal B cell differentiation, details 
about its role in plasma cell development or whether it is required for the 
formation of plasma cells are not known (Gass et al., 2002). 
 
1.2.6.3 PERK 
PERK is an ER transmembrane protein that contains a luminal stress-sensing 
domain and a cytoplasmatic kinase domain. Similar to IRE1, dissociation of BiP 
from the luminal portion of PERK upon accumulation of unfolded proteins results 
in PERK oligomerisation and trans-autophosphorylation of its kinase domain. 
This leads to activation of the kinase domain, which catalyses phosphorylation of 
the alpha subunit of eIF2α at serine 51. This phosphorylation inhibits the guanine 
exchange factor eIF2B, which recycles eIF2α to its active, guanine triphosphate-
bound form. This results in reduced activity of the translation initiation complex, 
which is required for the initiation of protein translation. The ensuing global 
reduction in protein synthesis acts to reduce the protein burden in the ER. 
Interestingly, phosphorylation of eIF2α leads to selectively increased translation 
of activating transcription factor-4 (ATF4). ATF4 induces a number or genes that 
encode for proteins involved in the UPR, such as proteins with roles in amino 
acid biosynthesis and transport. ATF4 also induces transcription of 
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CAAT/Enhancer binding protein (C/EBP) homologous protein (CHOP, also 
termed GADD153), which is involved in the regulation of ER stress-induced 
apoptosis. Thus, PERK signaling protects the stressed ER in two ways, by 
overall reduction in protein synthesis and selective induction of a few genes with 
roles in the UPR. 
   Given that the key role of plasma cells is the synthesis and secretion of huge 
amounts of immunoglobulins, it is not surprising that PERK is not activated 
during plasma cell differentiation, and that Perk-/- B cells develop normally into 
fully functional plasma cells (Gass et al., 2008). However, the fact that one major 
arm of the UPR is not used in plasma cells (PERK) while another arm is 
indispensable for their formation and function (IRE1/XBP1) indicates that the ER 
stress response in plasma cells differs substantially from that in most of all other 
cell types. 
 
1.2.7 Autophagy 
Autophagy (also termed macroautophagy) is a process by which a cell reacts to 
various stressful conditions by recycling of macromolecules or organelles, such 
as damaged mitochondria. Depending on the type and duration of the stress 
condition, autophagy can promote cell survival or commit cells to non-apoptotic 
cell death (Kroemer and Jaattela, 2005). 
    Autophagy begins with the envelopment of macromolecules or organelles by 
isolating membranes. The initial steps of membrane formation require a protein 
complex that contains phosphatidylinositol 3-kinase (PI3K), p150 myristylated 
 73
protein, and autophagy-related protein-6 (Atg6). The isolating membrane then 
elongates around its target cargo until the edges fuse to form the 
autophagosome (Levine and Klionsky, 2004). Elongation of the isolation 
membrane is mediated by a complex containing Atg5 and Atg12, and 
microtubule-associated protein light chain 3 (LC3). The conversion of the free 
form of LC3 (LC3-I) to the autophagosome membrane-bound form (LC3-II) by 
conjugation with phosphatidylethanolamine is critical for autophagosome 
formation and is often used as a marker for the induction of autophagy. The 
autophagosome then fuses with lysosomes in order to degrade the cargo (Hoyer-
Hansen and Jaattela, 2007). 
    Recent observations indicate that ER stress and the UPR can activate 
autophagy, although the exact mechanisms remain to be elucidated. While one 
group showed that LC3 conversion and induction of Atg12 by ER stress is 
mediated by the PERK-eIF2α pathway (Kouroku et al., 2007), another group 
found that a pathway including IRE1 and JNK, but not PERK, plays a key role in 
ER stress-induced autophagosome formation (Ogata et al., 2006). The 
physiological relevance of ER stress-induced autophagy is still not entirely clear, 
but it is generally assumed that autophagy contributes to the protection of cells 
from misfolded proteins, which might be executed by the removal of degraded 
proteins or recycling of components of the secretory machinery (Hoyer-Hansen 
and Jaattela, 2007). At present, there is no published information about a 
potential role of autophagy in plasma cells, but preliminary data indicate that 
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autophagy does occur during terminal differentiation from B cells to plasma cells 
(Simone Cenci, San Raffaele Scientific Institute Milan, personal communication). 
 
1.2.8 ER stress-induced apoptosis 
If the UPR fails to restore homeostasis in the ER, apoptosis is initiated 
presumably to protect the tissue and organism from potentially deleterious effects 
of continued protein misfolding. The mechanisms that are involved in ER stress-
induced apoptosis will be discussed in detail in chapter 1.3.9. 
 
1.3 Apoptosis 
Programmed cell death is indispensable for correct tissue development and 
homeostasis. It can either be pre-programmed to take place at a certain time 
point during tissue formation or cellular differentiation, or occur as a 
consequence of external stimuli that render the death of a specific cell more 
advantageous to the entire organism. By far the most common form of 
programmed cell death is apoptosis (derived from the Greek word for “falling 
from”, for cells dying like leaves falling from a tree), which is defined by certain 
morphologic features of the dying cell. These include plasma membrane 
remodelling and blebbing, chromatin condensation and fragmentation, cell 
shrinkage, and finally disintegration into apoptotic bodies that are then engulfed 
by phagocytes. Apoptosis allows for the orderly and non-inflammatory removal of 
a dying cell (Kerr et al., 1972). In contrast, necrosis is a form of “violent” cell 
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death that occurs following damage so abrupt and substantial that co-ordinated 
death is impossible and the remnants of the destroyed cell cause a pathological 
immune reaction (Danial and Korsmeyer, 2004). Apoptosis is of particular 
importance in the immune system, where large numbers of differentiating cells 
that do not pass the stringent selection criteria for high antigen specificity have to 
be disposed of (Rossi and Gaidano, 2003).  
     Apoptosis can be induced by ligands present in the microenvironment of a cell 
that bind to specific cell surface receptors, which mediate further pro-apoptotic 
signalling inside the cell (“extrinsic pathway”). Alternatively, apoptosis can be 
initiated from inside the cell, with sensors translating pro-apoptotic conditions 
such as DNA damage into the relevant signalling cascade (“intrinsic pathway”). 
Both pathways partly overlap and involve the co-ordinated activation of members 
of a family of cystein proteases, the caspases (Danial and Korsmeyer, 2004). 
During the initiation phase of apoptosis, “initiator” caspases, which are in part 
specific for the type of apoptotic trigger, undergo activation. They then cleave 
and thereby activate “effector” or “executioner” caspases, the most prominent of 
which is caspase-3 (Figure 1.3 and Figure S2, p.215). Active caspase-3 targets a 
large number of substrates throughout the cell and is largely responsible for the 
defining outcomes of apoptosis (Boatright and Salvesen, 2003; Denault and 
Salvesen, 2008). The important role of caspases is underlined by the resistance 
of cells to apoptotic insults when caspases are chemically inhibited or genetically 
deleted. Although caspase-independent forms of programmed cell death have 
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been described, they are rare and it is still a matter of debate whether 
physiological caspase-independent apoptosis exists (Chipuk and Green, 2005). 
    The initiation of apoptosis is in part regulated by the balance of pro- and anti-
apoptotic proteins, the most prominent of which is the Bcl-2 family of proteins, 
that can be altered in response to internal or external conditions (Danial and 
Korsmeyer, 2004). Recent years have also seen the identification of proteins that 
can inhibit the activation of effector caspases, such as the Inhibitor of Apoptosis 
(IAP) family of proteins (Schafer and Kornbluth, 2006). Imbalances in the levels 
of apoptosis-regulating proteins have been implicated in a variety of neoplastic 
diseases, which are often characterised by a decreased rate of basal apoptosis 
and resistance to apoptosis induced by anti-neoplastic therapies (Rossi and 
Gaidano, 2003).  
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Figure 1.3 The intrinsic and extrinsic pathway of apoptosis. The extrinsic 
pathway of apoptosis is initiated when death signals in the cellular 
microenvironment, such as Fas-Ligand, bind to death receptors. This leads to the 
recruitment of adaptor proteins such as FADD and activation of caspase-8. The 
intrinsic pathway is initiated when intracellular insults lead to a pro-apoptotic 
imbalance within the BCL-2 family of proteins, resulting in mitochondrial outer 
membrane permeabilisation and formation of the apoptosome. Both pathways 
converge on effector caspases that execute cell death. Reproduced, with 
permission, from Schafer and Kornbluth, Developmental Cell (2006) © 2006 by 
Elsevier. 
 
 
1.3.1 The extrinsic pathway of apoptosis 
Pro-apoptotic signals that are present in the cellular microenvironment are 
transduced into the intracellular space by a family of death receptors (DRs), 
which include DR3, DR4, DR5, DR6, CD95 (Fas/APO-1), and tumour necrosis 
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factor-receptor 1 (TNF-R1). The DRs are transmembrane proteins that have in 
common an extracellular ligand-binding domain and an intracellular signal 
transduction domain that is termed death domain (DD). The ligands that bind to 
the DRs belong to the TNF family of cytokines and function in an autocrine or 
paracrine manner. They include TNFα, lymphotoxin, Apo3-Ligand, Fas-Ligand 
(Fas-L), and TRAIL. Upon binding of the ligand to its receptor, the DR undergoes 
homotrimerisation, which causes its DD to recruit an adaptor protein such as 
Fas-associated death domain (FADD). The death effector domain (DED) of the 
adaptor protein then interacts with the DED of the proenzymatic form of caspase-
8/FADD-like IL-1ß–converting enzyme (FLICE) to form the death inducing 
signalling complex (DISC). Caspase-8 acts as the initiator caspase of the 
extrinsic pathway, and its recruitment into the DISC results in auto-cleavage that 
activates caspase-8. Active caspase-8 then cleaves caspase-3 for execution of 
programmed cell death (Krammer, 1999). However, recent evidence suggests 
that cleavage is not required for activation of caspase-8 but rather a 
consequence of activation, which is achieved by dimerisation (Donepudi et al., 
2003). This is compatible with other findings that initiator caspases are activated 
by dimerisation and not cleavage (Boatright and Salvesen, 2003). 
    The cellular homologue of FLICE-inhibitory protein (c-FLIP) has the ability to 
interfere with DISC formation (Krueger et al., 2001). In GC B cells that do not 
receive the survival signal CD40L from T cells, c-FLIP is rapidly lost from DISC 
which leads to activation of caspase-8 and apoptosis (Hennino et al., 2001). 
Contact with FDCc or with CD40L inhibits c-FLIP degradation, indicating that 
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FDCs and activated T cells contribute to inhibition of  GC B cell apoptosis 
mediated by the extrinsic pathway (van Eijk et al., 2001). Thus, DR-mediated 
apoptosis is likely to play an important role in the negative selection of B cell 
during the GC reaction. In plasma cells, the role of the extrinsic pathway of 
apoptosis is controversial: one study that investigated plasma cells differentiated 
in vitro from human tonsillar B cells found that plasma cells up-regulate DR3 and 
CD95, but a reduction of plasma cell death upon inhibition of these DRs was not 
observed. In addition, only minimal cleavage of caspase-8 occurred, thus arguing 
against a relevant role of the extrinsic pathway in plasma cell apoptosis (Pelletier 
et al., 2006). Another study used plasma cells differentiated in vitro from murine 
B cells and ex vivo isolated murine plasma cells after T-independent 
immunisation (Ursini-Siegel et al., 2002). The investigators observed that plasma 
cells maintain expression of TRAIL and its receptors, DR4 and DR5. Since the 
exogenous inhibitory TRAIL receptor, DR5-Fc, reduced plasma cell apoptosis, 
and plasma cell death was associated with cleavage of caspase-8, a key role for 
the extrinsic apoptotic pathway in plasma cell death was proposed by the 
authors. 
 
1.3.2 The intrinsic pathway of apoptosis 
A number of cellular insults such as DNA damage, withdrawal of growth or 
survival factors, mitochondrial damage, and ER stress, can activate the intrinsic 
pathway of apoptosis. The initiation of the intrinsic pathway is to a large extent 
regulated by the balance of a structurally related group of pro- and anti-apoptotic 
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molecules, the BCL-2 family (Danial and Korsmeyer, 2004). The founding 
member of the family, BCL-2, was first identified as a proto-oncogene in human 
B cell lymphomas, in which the chromosomal translocation t(14;18) brings Bcl-2 
under the transcriptional control of the IgHµ enhancer. This results in the 
overexpression of BCL-2 and reduced apoptosis of B lymphocytes (McDonnell et 
al., 1989; McDonnell et al., 1990; Tsujimoto et al., 1985a; Tsujimoto et al., 
1985b). In contrast, Bcl-2 knock-out mice display a selective increase in 
apoptosis in lymphocytes and a few other cell types (Veis et al., 1993).  
    The BCL-2 family is divided into three subclasses based on their pro- or anti-
apoptotic function and the number of BCL-2 homology (BH) domains. The anti-
apoptotic proteins BCL-2, BCL-XL, BCL-W, MCL-1, and A1 contain all four highly 
conserved BH domains BH1-4. BCL-2 members with fewer BH domains are pro-
apoptotic and can be further divided into the “multidomain” BCL-2 members such 
as BAX and BAK that share the BH1-3 domains, whereas the “BH3-only” 
proteins such as BID, BIM, and PUMA have homology only with the BH3 domain 
(Kuwana and Newmeyer, 2003).  
    In healthy cells, BAX exists in the cytosol as an inactive monomer. Upon 
receipt of a death stimulus, BAX stably inserts into the outer mitochondrial 
membrane as a homo-oligomer. Similarly, activation of inactive monomeric BAK 
that resides at the mitochondria leads to its homo-oligomerisation within the outer 
mitochondrial membrane (OMM) (Griffiths et al., 1999; Gross et al., 1998; Makin 
et al., 2001). It is thought that both BAX and BAK form pores in the OMM that 
result in the release of mitochondrial intermembrane space proteins such as 
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cytochrome c into the cytosol, which is critical for the activation of caspases 
downstream of the mitochondria (Jurgensmeier et al., 1998; Kuwana et al., 
2002). The importance of BAX and BAK for induction of apoptosis is underscored 
by the observation that cells form mice lacking both bax and bak (but not those 
lacking just one of them) are highly resistant to a wide variety of apopotic stimuli 
(Wei et al., 2001). 
    In order to induce apoptosis, the multidomain proteins need to be activated by 
BH3-only proteins, which are regarded as the most proximal sentinels of the 
apoptotic pathway (Danial and Korsmeyer, 2004). The activation of BH3-only 
proteins is guarded by transcriptional and post-translational mechanisms. Most 
relevant to this study, ER stress leads to CHOP-mediated transcriptional up-
regulation of BIM, which also undergoes dephosphorylation by protein 
phosphatase 2A, thereby reducing proteasomal degradation of BIM (Puthalakath 
et al., 2007). Cleavage and activation of BID by caspase-8 provides a link 
between the extrinsic and intrinsic apoptotic pathways (Li et al., 1998). Activated 
BH3-only proteins directly interact with the pro-apoptotic multidomain BCL-2 
proteins, and the ensuing conformational change of BAX and BAK allows them to 
insert into the outer mitochondrial membrane. The predominant role of the anti-
apoptotic BCL-2 proteins such as BCL-2 and BCL-XL is to sequester BH3-only 
proteins into stable complexes, prohibiting interaction with BAX or BAK (Cheng et 
al., 2001). 
   In summary, the presence of irreparable cellular damage leads to activation of 
BH3-only molecules, leading to their interaction with pro-apoptotic BCL-2 
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members, which undergo conformational changes to oligomerise and form pores 
in the outer mitochondrial membrane. In healthy cells and in a number of 
tumours, anti-apoptotic BCL-2 members prevent the interaction of BH3-only 
proteins with the pro-apoptotic BCL-2 members and thereby block apoptosis. 
 
1.3.3 The mitochondria in apoptosis 
Both the inner and outer mitochondrial membranes play important roles in 
apoptosis. It is generally accepted that mitochondrial outer membrane 
permeabilisation (MOMP) by multidomain pro-apoptotic BCL-2 proteins leads to 
the loss of intermembrane proteins with various apoptotic functions into the 
cytosol (discussed further below), but it is only partly understood how apoptotic 
events involving the inner and outer mitochondrial membranes are linked. Until 
recently, it was believed that apoptotic signals lead to the formation of the 
mitochondrial permeability transition pore, a protein complex that spans the inner 
(IMM) and outer mitochondrial membranes (OMM) and allows for influx of water, 
ions and small molecules into the mitochondrial matrix, resulting in mitochondrial 
swelling and MOMP. However, recent observations indicate that the 
mitochondrial permeability transition pore is involved in necrosis but is not 
required for MOMP (Chipuk et al., 2006).  
    Alternatively, it has been suggested that the IMM contributes to the regulation 
of the OMM by changes in the mitochondrial transmembrane potential ∆ψM. In 
healthy cells, electrons are continuously transferred from NADH and FADH2 to 
molecular oxygen by the mitochondrial OXPHOS (oxidative phosphorylation) 
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system, which consists of the mitochondrial respiratory chain complexes I to IV 
(in addition to cytochrome c and coenzyme Q) that are localized in the inner 
mitochondrial membrane. The energy created during this redox reaction is used 
to import protons into the mitochondria, which creates a proton gradient across 
the inner mitochondrial membrane that is measured as the ∆ψM. The ∆ψM is not 
only required for ATP production but also for other vital cellular functions such as 
protein and metabolite transport. Therefore, loss of ∆ψM is widely considered to 
be an indicator of cell death (Chipuk et al., 2006). When populations of cells in 
which apoptosis has been induced by various insults are investigated, MOMP 
and loss of ∆ψM generally occur in parallel and over a prolonged time, reflecting 
the gradual onset of apoptosis in different cells. Single cell studies have 
demonstrated that cells maintain cytochrome c within the mitochondria for up to 
several hours after the beginning of an apoptotic insult, which is followed by a 
sudden and complete loss of all the cytochrome c from all the mitochondria of a 
cell. This rapid loss of cytochrome c occurs within a few minutes and precedes 
loss of ∆ψM. Furthermore, release of cytochrome c from the mitochondria does 
not depend on the activity of caspases (Goldstein et al., 2005; Goldstein et al., 
2000). The somewhat unexpected finding that the low levels of cytochrome c that 
are dispersed throughout the cell after mitochondrial release are capable of 
maintaining ∆ψM when caspases are inhibited indicated that MOMP and loss of 
∆ψM could be separate events (Waterhouse et al., 2001). Another study that 
used growth factor withdrawal to induce apoptosis in sympathetic neurons also 
found that caspase-inhibition resulted in the maintenance of ∆ψM and cell 
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survival despite cytochrome c release (Deshmukh et al., 2000). The notion that 
MOMP and loss of ∆ψM are separately regulated events was then firmly 
established by the identification of the 75kD subunit of respiratory chain complex 
I as a caspase target (Ricci et al., 2004). Cells expressing a non-cleavable p75 
mutant maintained their ∆ψM and mitochondrial morphology, and loss of plasma 
membrane integrity was delayed, although DNA fragmentation and cytochrome c 
release were unaffected. The current model therefore favors the view that the 
release of cytochrome c during MOMP (which is mediated by BAX and BAK) 
does not itself affect the IMM, but rather leads to the activation of caspases, 
which then cleave p75 (and possibly other as yet unidentified mitochondrial 
targets) to cause a breakdown of the electron transport chain and loss of ∆ψM. 
 
1.3.4 Apoptosome formation 
The mitochondrial release of cytochrome c is the key step in the formation of a 
large protein complex, the apoptosome, that is required for the efficient activation 
of effector caspases that execute apoptosis (Schafer and Kornbluth, 2006). The 
protein Apaf-1 is believed to exist in the cytosol as an inactive monomer that 
contains an N-terminal caspase recruitment domain (CARD) and a C-terminal 
domain that has an auto-inhibitory function by binding to the N-terminus. Upon 
binding of cytochrome c to the C-terminal domain of Apaf-1 and in the presence 
of ATP, a conformational change in Apaf-1 allows for its activation. Apaf-1 and 
cytochrome c form a wheel-like heptameric complex that promotes the interaction 
of Apaf-1 with caspase-9 through their respective CARD domains (Acehan et al., 
 85
2002; Srinivasula et al., 1998; Yu et al., 2005; Zou et al., 1999). This new 
complex is termed the apoptosome, in which the close contact of caspase-9 
molecules to one another allows for formation of caspase-9 dimers, which is 
required for activation of caspase-9. Within the caspase-9 dimers, one of the two 
caspase-9 molecules then undergoes activation and cleaves the effector 
caspases, caspase-3 and caspase-7, to activate them (Boatright et al., 2003; Li 
et al., 1997; Pop et al., 2006).  
    Apoptosome formation and activation of downstream effector caspases is 
regulated at different levels. It has recently been shown that the efficiency of 
caspase-3 activation by caspase-9 depends on recruitment of caspase-9 to the 
apoptosome, which enhances the affinity of caspase-9 for caspase-3 (Yin et al., 
2006). Cytochrome c itself can undergo various modifications that affect its 
activity in the apoptosome. Since treatment of cytochrome c with reducing agents 
abolishes its ability to activate caspases, the redox state of a cell may play an 
important role in regulating apoptosome activity (Schonhoff et al., 2003; Suto et 
al., 2005). This could be of relevance in plasma cells, which are thought to 
experience considerable oxidative stress because of the huge number of 
disulfide bonds that need to be formed when immunoglobulins attain their native 
conformation (Anelli and Sitia, 2008; Masciarelli and Sitia, 2008). In addition, It 
has been shown that nitrosylation of cytochrome c on its heme group is important 
for activation of caspases, and that this process is sensitive to the redox state of 
the cell (Schonhoff et al., 2003). In line with this observation is the finding that the 
heme group is required for caspase activation by cytochrome c. Only the holo-
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form of cytochrome c that is formed within the mitochondria by addition of a 
heme can activate caspases, but not its heme-free apo-form (Martin et al., 2004). 
Another level of regulation of apoptosome formation is provided by cellular ATP 
levels. In the absence of sufficient amounts of ATP, Apaf-1 still oligomerizes but 
fails to activate caspases (Kim et al., 2005). Recent work has shown that 
catalytically active apoptosomes also contain caspase-3 and X-linked inhibitor of 
apoptosis (XIAP), a member of the IAP family of proteins (Bratton et al., 2001; 
Hill et al., 2004; Twiddy et al., 2004). This was a surprising finding since XIAP 
can bind and inhibit caspase-3 and caspase-9. Since purified highly active 
apoptosome complexes were found to contain Smac/DIABLO and Omi/HtrA2, 
proteins that are released from the mitochondria in parallel with cytochrome c 
and antagonize IAPs, it has been suggested that caspase-3 may first be 
recruited to the apoptosome by XIAP, which is then displaced by Smac/DIABLO 
and Omi/HtrA2 to allow for caspase-3 activation (Hill et al., 2004; Twiddy et al., 
2004). 
 
1.3.5 Effector caspases  
Caspase-3, caspase-7, and caspase-6 are commonly regarded as effector (or 
executioner) caspases that cleave a huge number of cellular targets to execute 
cell death. Caspase-6 is the least well studied and classed as an effector 
caspases mainly because of structural similarities with the other two executioners 
(Boatright and Salvesen, 2003).  
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    Activation of effector and initiator caspases differs substantially. All apoptotic 
caspases (some caspases, such as caspase-1 and caspase-11, appear not to 
participate in apoptosis but act as cytokine activators (Martinon and Tschopp, 
2007)) need to be kept in a quiescent state in healthy cells in order to prevent cell 
death. Therefore, caspases are stored in the cytosol as inactive precursors that 
are often termed pro-caspases. Structural analyses have shown that all active 
caspases are dimers of catalytic units that each consist of one small and one 
large subunit. The subunits are generated by cleavage of the intact caspase at a 
linker region between the small and large subunit, which has led to the 
assumption that caspases are activated by proteolytic cleavage at the linker . 
However, as already discussed above for caspase-8 and caspase-9, recent data 
provide strong evidence that initiator caspases are activated by dimerisation of 
inactive monomers which is generally followed by cleavage, possibly to stabilize 
the complex (Boatright and Salvesen, 2003). In contrast, the effector caspases 
exist in the cytosol as dimers that are inactive and require cleavage at the linker 
to become activated (Fuentes-Prior and Salvesen, 2004 ). This proteolytic 
processing is carried out by an initiator caspase or results from auto-activation 
(Boatright and Salvesen, 2003; Porter, 2006). Activating cleavage of caspase-3, 
the major apoptotic executioner, occurs at two sites: at Asp(D)28 to remove an N-
terminal pro-domain from the large p17 subunit, which may contribute to 
activation, and more critically at D175 between the large and small p12 subunit 
(Denault and Salvesen, 2003; Meergans et al., 2000). It is of note that the 
caspase-3 pro-enzyme has substantial catalytic potential for self-cleavage, but is 
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at the same time remarkably resistant to auto-activation in vitro and in vivo. This 
was shown to be due to the presence of a DDD179-181 repeat that is located near 
the junction between the small and large subunit (Roy et al., 2001). Removal of 
this triple-D repeat and acidification, which occurs during apoptosis, made 
caspase-3 substantially more susceptible to auto-cleavage and cleavage by 
caspase-9 (Roy et al., 2001). A recently identified small molecule, PAC-1, has 
been shown to specifically target the DDD “safety-catch” and induce apoptosis in 
vitro and in vivo (Putt et al., 2006). Importantly, caspase-7, which contains only 
two of the three aspartate residues, is ten times more resistant to activation by 
PAC-1 (Putt et al., 2006).  
 
1.3.6 Caspase inhibition and caspase-independent cell death 
Caspases can be inhibited pharmacologically with peptides that are preferred 
substrates for individual caspases. These short peptides act by competition and 
can inhibit individual caspases more or less specifically. As an example, the 
peptide DEVD inhibits caspase-3 but may have effect on caspase-6 and 
caspase-8 as well. The peptides are usually modified chemically to confer good 
cell permeability, which is often done by adding a flouromethylketone (fmk) 
moiety. For general caspase inhibition, the trimer peptide VAD has been used 
extensively. Benzyloxycarbonyl (z)-VADfmk inhibits caspases irreversibly at 
concentrations of less than 150nM in cells, but the concentration required to 
inhibit caspase-2 is about 1,000 times higher compared with caspase-1, at least 
in vitro (Chipuk and Green, 2005). 
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    Despite the critical role for caspases in the execution of apoptosis, it is now 
accepted that programmed cell death can occur in the absence of caspase 
activity. However, the forms of programmed cell death that do not involve 
caspases are rare, seem to occur only under particular pathological or 
experimental conditions such as mitotic catastrophe or caspase inhibition, and 
have a distinctly different appearance from apoptosis, notably lacking the typical 
chromatin condensation. So far, physiological developmentally regulated 
caspase-independent cell death has not been definitively demonstrated (Broker 
et al., 2005; Chautan et al., 1999; Chipuk and Green, 2005). In the few described 
form of seemingly caspase-independent cell death, mitochondrial proteins have 
been implicated to play a role in the execution of cell death. They include 
apoptosis-inducing factor (AiF) and Endonuclease G, which have both been 
shown to contribute particularly to nuclear apoptotic events, although the 
mechanisms by which they exert their apoptotic function are poorly understood 
(Bahi et al., 2006; Sanges et al., 2006). 
     The generation of mice that lack specific caspases has provided interesting 
insights into the role of caspases. While mice lacking caspase-6 develop 
normally, most mice deficient in caspase-9 die before or shortly after birth with 
severe brain abnormalities due to decreased caspase-3 activation and apoptosis 
(Kuida et al., 1998; Zheng et al., 1999). Caspase-8-/- mice die during 
embryogenesis with a variety of developmental abnormalities (Varfolomeev et al., 
1998). While caspase-7-/- mice develop normally, the majority of mice deficient in 
caspase-3 die shortly after birth with substantial brain malformation (Kuida et al., 
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1996). Interestingly, it has been reported that the B cells of caspase-3-/- mice that 
survive until adulthood are equally responsive to apoptotic stimuli as B cells from 
wild-type mice and are hyperproliferative, which was ascribed to the cleavage of 
p21, a cyclin-dependent kinase (CDK) inhibitor (Woo et al., 2003). Mice double-
deficient for caspase-3 and caspase-7 die immediately after birth with cardiac 
malformations, and caspase-3-/-/caspase7-/- mouse embryonic fibroblasts (MEFs) 
are highly resistant to mitochondrial and DR-mediated apoptosis  (Lakhani et al., 
2006). It is important to note that the lack of certain caspases can led to 
compensatory activation of others so that similar amounts of cell death occur 
(Zheng et al., 2000). It is of particular relevance to this study that caspase-3-/-
/caspase7-/- double-knockout MEFs (and MEFs deficient in caspase-9) are highly 
resistant to ER stressors such as tunicamycin or brefeldin A. However, MEFs 
lacking either caspase-3 or caspase-7 exhibit similar ER stress-induced 
apoptosis rates to each other and to wild-type MEFs, indicating that functional 
caspase-3 and caspase-7 can largely compensate for the loss of the other in this 
situation (Masud et al., 2007). 
 
1.3.7 Apoptotic phagocytosis 
The non-inflammatory nature of apoptotic cell death is to a large extent due to 
the uptake of the dying cell and its fragments by phagocytes. Mammalian cells 
have an asymmetrical distribution of phospholipids in the two layers of the 
plasma membrane. The phospholipid, phosphatidylserine (PS), is predominantly 
found in the inner leaflet in healthy cells but “flipped” to the outer leaflet in cells 
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undergoing apoptosis where it acts as the most important “eat-me signal” to 
phagocytes (Henson et al., 2001). It was initially identified on lymphocytes 
undergoing programmed cell death, and phagocytic up-take of apoptotic 
lymphocytes was found to be inhibited in a dose-dependent manner by the 
presence of liposomes that contained PS, but not by liposomes containing other 
anionic phospholipids (Fadok et al., 1992). Although other cell surface molecules 
such as specific carbohydrates appear to contribute to the binding of apoptotic 
cells to phagocytes, phagocytic up-take of apoptotic cells that specifically lack PS 
is minimal and can be repleted by reconstitution of outer leaflets with PS (Fadok 
et al., 2001). The importance of externalized PS is further underscored by the 
observation that ectopic expression of a PS receptor, which is normally found on 
macrophages, fibroblasts, and epithelial cells, enables B and T lymphocytes to 
engulf apoptotic cells (Fadok et al., 2000). Furthermore, PS on apoptotic cells 
stimulates the efflux of cholesterol from phagocytes that is required to 
compensate for the uptake of lipids subsequent to engulfment of apoptotic cells 
(Kiss et al., 2006). The process of PS exposure on the outer membrane leaflet is 
believed to occur downstream of cytochrome c release, but it is still unclear 
whether caspases are directly involved in PS exposure (Balasubramanian et al., 
2007). PS exposure can be measured by staining with fluorescently labeled 
Annexin V, which binds specifically to PS, allowing for flow cytometric analysis to 
determine the proportion of apoptotic cells. PS exposure in apoptotic cells usually 
precedes more dramatic membrane changes that lead to the cellular up-take of 
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non-vital dyes such as ethidium bromide or propidium iodide (Koopman et al., 
1994; van Engeland et al., 1998). 
 
1.3.8 Apoptotic DNA degradation 
Fragmentation and condensation of nuclei is a hallmark of apoptosis. Shortly 
after the first description of apoptosis by Kerr (Kerr et al., 1972), it was observed 
that thymocytes undergoing glucocorticoid-induced cell death released 
fragmented chromatin from their nuclei, and that the DNA in the chromatin was 
double-stranded and consisted of multimers of about 180bp – approximately the 
length of DNA that is contained in one nucleosome (Wyllie, 1980). It was 
therefore postulated that an apoptosis-specific nuclease cleaves DNA at 
internucleosomal sequences (Nagata et al., 2003). When the DNA of apoptotic 
cells is separated by gel electrophoresis, these DNA fragments form the “DNA 
ladder”, which has since then been regarded as proof of apoptotic cell death. It 
was subsequently discovered that prior to or in the absence of internucleosomal 
DNA cleavage, DNA is cleaved at A/T-rich sequences into large fragments of 50-
300kb (Oberhammer et al., 1993).  
    The search for the responsible DNase first led to the identification of DNA 
fragmentation factor (DFF), a heterodimer of 40kd and 45kd subunits (DFF40 
and DFF45). DFF45 was found to induce nuclear fragmentation when cleaved by 
caspase-3 in vitro and in vivo (Liu et al., 1997). Further studies then identified 
DFF40 as a DNase that is inhibited by DFF45. Cleavage of DFF45 by caspase-3 
releases DFF40 to bind to and cleave DNA double strands. Therefore, DFF40 is 
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commonly named Caspase-activated DNase (CAD), and DFF45 is frequently 
called Inhibitor of CAD (ICAD) (Enari et al., 1998; Enari et al., 1996; Liu et al., 
1998; Liu et al., 1999; Mukae et al., 1998). CAD preferentially generates DNA 
fragments with blunt ends that carry a 5’-phosphate and a 3’-hydroxyl group 
(Widlak et al., 2000). The 3’-hydroxyl group of apoptotic DNA serves as a 
substrate for terminal deoxynucleotidyl transferase (TdT), which adds dUTP to 
the OH-group. The incorporation of fluorescein-labelled dUTP (or biotinylated 
dUTP for colorimetric assays) by TdT into DNA breaks of apoptotic cells forms 
the basis of the TdT-mediated dUTP Nick-End Labeling (TUNEL) assay, which 
allows for the detection of apoptotic cells by flow cytometry or microscopy  (Ben-
Sasson et al., 1995; Gavrieli et al., 1992). Human and murine ICAD contain two 
caspase cleavage sites, which have to be cleaved by caspase-3 in order to 
mediate DNA fragmentation (Nagata et al., 2003). 
    ICAD assists in the correct folding of CAD by forming a complex with newly 
synthesized CAD and is thus required for the generation of functional CAD. Thus, 
cells lacking ICAD or CAD are generally resistant to DNA fragmentation caused 
by various apoptotic stimuli. However, the cells still undergo apoptosis, indicating 
that DNA fragmentation by CAD is not required for cell death itself. This view is 
supported by observations that mice lacking ICAD or CAD do not show any 
adverse phenotypes or accumulate undigested nuclei in their tissues (Danial and 
Korsmeyer, 2004; Nagata et al., 2003; Sakahira and Nagata, 2002). Mice 
expressing caspase-resistant ICAD were found to have similar numbers of 
TUNEL-positive cells in their tissues, which were all located within macrophages. 
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When widespread thymocyte apoptosis was induced by gamma irradiation, 
similar numbers of dead cells were observed in wild-type and mutant mice, which 
were mostly outside macrophages. Interestingly, only mice with functional ICAD 
showed an substantial increase in TUNEL positive cells (McIlroy et al., 2000). 
This led to the proposal that physiological amounts of apoptosis in a tissue do not 
require ICAD/CAD for DNA degradation, which can take place in macrophages. 
However, when massive cell death occurs, the capacity of macrophages to 
engulf dead cells is insufficient and the DNA will only be digested if ICAD and 
CAD are functional. The ability of macrophages to digest DNA is largely due to 
DNase II, which generates DNA breaks with a 3’-phosphate and a 5’-hydroxyl 
group. Since lysosomes also contain phosphatases that may remove the 3’-
phosphate, TUNEL-positivity may still occur on DNA digested in lysosomes 
(Nagata et al., 2003). Mice lacking DNase II die in utero, and the embryos 
accumulate undigested DNA (Krieser et al., 2002). In Drosophila, lack of 
functional DNase II but not ICAD/CAD results in the accumulation of undigested 
DNA in vivo, which is accompanied by the activation of genes involved in innate 
immunity and enhanced by additional loss of functional ICAD/CAD (Mukae et al., 
2002). Thus, it appears that ICAD/CAD-mediated DNA degradation contributes to 
the appropriate execution of apoptosis, but that DNA degradation by DNase II in 
macrophages constitutes the more important pathway whose inactivation may 
result in pathological immune reactions. 
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1.3.9 ER stress-induced apoptosis 
When the UPR fails to restore homeostasis in the ER, apoptosis is induced via 
several pathways that may differ between cell types and the type of ER stress. 
One of the major signaling pathways in ER stress-induced apoptosis involves 
CHOP, a transcription factor that is induced by PERK (Harding et al., 2000). The 
first and strongest indication that CHOP has a major role in ER stress induced 
apoptosis came from the observation that embryonic fibroblasts from mice 
deficient in CHOP are resistant to ER stress-induced apoptosis (Zinszner et al., 
1998). The exact mechanisms by which CHOP functions are unclear, but it up-
regulates a number of genes that may amplify the apoptotic signal, i.e. the death 
receptor DR5 (Yamaguchi and Wang, 2004), and growth arrest and DNA 
damage 34 (GADD34). GADD34 encodes for a subunit of a protein phosphatase 
that enhances dephosphorylation of eIF2α – thereby promoting protein 
translation, which is predicted to further increase ER stress (Marciniak et al., 
2004; Novoa et al., 2001). CHOP also contributes to contributes to a pro-
apoptotic balance in the cell by downregulating BCL2 (McCullough et al., 2001). 
Its role in plasma cell apoptosis is not known, but Cenci and co-workers 
observed that CHOP levels increase during plasmacytic differentiation of I.29µ+ 
cells, but sharply decrease again when widespread apoptosis occurs in 
differentiated plasmacytic I.29µ+ (Cenci et al., 2006), arguing against a 
predominant role of CHOP in plasma cell apoptosis.   
BCL-2 family proteins also play important roles in ER stress-induced apoptosis. 
ER stress leads to translocation of the BH3-only protein Bim to the ER and 
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activation of caspase-12, which is believed to act specifically during ER stress-
induced apoptosis (discussed further below). Targeting of Bim to the ER was 
found to be sufficient to induce apoptosis and is inhibited by the anti-apoptotic 
BCL-XL (Morishima et al., 2004). This finding is compatible with a recent report 
demonstrating that Bim is required for ER stress-induced apoptosis and is of 
particular interest for this study, since Bim deficient mice accumulate plasma 
cells and develop an autoimmune syndrome (Bouillet et al., 1999; Puthalakath et 
al., 2007). ER stress leads to the oligomerisation of the multidomain BCL-2 
proteins BAX and BAK at the ER membrane, resulting in the release of large 
amounts of Ca2+ into the cytosol. This is believed to cause activation of the 
protease, m-calpain, which then cleaves and activates caspase-12. Ca2+  
released from the ER can also induce MOMP and loss of the mitochondrial 
transmembrane potential ∆ψM, since these events are reduced upon Ca2+ 
chelation (Deniaud et al., 2008). Translocation of BAX to the ER has been 
observed in human plasma cells (Pelletier et al., 2006).  
    Activation of IRE1 during the UPR leads to activation of c-Jun NH2-terminal 
kinases (JNKs) via TNF receptor-associated factor 2 (TRAF2) and apoptosis 
signaling-related kinase 1 (ASK1). JNKs are a family of kinases that can be 
phosphorylated and thus activated by a plethora of signals. Activated JNKs exert 
their biologic effects by phosphorylation of transcription factors such as c-Jun 
and ATF2 (Gupta et al., 1996; Gupta et al., 1995; Hibi et al., 1993), and are 
required for apoptosis induced by a variety of signals (Liu et al., 2004; Sabapathy 
et al., 1999; Sabapathy et al., 2001). ER stress or overexpression of IRE1 induce 
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JNKs activation, and IRE1-/- fibroblasts are impaired in their capacity to activate 
JNKs in response to ER stress (Urano et al., 2000), and ASK1-/- cells are 
partially resistant to ER stress-induced apoptosis (Nishitoh et al., 2002). The role 
of JNKs in plasma cell apoptosis has not been directly investigated. 
 
1.3.10 Caspase-12 
Murine caspase-12 is a ubiquitously expressed caspase that shares high 
homology particularly with caspase-1 and caspase-11 (Nakagawa et al., 2000). 
Two research groups have so far developed mice deficient in caspase-12, and 
the observations made in these mice have caused considerable debate about the 
role of caspase-12 in apoptosis. Cells from caspase-12-/- mice developed by 
Yuan and colleagues were found to be partly resistant to ER stress-induced 
apoptosis, but not to other cellular insults (Nakagawa et al., 2000). The same 
group observed that neural cells from caspase-12-/- mice were resistant to 
amyloidß-induced apoptosis, which is largely due to ER stress. Consistent with a 
role of caspase-12 in ER stress-induced apoptosis, the investigators found that 
overexpression of caspase-12 induces cell death, which can be partly blocked by 
BCL-XL. Furthermore, caspase-12 has been shown to be predominantly 
associated with the ER and to undergo cleavage in response to agents that 
cause ER stress, but not during apoptosis caused by other insults (Nakagawa et 
al., 2000). These observations on a close link between caspase-12 and ER 
stress-induced apoptosis are supported by a number of other studies. Hetz and 
colleagues found that caspase-12 mediates prion protein-induced neural cell 
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death and observed activation of caspase-12 in murine neural cells infected with 
scrapie and human brains affected by Creutzfeld Jacob Disease, which are 
linked to ER stress (Hetz et al., 2003). Sanges and co-workers showed that 
caspase-12 contributes to apoptosis of rod photoreceptors in a mouse model of 
retinitis pigmentosa, which is linked to ER stress (Sanges et al., 2006). Another 
study demonstrated that TRAF2 interacts with caspase-12 and promotes its 
activation in response to ER stress (Yoneda et al., 2001), while Rao and 
colleagues observed that ER stress-induced cleavage of caspase-12 is mediated 
by caspase-7 (Rao et al., 2001). Using a cell free system, the same group found 
that caspase-12 contributes to the Apaf-1-independent activation of effector 
caspases by microsomes isolated from ER stressed cells (Rao et al., 2002). 
    Recently, Saleh and co-workers developed another caspase-12-/- mouse 
(Saleh et al., 2006). Surprisingly, they did not observe a decrease in the rate of 
ER stress-induced apoptosis in embryonic fibroblasts from the knock-out mice 
compared to wild-type mice. Instead, they identified an anti-inflammatory role for 
caspase-12, which inhibits the production of cytokines (IL-1ß, IL-18, and IFNγ) in 
splenocytes in response to bacterial sepsis. Mechanistically, it was found that 
caspase-12 exerts this function by inhibiting the inflammatory caspase, caspase-
1, without a requirement for the proteolytic activity of caspase-12. The same 
group observed that caspase-12 dampens mucosal immune responses to enteric 
pathogens by binding to and inhibiting a member of the pro-inflammatory Nod 
complex (LeBlanc et al., 2008). In this respect it is of note that in most humans, a 
single nucleotide polymorphism results in the synthesis of either a truncated 
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(Csp12-S) or a full-length (Csp12-L) caspase-12 protein. Of all humans, only 
20% of individuals of African origin translate Csp12-L, which is associated with 
an increased risk for sepsis, providing further evidence for an anti-inflammatory 
role of caspase-12 (Saleh et al., 2004). A recent investigation found that 
caspase-12 is proteolytically competent to induce its own maturation by auto-
cleavage in cis and trans. This auto-proteolysis is limited to Asparagin319 within 
the sequence ATAD319T that is located between the large and small subunit. 
Caspase-12 was unable to cleave any other peptide substrates in vitro, with a 
proteolytic efficiency that is substantially lower than that of most other caspases 
(for their preferential target). It was therefore proposed that caspase-12 might 
inhibit an overwhelming caspase-1 (or Nod) -mediated inflammatory reaction at 
the onset of the immune response, which is then self-terminated by caspase-12 
auto-cleavage (Roy et al., 2008).  
    In summary, several lines of evidence suggest that caspase-12 is involved in 
ER stress apoptosis, whereas other investigations draw a picture that is more in 
favor of an immuno-modulatory role of caspase-12. 
 
1.4 Aim of the project 
Plasma cells play important roles in both the immediate immune response and in 
long-term immunological memory. Auto-antibodies produced by plasma cells 
contribute to the pathogenesis of auto-immune diseases, and malignant 
transformation of plasma cells results in incurable neoplastic diseases such as 
multiple myeloma. A thorough understanding of the mechanisms that regulate 
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the life-span of plasma cells may therefore lead to the development of novel 
therapeutic approaches that target the survival of plasma cells.  
    Plasma cells also serve as a model system to study the regulation of survival 
in cells that experience secretory challenge. Plasma cells require activation of the 
ER stress response during terminal differentiation and cannot use all the 
mechanisms that other cells employ to cope with secretory challenge (i.e. 
inhibition of protein translation through activation of PERK). They may therefore 
provide insight into hitherto unknown alternative mechanisms that a cell can use 
to avoid ER stress-induced cell death. Such knowledge could provide a platform 
for the development of therapeutic strategies for diseases that have been linked 
to ER stress-induced apoptosis, such as diabetes. 
    As outlined above, the UPR becomes activated during early stages of plasma 
cell development. Therefore, the secretion of vast amounts immunoglobulins in 
differentiated plasma may lead to an imbalance between secretory load and 
capacity that could be incompatible with cell survival. The goal of this project was 
to analyse whether excessive ER stress contributes to the termination of the 
plasma cell life span. It was also investigated whether developmentally regulated 
inhibition of apoptotic effector caspases, the major executioners of programmed 
cell death, could serve as an intrinsic modulator of the timing of plasma cell 
apoptosis. In addition, the role of caspase-12, a putative ER initiator caspase, in 
plasma cell apoptosis was studied. 
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2      Materials and Methods 
 
2.1 Cell culture and selection 
 
2.1.1  In vitro differentiated plasma cells 
Mouse plasma cells were differentiated in vitro and purified as previously described 
(Sabbattini et al., 2007). In detail, spleens of approximately 8-week-old CBAB6F1 
mice were homogenised by passing them through cell strainers, and single cell 
suspensions were resuspended in approximately 5mL RPMI1640 medium (Sigma) per 
spleen, which was supplemented with 15% fetal calf serum (FCS; Sigma) 2mM 
glutamine (Sigma), 50µM 2-mercaptoethanol (Sigma), and 50 µg/ml gentamycin 
(Sigma). Typically, 5 spleens were used for each in vitro differentiation. 12.5ml of the 
cell suspension were carefully layered over 2ml of Ficoll Paque Plus (Amersham) and 
centrifuged at 2000rpm for 10min at room temperature with no brake applied at the 
end of the centrifugation. Live mononuclear cells at the interface between medium and 
the Ficoll Paque Plus were carefully aspirated and transferred into supplemented 
RPMI1640 at a density of 4x105 cells/ml. Plasma cell differentiation was induced by 
adding 25 µg/ml LPS (Sigma), 5ng/ml IL-5, 5ng/ml IL-6, and 10ng/ml IL-10 (all from 
R&D Systems, dissolved in PBS with 0.1% BSA, and stored at -20ºC). Typically, the 
mononuclear cells from 5 spleens amounted to 1x108 cells in total and were put into 
approximately 250ml of medium split between 2-3 flat-bottom 175cm2 culture flasks 
with vented caps (Nunc). Cultures were performed at 37ºC in 5% CO2, and cells split 
1:2 with addition of fresh medium with LPS and cytokines after 3 days of culture, when 
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cell numbers had doubled. After seven days in culture, cells were pelleted and then 
resuspended in approximately 5ml of medium per spleen used. Live cells were purified 
by density gradient centrifugation with Ficoll Paque Plus as described above and 
resuspended in Hank’s Salt Solution (HSS; Sigma) supplemented with 0.1% bovine 
serum albumin (BSA; Sigma) at a concentration of 106 cells per 100µl. Typically, 
approximately 2x108 cells were recovered at this point when 5 spleens were used. Fc-
receptors were blocked with 5µg/ml anti-CD16 antibody (BD Bioscience Pharmingen) 
and 5% goat serum (Vectalabs) for 20 minutes on ice. Cells were pelleted, 
resuspended in HSS supplemented with 0.1 % BSA, and incubated for 15 minutes 
with gentle agitation at 40C with 12.5 µg/ml anti-Syndecan1-biotin antibody (BD 
Bioscience Pharmingen) conjugated to 1x108 CELLection Biotin binder magnetic 
beads (Dynal) per 2.5x107 cells to isolate cells expressing the plasma cell marker 
Syndecan-1 (CD138). Cells were purified by placing the tube containing the cell 
suspension on a magnet on ice for 1min. The supernatant was removed and 
discarded, and the cells washed with ice-cold RPMI1640 supplemented with 1% FCS. 
Magnetic selection and washing was repeated twice and the cells resuspended in 
400µL RPMI1640 with 1% FCS pre-warmed to 37oC. This purification step typically 
resulted in the recovery of approximately 2.5x107 cells per 5 spleens used. A volume 
of 5µl of Release Buffer (Dynal) containing DNase I at a concentration of 62U/µl was 
added per 1x107 cells and incubated with gentle agitation at room temperature for 
15min to cleave the DNA linker between the magnetic beads and the Streptavidin-
conjucagetd anti-Syndecan antibody. Cells were flushed vigorously eight times 
through a 200µl pipette tip for further disruption of binding and the beads removed 
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magnetically with three washes in RPMI supplemented with 1% FCS. Cells in the 
pooled supernatant were pelleted, resuspended in RPMI1640 with 15% FCS and 
incubated for 15 minutes with gentle agitation at 40C with 100µl of anti-B220 
conjugated magnetic beads (Dynal) to remove B220+ plasmablasts. Cells suspensions 
were again placed on a magnet on ice for 1min and this time the supernatant was 
collected. This negative selection step depleted approximately 50-70% of the cells, 
typically resulting in the recovery of 1-1.5x107 plasma cells from 5 spleens. The 
plasma cells were then cultured in RPMI with supplements and cytokines but without 
LPS as described above at a concentration of 6-10x105 cells/ml. 
 
2.1.2 Primary plasma cells 
In order to obtain a sufficient number of primary ex vivo plasma cells, mice were 
immunized by intraperitoneal injection with 60 µg LPS. After 8-10 days, the mice were 
sacrificed. Spleens were homogenised and CD138+ plasma cells and plasmablasts 
isolated using magnetic beads as described in chapter 2.1.1, omitting the B220 
negative selection, which resulted in approximately 2x106  CD138+ cells per 10 
spleens used. The cells were dissolved in medium supplemented with FCS, 
glutamine, 2-mercaptoethanol, gentamycin, and cytokines (IL-5, IL-6, IL-10) as 
described in chapter 2.1.1.  
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2.1.3 Primary resting B cells  
Primary resting B cell were isolated by from spleens as described previously 
(Sabbattini et al., 2001). One spleen of an approximately 8-week-old CBAB6F1mouse 
was homogenised, the cells resuspended in 10ml RPMI1640 medium supplemented 
as described in chapter 2.1, and live mononuclear cells purified by Ficoll Paque 
density gradient centrifugation. The cells were washed once with supplemented 
RPMI1640 medium and resuspended in 2ml of HSS supplemented with 0.1% BSA. 
Fc-receptors are blocked with 5µg/ml anti-CD16 antibody and 5% goat serum on ice 
for 15 minutes. Cells were pelleted, resuspended in 2ml HSS supplemented with 0.1% 
BSA, and incubated with 10µl biotinylated anti-CD43 antibody (Dynal) for 15 minutes 
with gentle agitation at 40C. CD43 is sialoglycoprotein expressed on various 
leukocytes (granulocytes, monocytes/macrophages, T-lymphocytes, activated B cells, 
and plasma cells) but not on resting naïve B cells (Bjorck et al., 1991; Fukuda, 1991). 
After washing the cells twice with PBS supplemented with 0.1% BSA to remove 
unbound anti-CD43, the cells were resuspended in 3ml HSS supplemented with 0.1% 
BSA and incubated with 100ul of CELLection Biotin binder magnetic beads (Dynal, 
4x108 beads/ml) for 15 minutes with gentle agitation at 40C. CD43-positive cells were 
removed by magnetic selection, the remaining CD43-negative cells pelleted, and 
10x106 resuspended in supplemented RPMI1640 medium at 5x105 cells/ml.  
 
2.1.4 I.29µ+ cells 
The murine lymphoma line I.29µ+ (a gift from Roberto Sitia, San Raffaele Scientific 
Institute, Milan, Italy) was cultured in RPMI1640 supplemented with 7.5% FCS, 2mM 
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glutamine, 50µM 2-mercaptoethanol, and 50 µg/ml gentamycin. Plasmacytic 
differentiation was carried out as previously described by adding LPS (Cenci et al., 
2006; van Anken et al., 2003). LPS was used at 20µg/ml on the first day (day 0) of 
activation and was added at a concentration of 10µg/ml in the fresh additional medium 
on day +1. Cell density was maintained at 3-10x105 cells/ml for both LPS-stimulated 
and untreated cells by splitting the cultures daily. 
 
2.1.5 Activated B cells 
Mononuclear single cell suspensions of total live splenic cells were prepared as 
described above from homogenised spleens, and resuspended in RPMI1640 
supplemented with 15% FCS, 2mM glutamine, 50µM 2-mercaptoethanol, and 50 
µg/ml gentamycin at a density of 4x105 cells/ml. LPS was added at a concentration of 
10µg/ml to activate B cells, and all surviving cells (T cells undergo apoptosis in culture 
without appropriate stimulation after 1-2 days) used after 3-4 days.  
 
2.1.6 Human myeloma cell lines 
The human myeloma cell lines OPM-2 and RPMI8226 (provided by Junia Melo, 
Imperial College, London, UK) were maintained in RPMI1640 supplemented with 10% 
FCS, 2mM glutamine and 50µM 2-mercaptoethanol. Cell density was kept at 4-8x105 
cells/ml.  
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2.1.7 Mouse embryonic fibroblasts 
The caspase-3 and caspase-7 double-knockout (-/-) and heterozygote (+/-) embryonic 
fibroblasts were a gift from Richard Flavell and have been described before (Masud et 
al, 2007). Cells were grown in DMEM medium and supplemented with 10% FCS. 
 
2.2 Chemicals and inhibitors 
 
Tunicamycin (Calbiochem), PAC-1 (Cayman), Etoposide (Sigma), zVADfmk (Caspase 
Inhibitor I, Calbiochem), and zATADfmk (Caspase-12 Inhibitor, Biovision) were 
dissolved in DMSO (Sigma) and stored in single-use aliquots at -20ºC. Dithiotreitol 
(DTT, Sigma) was dissolved in water and stored at -20ºC. Arsenic trioxide (Sigma) 
was dissolved at a concentration of 0.33M in 1M NaOH, heated to 95°C for 5 minutes, 
and then stored in single-use aliquots at -20°C.  
 
2.3 Apoptosis assays 
 
2.3.1 Apoptotic cell membrane alterations 
Exposure of phosphatidylserine on the outer leaflet of the cell membrane and loss of 
cell membrane integrity were assessed by double-staining with Annexin V-fluorescein 
isothiocyanate (Annexin V-FITC, BD Pharmingen) and propidium iodide (PI, BD 
Pharmingen), respectively. 1x106 cells were pelleted, washed once with ice-old PBS, 
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and resuspended in 95µL Annexin V-Binding Buffer (10mM Hepes/NaOH ph7.4, 
0.14M NaCl, 2.5mM CaCl2; BD Biosciences) plus 2.5 µL each of the Annexin V-FITC 
and PI Staining Solutions contained in the Annexin V-FITC Apoptosis Detection Kit I 
(BD Biosciences). After incubation in the dark at room temperature for 15min, 400µL 
of Binding Buffer were added and the samples were analysed immediately on a 
FACScan or FACSCalibur flow cytometer (Becton Dickinson) in the FL-1 (green, 
488nm, for FITC) and FL-2 (orange, 575nm, for PI) channels, using Cell Quest 
software (Becton Dickinson). A total of 10,000 cells were analysed per sample. Cells 
that were both Annexin V-FITC and PI negative were scored as live, and cells that 
were both Annexin V-FITC and PI positive were scored as dead. 
 
2.3.2 Mitochondrial transmembrane potential ∆ψM 
Apoptotic loss of ∆ψm was analysed using the MitoCaptureTM Apoptosis Detection Kit 
(Calbiochem) according to the manufacturer’s instructions with minor modifications. 
The kit makes use of a cationic dye that accumulates and aggregates in the 
mitochondria of healthy cells, emitting red fluorescence. In apoptotic cells that have 
lost their ∆ψm, the dye cannot enter the mitochondria and remains in the cytosol in its 
monomeric form, which emits green fluorescence (Calbiochem User Protocol 475866 
Rev. 11-December-06 RFH). Typically, 7.5x105 cells were pelleted by brief 
centrifugation and resuspended in a 2ml Eppendorf tube in 750µL MitoCaptureTM 
Incubation Buffer pre-warmed to 37ºC. After addition of 75µL MitoCaptureTM Reagent, 
the open tubes were incubated at 37ºC in 5% CO2 for 30min. The cells were pelleted, 
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re-suspended in 750µL of Incubation Buffer, and analysed on a FACScan or 
FACSCalibur flow cytometer using Cell Quest software.  
 
2.3.3 Nuclear apoptosis (chromatin condensation and TUNEL assay) 
Up to 1x106 cells were immobilized on cover slips coated with Poly-L-Lysine (Sigma) 
for 5 minutes and fixed with 2% paraformaldehyde in PBS for 10 minutes at room 
temperature. After 3 washes in PBS for 3min each, cells were incubated 50mM NH4Cl 
and washed again 3 times in PBS. Cells were then permeabilised with 0.4% Triton X 
in PBS for 10 minutes at room temperature and washed in PBS 3 times. Cells were 
then treated with reagents from the DeadEndTM Fluorometric TUNEL System 
(Promega) according to the manufacturer’s instructions (Technical Bulletin) with minor 
modifications. Slides were covered with 100µL of Equilibration Buffer at room 
temperature for 5min. During equilibration, 45µL of Equilibration Buffer plus 5µL of 
Nucleotide Mix and 1µL of rTdT were pipeted onto clean parafilm. The parafilm was 
placed onto Whatman paper that had been sprinkled with dH2O and placed inside a 
large petri dish wrapped with household foil for keeping samples humidified and 
protected from light. Then, the cover slips were placed upside-down onto the drop of 
reaction mixture and incubated at 37ºC for 60min. The cover slips were then carefully 
lifted and incubated in 2xSSC buffer (DeadEndTM Fluorometric TUNEL System, 
Promega) at room temperature for 15min to terminate the incorporation of fluorescein-
12-UTP(a). After 3 washes in PBS, cover slips were placed upside-down onto 10 µL of 
4',6-diamidino-2-phenylindole (DAPI; Sigma) in Vectashield (Vectalabs; 10µg/ml) and 
the edges of the coverslip sealed with standard nail polish. Slides were stored in the 
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dark at 4ºC until analysis on a Leica SP5 confocal microscope using Leica Confocal 
Software. For analysis of the proportion of cells displaying TUNEL-positive nuclei or 
apoptotic chromatin condensation, cells were counted in several randomly chosen 
fields per experiment at 63x magnification.  
 
 
2.4 Protein analysis 
 
2.4.1 Whole cell protein extracts 
Whole cell lysates were prepared by washing cells once in ice-cold PBS and 
subsequent incubation for 5 minutes on ice in 50mM Hepes ph 7.5, 50mM NaF, 5mM 
NaPyrophosphate, 1mM EDTA, 1mM DTT, 10%glycerol, 1% Triton, and Complete 
EDTA-free Protease Inhibitor Cocktail (Roche). 100µL of the lysis buffer were used 
per 5x106 cells. After 10 minutes of centrifugation at 12,000g at 4°C, the supernatant 
was recovered and aliquots stored at -80ºC until further use.   
 
2.4.2 Cytosolic protein extracts 
To separate the cytosolic fraction from other cellular components, cells were 
permeabilised for 5 minutes in 0.025% digitonin dissolved in HMKEE buffer (20 mM 
Hepes, pH 7.2, 5 mM MgCl2, 10 mM KCl, 1 mM EDTA, and 1 mM EGTA ) with 250 
mM sucrose and Complete EDTA-free Protease Inhibitor Cocktail (Roche). 100µL of 
the lysis buffer were used per 5x106 cells. After 10 minutes of centrifugation at 
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12,000g at 4°C, the supernatant was recovered and aliquots stored at -80ºC until 
further use.   
 
2.4.3 Quantification of proteins in whole cell and cytosolic extracts 
For quantification of proteins in the whole cell and cytosolic protein extracts, the Bio-
Rad Protein Assay (Bio-Rad) was used. The assay is based on the method of 
Bradford, which makes use of the shift in absorbance maximum from 465nm to 595nm 
of the cationic dye, Coomassie Blue G-250, upon its binding to protein (Sapan et al., 
1999). Protein extracts (2.5-10µL) were mixed with 1mL of a 1:5 dilution of the dye in 
dH2O. Absorbance was measured at 595nm and protein concentration calculated 
against a standard curve made from a serial dilution of BSA. 
 
2.4.4 Immunoblotting 
 
Approximately 25µg of cell extracts per sample were separated by sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) in 10% gels and transferred 
onto a 0.45µm pore size polyvinylidine fluoride (PVDF) membrane (PerkinElmer) 
using the Semiphor semi-dry transfer system (Hoefer). PVDF membranes were 
blocked in TBS/T (50mM Tris HCl pH 8.0, 138mM NaCl, 2.7mM KCl, 0.1% Tween20) 
with 5% nonfat dry milk (Tesco) at 37ºC with gentle agitation for 1-2 hours. Incubation 
with the primary antibody was carried out in TBS/T with 5% milk at 4ºC with gentle 
agitation overnight. Primary antibodies (all rabbit polyclonal) used were: anti-caspase-
12, anti-caspase-3, anti-Mst1, anti-AiF, anti-Cytochrome C, anti-Caspase-7, anti-
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mouse-Caspase-9, anti-BiP (all from Cell Signaling, 1:1000), anti-GRP94 (Abcam; 
1:2500), and anti-GAPDH (Santa Cruz Biotechnology; 1:250). After 4-5 washes with 
TBS/T for 5-10 minutes each, the secondary antibody anti-Rabbit IgG (whole 
molecule)–Peroxidase antibody (Santa Cruz) was incubated with the membranes at a 
dilution of 1:10,000 in TBS/T with 5% milk at room temperature for 1 hour. Proteins 
were visualised with a BioMax MR film (Kodak) using the ECL Western Blotting 
Detection Reagent (Amersham) or the Super Signal West Femto Maximum Sensitivity 
Substrate (Pierce). Semi-quantitative densitometric analysis of immunoblots was 
performed by scanning films and measuring band density relative to the background in 
the same lane, using Photoshop (Adobe) software. 
 
2.5 Caspase-12 activity assay 
 
The CaspGLOWTM Fluorescein Caspase-12 Staining Kit (Biovision) was used 
according to the manufacturer’s instructions. The kit makes use of the ATAD peptide, 
which is the site of proteolytic auto-cleavage of active caspase-12 (Roy et al., 2008) 
and is used as a specific caspase-12 inhibitor (Mao et al., 2006). In thee assay, the 
ATAD peptide is modified with a fluoromethylketone (fmk)-moiety that confers cell 
permeability (Callus and Vaux, 2007), and conjugated to FITC. FITC-ATADfmk 
irreversibly binds to activated caspase-12 in cells (Biovision CaspGLOWTM 
Fluorescein Caspase-12 Staining Kit User Manual). 1µL of FITC-ATADfmk was added 
to 5x105 cells in 300µL of culture medium. After incubation at 37ºC for 30min with 
5%CO2, cells were pelleted, washed twice with 0.5mL of Wash Buffer, resuspended in 
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0.5mL of Wash Buffer, and analysed immediately on a FACScan or FACSCalibur flow 
cytometer using Cell Quest software.  
 
2.6 Immunohistochemistry 
 
Immunohistochemical staining was carried out by Professor Christine Beham-Schmid, 
Institute of Pathology, Medical University, Graz, Austria. Tissue obtained from patients 
for haemato-pathological diagnosis as part of routine clinical investigations was fixed 
in 10% formalin and embedded in paraffin wax. Consecutive sections of 4µm were 
stained with haematoxylin/eosin and with Giemsa for morphological diagnosis. For 
immunohistochemical studies, the standard avidin-biotin-peroxidase technique 
(Cordell et al., 1984) was performed with prior microwave treatment, using an antibody 
against active caspase-3 (Cell Signaling, 1:400).  A total of 10 high-power fields were 
analysed per sample and apoptotic cells identified based on nuclear morphology. Use 
of the diagnostic material for research purposes was in accordance with local ethical 
guidelines. 
 
2.7 Statistical analysis 
 
The Chi-square test was used to compare proportions, and a p-value of <0.05 was 
considered to be significant. Calculations were done online using a contingency table 
matrix provided by Vassar College, Poughkeepsie, New York 
(http://faculty.vassar.edu/lowry/webtext.html, accessed 10-March-2009). 
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3      Excessive ER stress limits the life-span of short-
lived plasma cells 
 
The majority of plasma cells that are formed during an immune response are 
short-lived and undergo apoptosis in situ in secondary lymphoid organs within a 
few days of intense immunoglobulin secretion (Smith et al., 1996). The 
mechanisms that initiate and execute programmed cell death of short-lived 
plasma cells are largely unknown. The requirement of an activated UPR for 
plasma cell differentiation links secretory challenge to terminal B cell maturation. 
Recent work has demonstrated that the pro-apoptotic molecule Bax becomes 
activated at the ER in plasma cells, and that plasma cells that have completed 
differentiation and are destined to undergo apoptosis shortly have a decreased 
proteasomal capacity, which is likely to result in decreased degradation of 
misfolded proteins and increased ER stress (Cenci et al., 2006; Pelletier et al., 
2006). These observations raise the possibility that maximized immunoglobulin 
production may exceed the secretory capacity of plasma cells and cause 
overwhelming ER stress that cannot be rectified by the UPR, thus triggering 
apoptosis. In order to test this hypothesis, the levels of ER stress in plasma cells 
undergoing spontaneous programmed cell death was analysed by 
immunoblotting. In addition, it was tested whether the ER stress response 
continues beyond completion of differentiation until the onset of apoptosis and 
whether terminal differentiation makes plasma cells more susceptible to ER 
stress.  
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3.1 Spontaneous apoptosis of plasma cells is associated with 
increased ER stress 
To study the cellular events governing plasma cell apoptosis, two previously 
described model systems were used. In addition, ex vivo isolated primary cells 
were analysed in selected experiments. A method for in vitro differentiation and 
isolation of terminally differentiated mouse plasma cells was recently developed 
in the lab (Sabbattini et al., 2007). The systems allows for the purification of post-
mitotic IgM-secreting plasma cells that are CD138+B220-. When these 
differentiated plasma cells are maintained in culture after purification with the 
addition of IL-5, IL-6, and IL-10 (but without LPS), approximately 60% undergo 
spontaneous apoptosis after two days as measured by staining with Annexin V-
FITC and PI (Figure 3.1). The second system uses the murine lymphoma cell 
line, I.29µ+. Upon stimulation with LPS, I.29µ+ cells undergo plasmacytic 
differentiation within two to three days, as demonstrated by IgM secretion, 
plasma cell morphology, and up-regulation of the plasma cell marker CD138 (van 
Anken et al., 2003). Three days after LPS stimulation, the cells also begin to 
undergo spontaneous apoptosis, and after four days, around half of them are 
apoptotic (Figure 3.1). Both systems therefore closely resemble the situation in 
vivo, where short-lived plasma cells, which represent the majority of plasma cells 
formed in an immune response, rapidly undergo apoptosis in situ in secondary 
lymphoid organs (Smith et al., 1996). I first tested whether ER stress increases in 
plasma cells when they undergo programmed cell death. Although ER stress is 
difficult to quantify, it is generally accepted that the expression of major 
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chaperones correlates well with the level of ER stress. Since Glucose-regulated 
Protein 94 (GRP94) and Binding Protein (BiP) are considered to be major ER 
stress markers which are up-regulated by the ER stress response and play 
important roles as ER chaperones (Hendershot et al., 1996; Ron and Walter, 
2007), their expression was analysed by immunoblotting on extracts of in vitro 
differentiated plasma cells and I.29µ+ cells.  
 
 
Figure 3.1 Spontaneous apoptosis of plasma cells is associated with 
increased ER stress. In vitro differentiated plasma cells (PCs) were analysed 2h 
(d0) and 40h (d2) after purification. I.29µ+ cells were analysed before (d0) and 1 
day to 4 days after stimulation of differentiation with LPS. The proportion of 
apoptotic cells was determined by staining with Annexin V-FITC and PI. Mean 
and SEM of two independent experiments are shown (upper panel). The lower 
panel shows immunoblots on extracts from in vitro differentiated plasma cells and 
I.29µ+ cells, with antibodies against ER chaperones BiP and GRP94, and 
GAPDH as loading control. 
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Levels of GRP94 and particularly BiP sharply increased with the onset of 
apoptosis in in vitro differentiated plasma cells (Figure 3.1). Consistent with a 
previous proteomics study (van Anken et al., 2003), BiP was upregulated during 
plasmacytic differentiation of LPS-stimulated I.29µ+ cells, and BiP levels further 
increased considerably in parallel with the onset of apoptosis (Figure 3.1). 
Notably, levels of the chaperone GRP94 remained unchanged in the first two 
days after LPS-stimulation of I.29µ+ cells and only increased when apoptosis 
started to occur (Figure 3.1). These results demonstrate a substantial increase in 
ER stress in plasma cells that have completed differentiation and are beginning 
to undergo programmed cell death, indicating a correlation between high levels 
of ER stress and plasma cell apoptosis.  
 
3.2 The secretory apparatus continues to expand in 
differentiated plasma cells until apoptosis is initiated 
The finding that levels of BiP and GRP94 increase in plasma cells undergoing 
apoptosis indicates a rise in ER stress. In order to investigate further whether the 
ER stress response continues to be upregulated in differentiated plasma cells, it 
was next tested by flow cytometric analysis of side scatter values whether 
expansion of the secretory apparatus occurs as part of an ongoing ER stress 
response. Side scatter values, which correspond to the dispersion of light as it 
travels through a cell, correlate well with organelle density and with the amount of 
ER present in B cells (Shaffer et al., 2004). In order to exclude potential non-
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specific effects on light scattering in dying cells, side scatter values were 
analysed in the Annexin V-FITC and PI negative gate only. Light scattering 
increased during the first two days of plasmacytic differentiation of I.29µ+ cells, 
which is expected since the ER is known to expand during plasma cell 
differentiation (Wiest et al., 1990). However, a considerable further increase in 
light scattering was found until day four, when apoptosis takes place (Figure 3.2). 
Similarly, side scatter values increased between the time of purification of in vitro 
differentiated plasma cells, when they are fully differentiated, and the onset of 
apoptosis (Figure 3.2).  
 
 
Figure 3.2 The secretory apparatus continues to expand in differentiated 
plasma cells until apoptosis is initiated. Side scatter analysis of in vitro 
differentiated plasma cells 2h (d0) and 40h (d2) after purification. I.29µ+ cells 
were analysed before (d0) and two and four days after stimulation of 
differentiation with LPS. Cell counts on the Y-axis are normalised to d0. One 
representative result from three analyses is shown. 
 
These observations demonstrate that the secretory apparatus continues to 
expand in differentiated PCs until apoptosis is initiated, indicating that the ER 
stress response is activated not only during plasma cell differentiation, but also in 
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plasma cells that have completed differentiation and are destined to undergo 
apoptosis shortly.  
 
3.3 Plasmacytic differentiation results in increased susceptibility 
to ER stress-induced apoptosis 
The hypothesis that increasing ER stress plays a causative role in programmed 
PC death predicts that the capacity to tolerate additional insults to the ER should 
decrease with terminal differentiation despite the continued ER stress response. 
In order to test this hypothesis, I.29µ+ cells undergoing plasmacytic 
differentiation were treated with the pharmacological ER stressors tunicamycin 
and dithiotreitol (DTT). Tunicamycin specifically inhibits protein glycosylation, 
whereas DTT interferes with disulfide bond formation, and both drugs have been 
extensively used to study the ER stress response. The proportion of cells that 
survived these additional ER insults was determined by flow cytometric analysis 
of Annexin V-FITC binding and PI staining. Since I.29µ+ cells begin to undergo 
spontaneous apoptosis three days after LPS stimulation, the background level of 
apoptosis was subtracted so that only the effect of drug treatment on cells that 
were alive was considered. The proportion of cells surviving additional ER insults 
caused by tunicamycin or DTT decreased substantially in I.29µ+ cells that had 
undergone plasmacytic differentiation (Figure 3.3 A). In contrast, tolerance to 
etoposide and arsenic trioxide, which do not cause ER stress but generate DNA 
damage and reactive oxygen species, respectively, remained largely unchanged 
in differentiated cells (Figure 3.3 A). In order to test whether the increased 
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susceptibility to ER stress is also found in primary plasma cells, resting B cells 
and splenic plasma cells were isolated from mouse spleens and treated with 
tunicamycin. Tunicamycin induced apoptosis in approximately twice as many 
primary plasma cells as resting B cells (Figure 3.3 B). These observations show 
that plasmacytic differentiation results in increased susceptibility specifically to 
ER stress-induced cell death, but does not lead to a generally increased 
susceptibility to apoptotic stimuli. 
 
Figure 3.3 Plasmacytic differentiation results in increased susceptibility to 
ER stress-induced apoptosis. (A) I.29µ+ cells after 1-4 days of stimulation of 
plasmacytic differentiation with LPS were treated with Tunicamycin (1µg/ml, 14h), 
DTT (1mM, 4h), etoposide (1µg/ml, 16h), or arsenic trioxide (As2O3, 1µM, 24h). 
The proportion of live cells (Annexin V-FITC and PI-negative) relative to 
untreated LPS-stimulated controls is shown (mean and SEM of two independent 
experiments).  (B) Freshly isolated ex vivo isolated resting B cells and splenic 
plasma cells were treated with Tunicamycin (1µg/ml, 14h). The proportion of live 
cells was determined as described in (A). 
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3.4 Summary 
The considerable increase in levels of major ER chaperones in plasma cells that 
have completed differentiation and begin to undergo apoptosis indicates a close 
link between programmed plasma cell death and ER stress. In parallel with the 
rise in ER stress, the ability of plasma cells to tolerate ER stress, but not other 
types of cellular insults, decreases dramatically. This increased susceptibility 
specifically to ER stress-induced apoptosis occurs despite the ongoing ER stress 
response that is demonstrated by the continued expansion of the secretory 
apparatus. These findings therefore suggest that overwhelming ER stress that 
exceeds the capacity of the UPR plays a central role in the initiation of plasma 
cells apoptosis. 
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4      Apoptosis of plasma cells does not depend on 
activation of key apoptotic caspases 
 
Activation of the IRE1-XBP1 pathway is required for plasma cell formation 
(Iwakoshi et al., 2003b; Reimold et al., 2001; Zhang et al., 2005), indicating 
activation of the UPR and therefore the existence of some form of ER stress 
during terminal differentiation. Importantly, one major arm of the UPR generally 
involves inhibition of translation, which acts to reduce the secretory protein load 
in the ER and is mediated by (PKR)-like ER kinase (PERK), (Ron and Walter, 
2007). This protective pathway is not activated in plasma cells, which presumably 
facilitates their task of secreting huge amounts of Ig (Gass et al., 2008). This 
raises the question of how plasma cells reconcile the need to tolerate the ER 
stress that is predicted to result from unrestricted Ig secretion with the 
requirement to maintain a controlled immune response by undergoing timely 
apoptosis.  
    It is generally accepted that the defining outcomes of apoptosis, such as 
chromatin condensation, DNA fragmentation, plasma membrane asymmetry, and 
loss of mitochondrial transmembrane potential (∆ψM), are largely mediated by 
the concerted activation of a family of cysteine proteases, the caspases. 
Depending on the apoptotic trigger, different initiator caspases may be activated, 
but signals ultimately converge on common apoptotic effector caspases 
downstream of the mitochondria. The most prominent effector is caspase-3, 
which acts as the major executioner of apoptosis by cleaving a large number of 
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molecular targets throughout the cell (Timmer and Salvesen, 2007). When 
caspases are chemically inhibited or genetically deleted, cells can temporarily 
recover from MOMP but will eventually undergo delayed programmed cell death 
if the apoptotic insults persist (Deshmukh et al., 2000; Oppenheim et al., 2001). 
This raised the possibility that intrinsic inhibition of caspase activation might 
occur in differentiated plasma cells in order to modulate the timing of apoptosis 
under conditions of ER stress. I set out to test this hypothesis by analysing 
whether caspases are activated during plasma cell apoptosis. The strategy used 
was to investigate the effect of chemical inhibition of caspases with the widely 
used pan-caspase inhibitor zVADfmk on plasma cell apoptosis. In addition, 
immunoblotting was used to analyse whether activating cleavage of key 
apoptotic caspases occurs during programmed plasma cell death. 
 
4.1 Apoptotic loss of plasma membrane integrity occurs without 
activation of key apoptotic caspases in fully differentiated 
plasma cells 
To test whether apoptotic effector caspases play a role in plasma cell death, the 
effect of chemical caspase inhibition was investigated using the pan-caspase 
inhibitor zVADfmk (Chipuk and Green, 2005). The zVADfmk failed to inhibit 
apoptotic loss of plasma membrane integrity during spontaneous programmed cell 
death of differentiated plasmacytic I.29µ+ cells, in vitro differentiated plasma cells, 
and primary ex vivo isolated plasma cells (Figure 4.1 A).  
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Figure 4.1 Apoptotic loss of plasma membrane integrity during programmed 
plasma cell death is caspase-independent.  (A) Survival was determined by flow 
cytometry (lack of staining for FITC-Annexin V and PI) at the indicated time-points 
before (d0) or after LPS treatment (I.29µ+ cells) or purification (in vitro 
differentiated and ex vivo primary plasma cells). Cells were treated with vehicle 
(DMSO) or zVADfmk (100µM) between the earlier and later point of analysis. 
Fresh zVADfmk and vehicle were added after 24 hours if treatment was more than 
one day. (B) Survival was determined as in (A). zVADfmk was used at 100µM and 
added 30min before tunicamycin. Tunicamycin was used at 1µg/ml and analyses 
were performed after 14h of treatment. Owing to the differences in susceptibility to 
ER stress-induced apoptosis, tunicamycin was used at 5µg/ml in resting B cells, 
and treatment was extended to 24h in I.29µ+ cells to achieve apoptosis levels 
similar to plasma cells. 
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In addition, treatment with zVADfmk did not reduce tunicamycin-induced apoptosis 
in primary and in vitro differentiated plasma cells (Figure 4.1 B). In contrast, 
zVADfmk almost completely blocked tunicamycin-induced apoptosis of 
undifferentiated I.29µ+ cells and primary resting B cells (Figure 4.1 B). These 
observations indicate that programmed plasma cell death is unperturbed under 
caspase-inhibiting conditions and suggest that the central role of caspases in the 
execution of ER stress-induced programmed cell death is lost during terminal 
differentiation from B cells to plasma cells. 
 
4.2 Apoptotic loss of the mitochondrial transmembrane potential 
∆ψM during plasma cell death is caspase-independent 
In addition to loss of plasma membrane integrity, loss of ∆ψM is another terminal 
event during apoptosis. It is mediated by effector caspases, notably caspase-3, but 
can occur in the absence of caspase activity (Deshmukh et al., 2000; Lakhani et 
al., 2006; Ricci et al., 2004). In order to test whether loss of ∆ψM during plasma 
cell apoptosis is caspase-independent, the effect of zVADfmk on ∆ψM in primary 
plasma cells and plasmacytic I.29µ+ cells undergoing apoptosis was investigated 
using the MitoCaptureTM Apoptosis Detection Kit. The kit makes use of a dye that 
emits red fluorescence in live cells with a maintained ∆ψM, but green fluorescence 
in cells that have lost their ∆ψM (also see Materials and Methods and Figure 4.2). 
Consistent with the observations on apoptotic cell membrane alterations, loss of 
 125
∆ψM during programmed cell death of in vitro differentiated plasma cells and 
plasmacytic I.29µ+ cells was largely caspase-independent (Figure 4.2, lower two 
panels). In contrast, tunicamycin-induced loss of ∆ψM in undifferentiated I.29µ+ 
cells was to a substantial extent blocked under caspase-inhibiting conditions 
(Figure 4.2, upper panel). Together with the observations made on apoptotic cell 
membrane alteration, these findings indicate that the central role of caspases in 
the execution of programmed cell death is lost in plasma cells. 
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Figure 4.2 Loss of the mitochondrial transmembrane potential ∆ψM during 
plasma cell death is caspase-independent. Analysis of ∆ψM in in vitro 
differentiated plasma cells and I.29µ+ cells by staining with MitoCaptureTM and 
flow cytometry. In live cells with intact ∆ψM the dye enters the mitochondria and 
emits red fluorescence (FL-2). Apoptotic cells that have lost their ∆ψM do not 
emit red fluorescence. Green fluorescence (FL-1) indicates cytosolic dye due to 
apoptotic loss of ∆ψM (lower right quadrant) or saturation in live cells (upper right 
quadrant). Apoptotic cells that have lost their ∆ψM are therefore found in the 
lower right quadrant. Undifferentiated I.29µ+ cells (d0), I.29µ+ cells 2 and 4 days 
after stimulation of plasmacytic differentiation with LPS, and in vitro differentiated 
plasma cells 2h (d0) and 40h (d2) after purification were treated as indicated with 
vehicle (DMSO), tunicamycin (1µg/ml), or zVADfmk (100µM). Cells were treated 
for 24h (undifferentiated I.29µ+ cells) or 48h (differentiated I.29µ+ cells, from d2 
to d4; in vitro differentiated plasma cells, d0 to d2). Numbers are % of cells in 
each quadrant. One representative result of at least two experiments is shown. 
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4.3 Key apoptotic caspases downstream of the mitochondria are 
not activated during plasma cell apoptosis 
To further investigate whether apoptotic caspases are activated during 
programmed plasma cell death, immunoblotting with antibodies against individual 
key apoptotic caspases, namely caspase-9, caspase-7 and caspase-3, was 
carried out. No cleavage products of these caspases, which would indicate 
activation, were detected in extracts from apoptotic in vitro differentiated plasma 
cells (Figure 4.3 A). The lack of activity of caspase-3 was further confirmed by 
immunoblotting with an antibody against Mammalian Sterile Twenty-like Kinase 1 
(Mst1). In the classical apoptotic pathway, cleavage of Mst1 is involved in 
apoptotic chromatin compaction and depends on activation of caspase-3 
(Cheung et al., 2003; Ura et al., 2001). In differentiated plasmacytic I.29µ+ cells 
undergoing apoptosis, only a minimal increase in cleavage products of caspases 
and Mst1 was observed (Figure 4.3 A). These small amounts of cleavage 
products are likely to be due to cells dying before terminal plasma cell 
differentiation, since the amount of cleavage products decreased on day 4, when 
differentiation is more complete (van Anken et al., 2003) and substantially more 
cells are undergoing apoptosis (Figure 3.1). Cleavage of caspases and Mst1 was 
also minimal in primary plasma cells undergoing apoptosis and lower than in 
primary resting B cells, which have a low baseline level of cell death in culture 
(Figure 4.3 B). The virtual absence of caspase cleavage in plasma cells is in 
sharp contrast to the substantial cleavage of caspase-3 during spontaneous 
apoptosis of in vitro activated B cells, which undergo apoptosis largely before 
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terminal differentiation into post-mitotic plasma cells has taken place, and during 
tunicamycin-induced apoptosis of activated B cells (Figure 4.3 C).  
 
 
Figure 4.3 Key apoptotic caspases downstream of the mitochondria are not 
activated during plasma cell apoptosis. Immunoblotting with antibodies 
against caspases and Mst1.The ratio of the band intensity of cleaved/uncleaved 
caspase-3 is shown (A) Extracts are from in vitro differentiated plasma cells 2h 
(d0) and 40h (d2) after purification, and from I.29µ+ cells before (d0) and one to 
four days after stimulation of plasmacytic differentiation with LPS. (B) 
Immunoblotting against caspases and Mst1 on extracts from primary resting B 
(RB) cells and primary plasma cells (PC) 24h after ex vivo isolation. The 
proportion of apoptotic cells at the time of analysis is shown. (C) Immunoblotting 
on extracts from LPS-activated B cells treated with vehicle or tunicamycin 
(1µg/ml, 14h), four days after activation with LPS.  
 
 
These findings corroborate the observations that loss of cell membrane integrity 
and ∆ψM during plasma cell apoptosis are caspase-independent events and 
demonstrate that the key effector caspases downstream of the mitochondria are 
not activated during plasma cell death. 
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4.4 Mitochondrial outer membrane permeabilisation does occur 
during plasma cell apoptosis 
The results described so far have shown that key apoptotic caspases 
downstream of the mitochondria are not activated during or required for plasma 
cell apoptosis. Classical apoptosis involves MOMP, which leads to release of 
Cytochrome C into the cytosol with subsequent formation of the apoptosome and 
activation of caspase-9 and caspase-3 (Schafer and Kornbluth, 2006). To test 
whether MOMP occurs during plasma cell apoptosis, immunoblotting was carried 
out on cytosolic extracts from plasmacytic I.29µ+ cells that were beginning to 
undergo apoptosis on day three after LPS-stimulation. The results of this analysis 
showed that Cytochrome C was released into the cytosol (Figure 4.4). 
 
 
Figure 4.4 Mitochondrial outer membrane permeabilisation with release of 
Cytochrome C and AiF occurs during plasma cell apoptosis. Immunoblotting 
with antibodies against Cytochrome C, AiF, and GAPDH (loading control) on 
cytosolic extracts from undifferentiated (d0) I.29µ+ cells, and differentiated (d3) 
I.29µ+ cells beginning to undergo apoptosis (as shown in Figure 3.1). 
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In addition, Apoptosis-inducing Factor (AiF) was found to be released into the 
cytosol of plasmacytic I.29µ+ that were beginning to undergo apoptosis (Figure 
4.4). The release of AiF from mitochondria during programmed cell death has 
been suggested to mediate apoptosis in some forms of caspase-independent cell 
death, although its precise role is not understood (Chipuk and Green, 2005). 
Thus, MOMP does occur during plasma cell apoptosis but is not followed by 
activation of the downstream effector caspases.  
 
4.5 Summary 
The role of caspases in the execution of programmed plasma cell death was 
analysed by investigating the effect of chemical caspase inhibition on major 
parameters of cell death. The pan-caspase inhibitor, zVADfmk, was found to 
block tunicamycin-induced apoptosis of undifferentiated I.29µ+ cells and primary 
resting B cells, demonstrating that ER stress-induced apoptosis is mediated by 
caspases in B cells. However, tunicamycin-induced cell death of in vitro 
differentiated plasma cells and primary plasma cells was not inhibited by 
zVADfmk. Furthermore, spontaneous programmed plasma cells death was not 
blocked under caspase-inhibiting conditions. In addition, the major effector 
caspases that lie downstream of the mitochondria and swiftly execute cell death 
in most cells undergoing apoptosis were not activated during plasma cell 
apoptosis. Importantly, the lack of activation of caspase-3 was confirmed by 
analyzing cleavage of Mst1, a caspase-3 target. These observations provide 
strong evidence that the key effector caspases that lie downstream of the 
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mitochondria are not activated during plasma cell death, despite MOMP and the 
release of Cytochrome C. This finding raises the intriguing possibility that the 
activation of the key apoptotic effector caspases downstream of the mitochondria 
becomes inhibited in terminally differentiated plasma cells. 
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5      Terminal plasma cell differentiation leads to a block 
in activation of apoptotic effector caspases  
 
Effector caspases mediate and execute the dismantling of the vast majority of 
cells undergoing apoptosis. However, examples of cells undergoing caspase-
independent programmed cell death have been reported, such as apoptosis of 
neuronal cells that have caspases chemically inhibited or genetically deleted 
(Chipuk and Green, 2005; Deshmukh et al., 2000; Oppenheim et al., 2001). The 
observations made so far in this project show that the key apoptotic caspases 
are not activated during spontaneous plasma cell death, which could mean that 
these caspases do not receive the appropriate activation signals, or that they are 
inhibited from getting activated despite the presence of activation signals. The 
finding that Cytochrome C is released from the mitochondria of plasmacytic cells 
when they undergo programmed cells death suggests that the activating signals 
are present but do not result in activation of effector caspases. A potential 
explanation for this would be the presence of a factor or condition that inhibits the 
activation of effector caspases. To address this question, B cells (activated B 
cells and undifferentiated I.29µ+ cells) and plasma cells (in vitro differentiated 
plasma cells, plasmacytic I.29µ+ cells, and primary plasma cells) were treated 
with tunicamycin in order to compare the potential for activation of caspases.  
    Auto-activation and activation of caspase-3 by caspase-9 is normally 
prevented by a tri-aspartic acid repeat that is located near the cleavage site 
between the p12 and p17 subunits and blocks access to the Ile-Glu-Thr-Asp 
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(IETD) site of proteolytical activation (Roy et al., 2001). Modification of this 
“safety catch”, which occurs during acidification at the onset of apoptosis, results 
in increased auto-activation and susceptibility to activation by upstream 
proteases (Porter, 2006; Roy et al., 2001). The recently discovered small organic 
molecule, PAC-1, targets the tri-aspartic acid repeat, which leads to cleavage of 
caspase-3 into its active subunits, thereby inducing apoptosis (Porter, 2006; Putt 
et al., 2006). Therefore, the potential of PAC-1 to cleave caspase-3 and induce 
apoptosis was tested in B cells, plasma cells, and myeloma cell lines. 
   To test whether activation of key effector caspases is also absent in human 
plasma cells in vivo, immunohistochemistry of human lymphoid tissue sections 
with an antibody against active caspase-3 was performed. 
 
5.1 Plasmacytic differentiation results in resistance to activation 
of the major effector caspases downstream of the mitochondria 
To test whether key apoptotic caspases become resistant to activation during 
terminal differentiation into plasma cells, the capacity of undifferentiated and 
differentiated plasmacytic I.29µ+ cells to cleave caspases in response to 
apoptotic ER stress was tested. To this end, unstimulated and plasmacytic 
I.29µ+ cells were treated with tunicamycin. Tunicamycin induced prominent 
cleavage of caspase-3, its target Mst1, and caspase-9, in undifferentiated I.29µ+ 
cells. However, no such effect was observed in differentiated plasmacytic I.29µ+ 
cells (Figure 5.1). Treatment with tunicamycin also resulted in considerable 
additional cleavage of caspase-3 in activated B cells that were beginning to 
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undergo spontaneous apoptosis (Figure 4.3 C, right lane). In addition, 
tunicamycin-induced apoptosis of plasma cells, but not B cells, was not blocked 
under caspase-inhibiting conditions (Figure 4.1 B). These observations provide 
evidence that terminal plasma cell differentiation leads to key apoptotic caspases 
becoming resistant to activation.  
 
 
 
 
Figure 5.1 Plasmacytic differentiation leads to inhibition of activation of 
apoptotic effector caspases. Immunoblotting with antibodies against the 
indicated proteins on extracts from undifferentiated (d0) and plasmacytic (d3) 
I.29µ+ cells treated with tunicamycin (1µg/ml, 14h). For comparison with 
immunoblots of untreated cells refer to Figure 4.3. 
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5.2 Plasmacytic differentiation leads to stabilisation of 
caspase-3 in its inactive form 
It was next tested whether inhibition of caspase-3 in plasma cells is due to 
stabilization of the inactive pro-enzyme. This set of experiments made use of the 
small molecule PAC-1, which targets a “safety catch” tri-aspartic acid repeat that 
keeps caspase-3 inactive in healthy cells, to activate caspase-3 (Porter, 2006; 
Putt et al., 2006). When undifferentiated I.29µ+ cells were treated with PAC-1, 
substantial cleavage of caspase-3 and its target Mst-1 was observed, whereas 
almost no effect on cleavage of these proteins was seen in differentiated 
plasmacytic I.29µ+ cells (Figure 5.2 A). Consistent with the important role of 
caspase-3 in disrupting mitochondrial function in apoptotic cells (Lakhani et al., 
2006; Ricci et al., 2004), treatment with PAC-1 led to considerable loss of ∆ψM in 
undifferentiated but not in differentiated plasmacytic I.29µ+ cells (Figure 5.2 B). 
Cleavage of caspase-9, which occurs downstream of the mitochondria, also 
increased sharply in undifferentiated I.29µ+ but not in plasmacytic I.29µ+ cells 
(Figure 5.2 A). PAC-1 substantially increased apoptotic loss of plasma 
membrane integrity in primary ex vivo isolated resting B cells, but not in primary 
splenic plasma cells (Figure 5.2 C). In LPS-activated B cells, substantial 
cleavage of caspase-3 was induced by PAC-1. However, no cleavage of 
caspase-3 was detected in in vitro differentiated plasma cells treated with PAC-1 
(Figure 5.2 D). In order to test whether resistance of caspase-3 to activation can 
be observed in human plasmacytic cells, the effect of PAC-1 on human multiple 
myeloma cell lines was investigated. Although myeloma cells are transformed 
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plasma cells, they retain the majority of cellular and molecular features of plasma 
cells. The results of this analysis showed that PAC-1, which is effective in a large 
number of tumour cell lines (Putt et al., 2006), failed to induce cleavage of 
caspase-3 in two human myeloma cell lines, OPM-2 and RPMI8226, even after 
prolonged treatment (Figure 5.2 E). These data demonstrate that terminal 
plasma cell differentiation leads to stabilisation of the tri-aspartic acid repeat that 
acts as a “safety-catch” in preventing activation of caspase-3. The observations 
also indicate that stabilisation of caspase-3 in its inactive form can occur in 
human transformed plasma cells.  
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Figure 5.2 Plasmacytic differentiation leads to stabilisation of caspase-3 in its 
inactive form. (A) Immunoblotting of the indicated proteins on extracts from 
undifferentiated (d0) and plasmacytic (d3) I.29µ+ cells treated with PAC-1 (10µM) or 
vehicle for 9h. (B) Fold loss of ∆ψM relative to vehicle-treated controls after treatment 
as described in (A). Mean and SEM of two independent experiments is shown. (C) 
Increase in loss of plasma membrane integrity as measured by staining with FITC-
Annexin V and PI after treatment of ex vivo isolated primary resting B cells and 
plasma cells with PAC-1 (10µM, 14h). (D) Immunoblotting for caspase-3 following 
treatment with vehicle or PAC-1 (10µM, 14h) of splenic B cells (3 days after in vitro 
stimulation with LPS) and freshly purified in vitro differentiated plasma cells. (F) 
Immunoblotting for caspase-3 on extracts from the indicated human myeloma lines, 
treated with vehicle or PAC-1 (10µM, 14h).  
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5.3 Human plasma cells and myeloma cells undergo apoptosis 
in vivo without activation of caspase-3 
It was next tested whether human primary plasma cells and myeloma cells 
undergo apoptotic programmed cell death in vivo without activation of major 
effector caspases.  To this end, immunohistochemistry of human lymphoid tissue 
sections containing infiltrates of reactive plasma cells and myeloma cells was 
performed. Immunohistochemical staining with specific antibodies permits 
detection of the presence or absence of a certain protein on a single-cell level. In 
this investigation, it was possible to identify single apoptotic cells in lymphoid 
tissue based on apoptotic nuclear morphology, and to test for activation of 
caspase-3 in the apoptotic cells using an antibody that specifically reacts with the 
cleaved and active form of caspase-3. These investigations were carried out by 
Professor Christine Beham-Schmid at the Institute of Pathology of the Medical 
University of Graz, Austria. Professor Beham-Schmid chose eight cases of 
reactive plasmacytosis, which represent physiological accumulations of non-
transformed polyclonal plasma cells in lymphoid tissue in response to infection or 
inflammation and seven cases of extramedullary myeloma (transformed 
monoclonal plasma cells). It was also agreed to analyse eight cases of diffuse 
large B cell lymphoma (DLBCL), a tumour of transformed germinal center B cells, 
as controls that were predicted to show activation of caspase-3 in the majority of 
apoptotic cells. The samples, which had been obtained for evaluation of 
lymphadenopathy, had undergone morphological and immunohistochemical 
diagnosis previously, which included staining with a panel of antibodies such as 
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CD138. The particular samples were chosen because the tissue infiltrates were 
highly homogenous and contained a sufficient number of apoptotic cells for 
analysis. Apoptotic cells were identified based on typical nuclear morphology, i.e. 
chromatin condensation and/or fragmentation. An average of 310 (DLBCL), 15 
(myeloma), and 24 (plasmacytosis) apoptotic cells per sample were analysed. 
The higher number of apoptotic cells in DLBCL was due to larger tumour 
volumes and higher rates of apoptosis. In DLBCL, 70% of apoptotic cells (mean, 
range 61-78%) showed reactivity with the antibody against active caspase-3. In 
myeloma and reactive plasmacytosis, respectively, only 13 % (mean, range 0-
27%) and 21% (mean, range 6-33%) of the apoptotic cells showed detectable 
caspase-3 activity (Figure 5.3). The proportion of apoptotic cells with detectable 
caspase-3 activity was significantly greater in DLBCL than in myeloma 
(p<0.0001) and reactive plasmacytosis (p<0.0001). These observations extend 
the findings from the murine systems and the myeloma cell lines to primary 
human cells and indicate that activation of caspase-3 (and therefore, by 
extrapolation, most likely also caspase-9) does not occur in the majority of either 
physiological or transformed human plasma cells undergoing apoptosis in vivo. 
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Figure 5.3 Human plasma cells and myeloma cells undergo apoptosis in 
vivo without activation of caspase-3. Immunohistochemical analysis of human 
lymphoid tissue sections (Diffuse large B cell lymphoma, DLBCL, n=8; myeloma, 
n=7; reactive plasmacytosis, reactive PCs, n=8) was carried out using an 
antibody reacting specifically with active caspase-3 (brown cytoplasmic staining). 
Apoptotic cells were identified based on nuclear condensation and fragmentation, 
and the proportion of apoptotic cells with positive staining for active caspase-3 
relative to total apoptotic cells determined. Mean percentages and SEM of 
apoptotic cells with detectable caspase-3 activity relative to the number of 
apoptotic cells are shown. Images show sample tissue sections stained for active 
caspase-3 (brown reactivity). Arrows indicate examples of apoptotic cells. 
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5.4 Summary 
The observation that apoptotic ER stress fails to activate caspases in plasma 
cells indicates the existence of a mechanism that protects caspases from 
activation. The finding that the small molecule PAC-1 fails to activate caspase-3 
in plasma cells provides evidence for a stabilisation of the tri-aspartic acid repeat 
that keeps caspase-3 inactive. The resistance of caspase-3 to activation by the 
small molecule PAC-1, which activates caspase-3 in large number of tumour cell 
lines, also occurs in myeloma cell lines, which may have clinical implications for 
the treatment of myeloma. The results of the immunohistochemical analyses 
provide important in vivo evidence on a single cell level that most reactive and 
transformed plasma cells do not activate caspase-3 when they undergo 
spontaneous programmed cell death, and demonstrate that typical apoptotic 
morphology is present despite the lack of caspase-3 activity. This raises the 
question of which molecules substitute for classical effector caspases during 
plasma cell death. 
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6      Caspase-12 mediates nuclear apoptotic events 
during plasma cell apoptosis 
 
The observations made so far indicate that terminal plasma cell differentiation 
results in developmentally regulated inhibition of the classical apoptotic effector 
caspases downstream of the mitochondria. Since a number of studies have 
demonstrated a role for caspase-12 specifically in ER stress-mediated apoptosis 
in different systems (Hetz et al., 2003; Nakagawa et al., 2000; Rao et al., 2001; 
Yoneda et al., 2001), it was tested whether caspase-12 is activated during 
plasma cell apoptosis, and whether caspase-12 might have a role in 
programmed plasma cell death. A flow cytometry-based caspase-12 activation-
assay and immunoblotting were applied to analyse activation of caspase-12, and 
a specific chemical inhibitor of caspase-12 was used to investigate the potential 
role of caspase-12 in plasma cell death. 
 
6.1 Caspase-12 is activated during programmed plasma cell 
death 
Activation of caspase-12 leads to auto-cleavage at D319 within the sequence 
ATAD (Roy et al., 2008). The FITC-conjugated cell permeable ATAD peptide, 
FITC-ATADfmk, binds irreversibly to active caspase-12, which permits the 
identification of cells with an activated pool of caspase-12 by flow cytometry. 
Using this system, activation of caspase-12 was observed in primary plasma 
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cells, in vitro differentiated plasma cells, and plasmacytic I.29µ+ cells undergoing 
apotposis. Caspase-12 was also activated in tunicamycin-treated undifferentiated 
I.29µ+ cells (Figure 6.1 A). Immunoblotting showed that proteolytic processing of 
the full-length protein, which indicates activation of caspase-12, correlated with 
tunicamycin-induced cell death of undifferentiated I.29µ+ cells and spontaneous 
apoptosis of plasmacytic I.29µ+ cells (Figure 6.1 B).  
    These results indicate that activation of caspase-12 is not inhibited in plasma 
cells. To further test this, additional apoptosis of plasmacytic I.29µ+ cells was 
induced with tunicamycin, which caused substantial additional processing of 
caspase-12 (Figure 6.1 B). These observations provide evidence that in contrast 
to classical apoptotic effector caspases downstream of the mitochondria, 
activation and proteolytic processing of caspase-12 is not inhibited in plasma 
cells and does occur during programmed plasma cell death. 
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Figure 6.1 Caspase-12 is activated during programmed plasma cell death. 
(A) In vitro differentiated plasma cells 2h (d0) and 40h (d2) after purification, 
undifferentiated (d0) and plasmacytic (d3) I.29µ+ cells, and primary ex vivo 
isolated plasma cells were stained with FITC-ATADfmk and analysed by flow 
cytometry. Tunicamycin denotes treatment with 1µg/ml for 14h. Numbers are 
percentages of cells with positive staining. Representative graphs of two 
independent experiments are shown. (B) Immunoblotting with an antibody that 
detects uncleaved (non-activated) caspase-12 on extracts from undifferentiated 
(d0) I.29µ+ cells and I.29µ+ cells two to four days after stimulation with LPS. 
Cells were treated with tunicamycin (1µg/ml) for the indicated times where 
indicated. The ratio of full length caspase-12/GAPDH, normalised to untreated 
d0, is shown. 
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6.2 Inhibition of caspase-12 with zATADfmk is specific 
Next, the role of caspase-12 in plasma cell apoptosis was investigated. Gene-
specific knock-down by means such as RNAi is extremely difficult in plasma cells 
because of low transfection efficiencies and imminent apoptosis. Therefore, the 
caspase-12 inhibitory peptide, zATADfmk, was used (Mao et al., 2006). 
  First, the specificity of the inhibitor was tested and it was observed that 
zATADfmk blocked tunicamycin-induced proteolytic processing of caspase-12 
but not of caspase-3 in undifferentiated I.29µ+ cells (Figure 6.2 A). zATADfmk 
also reduced proteolytic processing of caspase-12 but had no effect on the 
minimal cleavage of caspase-3 that occurs during apoptosis of differentiated 
plasmacytic I.29µ+ cells (Fig. 6.2 A). Furthermore, apoptosis induced by the 
specific caspase-3 activator PAC-1 in undifferentiated I.29µ+ cells was blocked 
by the pan-caspase inhibitor zVADfmk, but not by the caspase-12 inhibitor 
zATADfmk (Figure 6.2 B). These results demonstrate the specificity of 
zATADfmk in blocking caspase-12 activity without inhibition of caspase-3 (and 
thus, caspases upstream of caspase-3) in the plasma cell systems used in this 
study. 
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Figure 6.2 Inhibition of caspase-12 with zATADfmk is specific. (A) 
Immunoblotting for the indicated proteins in undifferentiated (d0) and plasmacytic 
(d3) I.29µ+ cells. Cells were treated with vehicle, tunicamycin (1µg/ml), zVADfmk 
(100µM), and zATADfmk (10µM) for 14h as indicated. The ratios of 
uncleaved/full-length caspase-3 (upper panel of immunoblots) and caspase-
12/GAPDH (lower panel, normalised to vehicle-treated d0) are shown. (B) 
Undifferentiated I.29µ+ cells were treated with vehicle, PAC-1 (10µM), PAC-1 
and zATADfmk (10µM), or PAC-1 and zVADfmk (100 µM) for 14h. Cell survival 
was determined by negative staining for Annexin V-FITC and PI upon flow 
cytometry. Mean and SEM of two experiments are shown. 
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6.3 Caspase-12 mediates nuclear apoptosis during programmed 
plasma cell death 
Using zATADfmk, it was first tested whether inhibition of caspase-12 affects 
plasma cell apoptosis as defined by loss of plasma membrane integrity and 
∆ψM. The zATADfmk was added to freshly isolated in vitro differentiated plasma 
cells and to I.29µ+ cells after two days of LPS-induced plasmacytic differentiation 
in order to inhibit caspase-12 before the onset of spontaneous apoptosis. After 
24 hours, staining with Annexin V-FITC/PI and MitoCaptureTM reagent, 
respectively, and subsequent flow cytometry were performed. No difference 
between zATADfmk-treated and vehicle-treated control cells was observed 
(Figure 6.3 A). This result indicates that although caspase-12 is activated during 
programmed plasma cell death, it does not contribute to the occurrence of 
apoptotic cell membrane changes or loss of the mitochondrial transmembrane 
potential ∆ψM.  
    A recent report has suggested a role for caspase-12 in nuclear apoptotic 
events during programmed cell death of rod photoreceptors in retinitis 
pigmentosa, which is related to ER stress (Sanges et al., 2006). Since nuclear 
apoptotic changes may be executed separately from other cellular death-related 
events, it was investigated whether caspase-12 is involved in apoptotic DNA 
fragmentation and chromatin condensation in programmed plasma cell death. 
Inhibition of caspase-12 with zATADfmk resulted in a substantial reduction of 
terminal uridine deoxynucleotidyl transferase nick end labeling (TUNEL)-positive 
DNA-fragmentation in both in vitro differentiated plasma cells and plasmacytic 
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I.29µ+ cells (Figure 6.3 A, B, C). In addition, both chromatin compaction and 
fragmentation of condensed chromatin were largely absent in zATADfmk-treated 
cells, but present in apoptotic plasma cells that were treated with vehicle (Figure 
6.3 A, B, C). These observations indicate that caspase-12 has a specific role in 
the mediation of nuclear events during programmed plasma cell death. 
    During classical apoptosis, the execution of cell death is rapidly mediated by 
effector caspases, notably caspase-3, which also plays a major role in nuclear 
apoptotic events. The results obtained so far in this study have demonstrated 
that plasma cells undergo apoptosis without activation of effector caspases, but 
still show typical chromatin compaction and DNA fragmentation, which can be 
blocked by inhibition of caspase-12. This observation suggests that caspase-12 
becomes involved in nuclear apoptosis if the major effector caspases are not 
activated. This would predict that inhibition of caspase-12 in non-plasmacytic B 
cells, in which classical effector caspases are not inhibited, would not affect 
nuclear apoptotic event. To test this hypothesis, undifferentiated I.29µ+ cells 
were treated with tunicamycin and zATADfmk. Inhibition of caspase-12 did not 
affect loss of plasma membrane integrity or loss of mitochondrial transmembrane 
potential, and failed to reduce TUNEL-positive DNA fragmentation and chromatin 
condensation (Figure 6.3 A and D). Thus, while caspase-12 is activated during 
ER stress-induced apoptosis in both B cells and plasma cells, it specifically 
mediates nuclear apoptotic events only in plasma cells undergoing programmed 
cell death.  
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Figure 6.3 (A). Inhibition of caspase-12 blocks nuclear apoptosis during 
programmed plasma cell death. Cells were treated with zATADfmk (10µM) for 
24h. Differentiated plasmacytic I.29µ+ cells were treated 2 days and analysed 3 
days after initiation of plasma cell differentiation with LPS. In vitro differentiated 
plasma cells (PCs) were treated immediately after purification and analysed on 
day+1. Undifferentiated I.29µ+ cells (d0) were treated with vehicle (DMSO) and 
tunicamycin (1µg/ml) or zATADfmk for 24h. Apoptosis-associated membrane 
changes (red bar, positive staining for Annexin V-FITC and PI), loss of ∆ψM 
(orange bar), TUNEL-positive DNA fragmentation (blue bar), and apoptotic 
chromatin condensation (green bar) were measured as described in Material and 
Methods. Results shown are relative to vehicle-treated controls and are means 
and SEM of two independent experiments. The total cell numbers analysed by 
microscopy for TUNEL positivity and chromatin condensation were 719 (PCs), 
894 (PCs with zATADfmk), 535 (plasmacytic I.29µ+), 726 (plasmacytic I.29µ+ 
with zATADfmk), 205 (Tunicamycin-treated I.29µ+), and 308 (Tunicamycin-
treated I.29µ+ with zATADfmk). 
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Fig 6.3 (B). Inhibition of caspase-12 blocks nuclear apoptosis during 
programmed plasma cell death. In vitro differentiated plasma cells were treated 
with vehicle (DMSO) or zATADfmk (10µM) immediately after purification for 24h 
and then stained with DAPI and TUNEL reagent. Sample microscopic images are 
shown. Note the reduced number of cells with compacted/fragmented chromatin 
(arrows) and positive TUNEL staining (arrowheads) in zATADfmk treated cells.  
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Figure 6.3 (C). Inhibition of caspase-12 blocks nuclear apoptosis during 
programmed plasma cell death. I.29µ+ cells were treated with vehicle (DMSO) 
or zATADfmk (10µM) for 24h and stained with DAPI and TUNEL reagent on day 
3 of LPS-induced plasmacytic differentiation. Sample microscopic images are 
shown. Note the reduced number of cells with compacted/fragmented chromatin 
or positive TUNEL staining (examples are indicated by arrows and arrowheads, 
respectively) in zATADfmk treated cells. 
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Figure 6.3 (D) Inhibition of caspase-12 blocks nuclear apoptosis during 
programmed plasma cell death. Undifferentiated I.29µ+ cells were treated with 
tunicamycin (1µg/ml) and vehicle (DMSO) or zATADfmk (10µM) for 24h and 
stained with DAPI and TUNEL reagent. Sample microscopic images are shown. 
Note the similar number of cells with compacted/fragmented chromatin and 
positive TUNEL staining (examples are indicated by arrows and arrowheads, 
respectively) in zATADfmk treated cells. 
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6.4 Classical effector caspases mediate nuclear events during 
ER stress-induced apoptosis in B cells but not in plasma cells 
To further investigate the contribution of classical effector caspases to nuclear 
apoptotic events during ER stress-induced programmed cell death, the effects of 
the pan-caspase inhibitor zVADfmk on chromatin condensation and DNA 
fragmentation was analysed. If caspase-12, but not classical executioner 
caspases, acts as the major mediator of nuclear apoptosis in plasma cells. This 
would predict that the pan-caspase inhibitor zVADfmk, which also inhibits 
caspase-12 (Fig. 6.2 A), will not have a greater effect on nuclear apoptosis in 
plasma cell than the caspase-12 inhibitor zATADfmk. On the other hand, 
zVADfmk is predicted to inhibit nuclear apoptosis in undifferentiated I.29µ+ cells 
undergoing ER stress-induced apoptosis, since the classical effector caspases 
can be activated in these cells. The zVADfmk did reduce nuclear apoptotic 
changes to a similar or smaller extent compared to zATADfmk in apoptotic in 
vitro differentiated plasma cells and plasmacytic I.29µ+ cells (Figure 6.4 A and 
B). However, zVADfmk almost completely blocked nuclear apoptotic changes in 
undifferentiated I.29µ+ cells undergoing tunicamycin-induced apoptosis (Figure 
6.4 A and B).  
    Since previous observations (Figure 6.2 A) have indicated that zVADfmk 
inhibits processing of caspase-12 at least as efficiently as zATADfmk, the 
reduced effect of zVADfmk on nuclear apoptosis is slightly unexpected. One 
possible explanation might be that small differences in the kinetics of caspase 
inhibition and processing over the time-course of the experiment account for the 
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attenuated effect of zVADfmk on nuclear apoptosis in plasma cells. Overall, 
these observations indicate that the role of caspase-12 in ER stress-induced 
apoptosis may be limited to situations in which more efficient effector caspases 
cannot be activated.  
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Figure 6.4 (A) Classical effector caspases mediate nuclear events during 
ER stress-induced apoptosis in B cells. Freshly isolated in vitro differentiated 
plasma cells, and plasmacytic (d3) I.29µ+ cells were treated with zVADfmk 
(100µM) for 24h. Undifferentiated I.29µ+ cells were treated with tunicamycin 
(1µg/ml) and zATADfmk for 24h. Representative microscopic images are shown. 
For untreated controls refer to Figures 6.3 B-D. 
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Figure 6.4 (B) Classical effector caspases mediate nuclear events during 
ER stress-induced apoptosis in B cells. Freshly isolated in vitro differentiated 
plasma cells, and plasmacytic (d3) I.29µ+ cells were treated with zVADfmk 
(100µM) for 24h. Undifferentiated I.29µ+ cells were treated with tunicamycin 
(1µg/ml) and zATADfmk for 24h. TUNEL-positive DNA fragmentation (blue bars), 
and chromatin condensation (green bars) were analysed as described in Material 
and Methods. Results shown are relative to vehicle-treated controls and are 
means and SEM of two independent experiments. 
 
 
6.5 Summary 
Using a flow cytometry-based caspase-12 activation assay and immunoblotting 
caspase-12 was found to be activated during spontaneous plasma cell apoptosis. 
Proteolytic processing of caspase-12 could be further increased by additional ER 
stress in plasmacytic cells. These results demonstrate that caspase-12 is not 
affected by the developmentally regulated inhibition of classical effector 
caspases that occurs during terminal plasma cell differentiation. The data also 
provide further support to the notion that ER stress is a major cause of plasma 
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cell death, since activation of caspase-12 has so far only been associated with 
ER stress-induced apoptosis, but not with other triggers of cell death. The results 
also indicate that caspase-12 has a specific role in mediating nuclear 
condensation and DNA fragmentation during plasma cell apoptosis. In non-
plasmacytic B cells undergoing ER stress-induced cell death, caspase-12 is not 
required for the execution of nuclear apoptotic events. Overall, these results 
suggest that caspase-12 exerts its role in the regulation of ER stress-induced 
nuclear apoptosis only when classical effector caspases are not activated. This 
view is compatible with the idea that inhibition of major effector caspases 
downstream of the mitochondria delays apoptosis in plasma cells until alternative 
mechanisms that mediate cell death come into play. 
 
 
 
 
 
 
 
 
 158
7      Lack of active apoptotic effector caspases delays 
but does not prevent ER stress-induced apoptosis 
The observations described above suggest that an imbalance between increasing ER 
stress and the ability to cope with it occurs in plasma cells as they begin to undergo 
programmed cell death. Intriguingly, my findings also indicate that the key apoptotic 
effector caspases that are instrumental in the execution of most forms of PCD 
undergo developmentally regulated inhibition during terminal plasma cell 
differentiation, at a time when apoptosis is imminent. This led me to hypothesize that 
the inhibition of effector caspases in plasma cells may act to delay apoptosis under 
conditions of secretory challenge, so that immunoglobulin production can continue 
until ER stress becomes overwhelming and induces programmed cell death via 
alternative pathways.  
 
7.1 Mouse embryonic fibroblasts double-deficient in caspase-3 
and caspase-7 undergo delayed apoptosis under conditions of 
prolonged ER stress 
Inhibition or loss of only one major effector caspase (i.e. caspase-3) allows for largely 
unperturbed programmed cell death through compensatory activation of other 
caspases (i.e.caspase-7), and single knock-out mice deficient in caspase-9 and 
double knock-out mice lacking both caspase-3 and caspase-7 are not viable (Kuida et 
al., 1998; Lakhani et al., 2006), precluding the analysis of apoptosis in plasma cells 
from such mice. To test in a genetic model the hypothesis that lack of active effector 
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caspases prolongs survival but does not prevent ER stress-induced programmed cell 
death, the kinetics of ER stress-induced apoptosis were studied in embryonic 
fibroblasts lacking both caspase-3 and caspase-7.  
    A previous study has shown that double knock-out embryonic fibroblasts that lack 
both alleles of caspase-3 and caspase-7 are largely resistant to apoptosis executed 
through the intrinsic pathway, whereas cells containing one allele of caspase-3 and 
caspase-7 (heterozygotes) undergo programmed cell death normally (Masud et al., 
2007). Consistent with the findings of Masud and colleagues, I observed that most 
heterozygote fibroblasts but only a small proportion of double-knockout embryonic 
fibroblasts underwent apoptosis as indicated by loss of ∆ψM after 24 hours of 
tunicamycin-induced ER stress (Figure 7.1 A and B). To simulate the situation in 
plasma cells, in which ER stress increases and persists over a few days, the 
fibroblasts were exposed to prolonged ER stress. After 48h of treatment with 
tunicamycin, apoptotic loss of ∆ψM occurred in almost all heterozygote and double-
knockout fibroblasts (Figure 7.1 A and B). These observations demonstrate that under 
conditions of persistent ER stress, lack of active key effector caspases substantially 
prolongs survival but does ultimately allow for programmed cell death. 
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Figure 7.1 Mouse embryonic fibroblasts double-deficient in caspase-3 and 
caspase-7 undergo delayed apoptosis under conditions of prolonged ER stress. 
Caspase-3 and caspase-7 double-knock-out (DKO) and heterozygote (Het) mouse 
embryonic fibroblasts were treated with tunicamycin (1µg/ml) for the indicated times 
and apoptotic loss of ∆ψM analysed by staining with MitoCaptureTM and flow 
cytometry. (A) Representative plots are shown and the number of live cells with 
maintained ∆ψM is indicated (mean and SEM of two independent experiments). (B) 
Graph displaying the number of live heterozygote and DKO fibroblasts after treatment 
with tunicamycin as described in (A). 
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7.2 Summary 
Using mouse embryonic fibroblasts double-deficient in caspase-3 and caspase-7, I 
found that lack of active effector caspases substantially delays ER stress-induced 
apoptotic loss of ∆ψM, a hallmark of programmed cell death. However, under 
conditions of prolonged ER stress, caspase-deficient cells do undergo delayed 
apoptosis. These results are important because they transfer the observations made 
in the plasma cell systems to another cell type and provide evidence for two central 
concepts of this study, namely that the lack of active effector caspases can serve to 
prolong cell survival under conditions of ER stress, but that cells ultimately do undergo 
ER stress-induced apoptosis in the absence of active effector caspases. 
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8      Discussion 
 
 
Plasma cells play a critical role in the immediate immune response and in long-term 
immunity by being the sole providers of specific antibodies. Plasma cells are also 
involved in the pathogenesis of autoimmune diseases by secreting auto-antibodies 
that contribute to the inflammatory reactions that damage tissue. Furthermore, 
transformation of plasma cells results in a group of diseases termed plasma cell 
dyscrasias, which include multiple myeloma, an incurable malignancy that responds 
poorly to anti-neoplastic treatment. Very limited data on the regulation of the life-span 
of plasma cells exist to date, and it is anticipated that a detailed understanding of the 
mechanisms that govern programmed plasma cell death may provide the basis for the 
design of specific therapeutic approaches in immunological and malignant diseases 
that involve plasma cells. The data described in this study provide new evidence that 
ER stress has a key role in mediating physiological programmed death of short-lived 
plasma cells. They also demonstrate that developmentally regulated inhibition of key 
apoptotic caspases downstream of the mitochondria occurs during terminal plasma 
cell differentiation, and that this involves stabilization of caspase-3 in its inactive form. 
Despite the block in activation of major caspases, programmed death of both mouse 
and human plasma cells has all of the hallmarks of apoptosis, and I have identified a 
possible role for caspase-12 in the mediation of apoptotic chromatin condensation and 
DNA fragmentation in plasma cells. Thus, the results identify a novel form of 
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regulation of apoptosis that implicates excessive ER stress and inhibition of major 
effector caspases in controlling the timing of programmed plasma cell death. 
 
8.1 Plasma cell systems 
Plasma cells are present in the organism in very small numbers that not generally 
allow comprehensive experiments. I therefore used two established model systems, 
I.29µ+ cells and in vitro differentiated plasma cells. Both systems have been used 
before to analyse regulatory mechanisms of plasma cell differentiation and apoptosis 
(Cenci et al., 2006; Sabbattini et al., 2007; van Anken et al., 2003). While LPS-
differentiated I.29µ+ cells show most of the features that characterise plasma cells, 
such as up-regulation of CD138, IgM secretion, and expansion of the ER, they do not 
down-regulate B220 and maintain a minimal cell cycle program. Thus, they can 
probably be regarded as plasmablasts rather than fully matured plasma cells, which 
are post-mitotic and downregulate B220. The in vitro differentiation and purification of 
CD138+B220- plasma cells that has been developed in the lab (Sabbattini et al., 2007) 
has the advantage of providing sufficient numbers of terminally differentiated plasma 
cells but also of being derived from primary mouse B cells. In addition, primary ex vivo 
isolated plasma cells and resting B cells were used to test whether the major findings 
obtained in the plasma cell model systems described above apply to primary cells.  
   It may be argued that the mechanisms that govern apoptosis in plasma cells in 
culture could be substantially different from the conditions in vivo. In particular, the 
lack of potential survival factors provided by the microenvironment could have a 
considerable impact on plasma cell apoptosis. The provision of cytokines in the culture 
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medium, particularly IL-6, should minimize such a possible confounding effect. 
Importantly, the immunohistochemical analysis of human lymphoid tissue sections has 
provided strong evidence that the inhibition of major apoptotic caspases, a key finding 
of the study, does occur in plasma cells in vivo.  
    It is important to note that the plasma cells investigated in this study correspond to 
short-lived plasma cells. It is an intermediate-term goal to investigate how ER stress 
and caspase-inhibition contribute to the regulation of the life-span of long-lived bone 
marrow plasma cells. These plasma cells survive for prolonged periods of time, 
possibly up to the life-time of an organism (Manz et al., 1999; Manz et al., 1998). 
Although it is generally assumed that the bone marrow microenvironment provides 
plasma cells with survival signals in anatomical niches, it is unknown whether extrinsic 
factors are sufficient to explain why the life-span of long-lived plasma cells exceeds 
that of their short-lived “siblings” many hundred times (Moser et al., 2006). It is 
conceivable that a difference in the levels of ER stress exists between short-lived and 
long-lived plasma cells, and that long-lived plasma cells survive longer at least partly 
because they undergo less ER stress. This could be due to the production of fewer 
antibodies or a better developed ER stress response apparatus. These questions 
could be addressed by comparing the expression of ER chaperones in bone marrow 
and splenic plasma cells, and by testing whether differences in the susceptibility to ER 
stress-induced apoptosis exist between the two types of plasma cells.  
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8.2 Excessive ER stress limits the survival of short-lived plasma 
cells 
Recent observations that the pro-apoptotic molecule Bax becomes activated at 
the ER in plasma cells, and that plasmacytic differentiation results in decreased 
proteasomal capacity (Cenci et al., 2006; Pelletier et al., 2006), led to 
speculations that overwhelming ER stress that cannot be rectified by the UPR 
has a major role in triggering plasma cell apoptosis. In order to test this 
hypothesis, the levels of ER stress in plasma cells undergoing spontaneous 
programmed cell death were analysed. Although there is no clear definition of 
“high” ER stress, it is assumed that increased levels of ER chaperones correlate 
well with ER stress (Malhotra and Kaufman, 2007; Wu and Kaufman, 2006). The 
observations made in this study demonstrate that there is a sharp increase in ER 
stress in plasma cells that have completed differentiation and begin to undergo 
programmed cell death. In addition, it was found that the expansion of the 
secretory apparatus continues until apoptosis is initiated, which is likely to reflect 
the ongoing response to an increasing protein load. Importantly, using 
pharmacological interference with protein folding and processing in the ER, it 
was observed that a substantial increase in the susceptibility specifically to ER 
stress-induced apoptosis occurs during terminal plasma cell differentiation. This 
is the opposite to what one would expect in a professional secretory cell and 
indicates that the UPR, which is required to prepare B cells for their secretory 
task during plasma cell differentiation (Iwakoshi et al., 2003b), becomes 
inadequate to cope with the progressively increasing ER stress in differentiated 
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plasma cells. These observations lead me to conclude that despite an ongoing 
ER stress response, the production of immunoglobulins ultimately overstrains the 
secretory capacity of the ER in differentiated PCs, resulting in the accumulation 
of misfolded proteins, which generates overwhelming ER stress that triggers 
apoptosis. Considering that short-lived plasma cells secrete IgM as a penta-
/hexamer, whereas the IgG produced by long-lived plasma cells is secreted as a 
dimer, it is also conceivable that the additional “folding” that is required for IgM 
enhances ER stress and thereby contributes to the limited life span. It will also be 
important to determine if and how autophagy, which appears to occur in plasma 
cells (Simone Cenci, personal communication), contributes to programmed 
plasma cell death. 
    It has been shown recently that the BH3-only protein Bim is a key mediator of 
ER stress-induced apoptosis (Puthalakath et al., 2007). Interestingly, mice 
lacking Bim accumulate plasma cells and develop autoimmune kidney disease 
(Bouillet et al., 1999). My observations could provide an explanation for this 
finding by directly linking ER stress to programmed plasma cell death. Taken 
together, the data obtained in this study and the observations from the Bim-
knockout mice suggest that ER stress-mediated apoptosis in short-lived plasma 
acts as a key modulator of the humoral immune response, which limits antibody 
production and prevents inappropriate immune responses. In order to investigate 
the role of ER stress in plasma cells in more depth, I am planning to study the 
role of the ER protein p58IPK in plasma cell development and apoptosis. The 
p58IPK has two major roles in protecting the stressed ER: it function as an ER co-
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chaperone for BiP, and it mediates co-translational degradation of misfolded 
proteins. Mice lacking p58IPK  are prone to diabetes due to increased ER stress-
induced apoptosis of insulin-secreting cells (Ladiges et al., 2005; Oyadomari et 
al., 2006; Rutkowski et al., 2007).  
 
8.3 Developmentally regulated inhibition of major apoptotic 
caspases during terminal plasma cell differentiation 
The findings that the combined effects of a substantial increase in ER stress and a 
considerable decrease in the tolerance of ER stress have a major role in plasma cell 
apoptosis raise an important question: how can plasma cells survive ER stress caused 
by intense immunoglobulin secretion for long enough to fulfill their immunological 
function? This question becomes even more pertinent when one considers that PERK, 
which normally acts to suppress protein translation as a major part of the UPR, is not 
activated during plasma cell differentiation (Gass et al., 2008). It has been shown that 
inhibition or deletion of apoptotic caspases can temporarily rescue cells from the 
effects of an apoptotic insult, but that the cells will eventually undergo delayed 
programmed cell death if the apoptotic insults persist (Chipuk and Green, 2005; 
Deshmukh et al., 2000; Oppenheim et al., 2001). I therefore considered the possibility 
that inhibition of the key apoptotic caspases might occur during terminal plasma cell 
differentiation as an alternative mechanism to the normal ER stress response. My 
observations show that not only are major caspases that lie downstream of the 
mitochondria in the classical apoptotic pathway not activated during programmed PC 
death, but they become resistant to activation by apoptotic ER stress. The findings 
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that primary plasma cells, in vitro differentiated plasma cells, plasmacytic I.29µ+ cells, 
and human myeloma cell lines are resistant to the effect of the small molecule PAC-1 
indicate that the tri-aspartic acid “safety-catch” that keeps caspase-3 inactive is 
stabilized in plasma cells. This could provide a mechanistic explanation for the 
inhibition of caspase-3 activation. Importantly, the findings from the murine systems 
that activation of the major apoptotic caspases is blocked specifically in plasma cells 
are substantiated by immunohistochemical analysis of human lymphoid tissue 
sections. It was observed that most primary reactive (inflammatory) and transformed 
plasma cells undergo spontaneous apoptosis in vivo without activation of caspase-3. 
These findings lead me to conclude that stabilization of caspase-3 in its inactive form 
occurs in both physiological and transformed plasma cells in vitro and in vivo. It has to 
be noted that many investigations have shown that a variety of anti-neoplastic agents 
such as the proteasome inhibitor bortezomib can activate caspases in myeloma cells 
(Hideshima et al., 2003). It is therefore likely that inhibition of caspases is not 
complete or does not occur in all myeloma cells, but varies depending on the subtype, 
differentiation grade, or the underlying genetic defect of the myeloma cells. However, 
even if the inhibition of caspases is only partial in myeloma cells, it may still contribute 
to myeloma cell survival or resistance to chemotherapy. The finding that patient-
derived leukaemic cells exhibit various degrees of functional blocks of caspase-
activation demonstrate that such a mechanism does exist in malignant cells 
(Schimmer et al., 2003). 
    As well as providing evidence for stabilization of caspase-3 in its inactive form, the 
results of this study also indicate that caspase-9 is subject to inhibition during terminal 
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plasma cell differentiation. During the classical apoptotic cascade, MOMP and release 
of cytochrome c into the cytosol lead to formation of the apoptosome and activation of 
caspase-9, which results in auto-cleavage of caspase-9 and activation of caspase-3 
(Schafer and Kornbluth, 2006). The results of this study indicate that MOMP with 
release of cytochrome c does occur in plasma cells undergoing programmed cell 
death, which raises the question of why caspase-9 is not activated. It has been shown 
that nitrosylation of cytochrome c on its heme group is important for activation of 
caspases and induction of apoptosis, and that this process is sensitive to the redox 
state of the cell (Schonhoff et al., 2003). Immunoglobulin heavy and light chains enter 
the ER in a reduced state and undergo oxidative folding by ER resident enzymes, 
which causes redox stress in plasma cells (Masciarelli and Sitia, 2008). Although it is 
not known how the redox state in different plasma cell organelles changes during 
terminal differentiation, it is conceivable that alterations in the redox balance reduce 
nitrosylation of cytochrome c and therefore its ability to activate caspases in plasma 
cells. The resistance to activation of caspases could also be mediated by a 
developmentally regulated decrease in the levels of Apaf-1, an integral part of the 
apoptosome (Schafer and Kornbluth, 2006). It has been shown that terminal 
differentiation of PC12 neuronal cells makes them refractory to cytochrome c-induced 
apoptosis, and that this is caused by a substantial decrease in the expression of Apaf-
1 (Vyas et al., 2004). An alternative explanation could be provided by in vitro and in 
vivo studies showing that members of the Inhibitor of Apoptosis (IAP) family of 
proteins can bind and inhibit apoptotic caspases (Dubrez-Daloz et al., 2008). A recent 
study has shown that survivin, a member of the IAP family, is up-regulated in myeloma 
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cells and contributes to myeloma growth and drug resistance (Romagnoli et al., 2007). 
The potential role of IAP family members in plasma cells could be addressed by using  
specific chemical inhibitors of IAP proteins, which have recently been developed 
(Schimmer et al., 2004). 
 
8.4 Caspase-12 mediates nuclear apoptotic events during 
programmed plasma cell death 
The observations made in this study demonstrate that in contrast to key effector 
caspases downstream of the mitochondria, caspase-12 does become activated and 
undergoes proteolytic processing during programmed plasma cell death. Although it is 
controversial whether caspase-12 is generally required for ER stress-induced 
programmed cell death (Saleh et al., 2006), a number of  studies have indicated a role 
for caspase-12 specifically in ER stress-induced apoptosis in a variety of systems 
(Hetz et al., 2003; Nakagawa et al., 2000; Rao et al., 2001; Yoneda et al., 2001). The 
finding that chemical inhibition of caspase-12 blocks apoptotic DNA fragmentation and 
chromatin condensation both in in vitro differentiated plasma cells and plasmacytic 
I.29µ+ cells therefore provides further evidence for a functional role of ER stress in 
programmed plasma cell death. Caspase-12 has recently been shown to dampen 
immune responses by inhibiting caspase-1 or Nod (LeBlanc et al., 2008; Saleh et al., 
2006), and it has been suggested that activation and auto-processing of caspase-12 
could serve to terminate this inhibition (Roy et al., 2008). Since the proteolytic capacity 
of caspase-12 appears to be confined to auto-cleavage (Roy et al., 2008), it is 
conceivable that caspase-12 itself does not directly participate in nuclear apoptosis in 
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plasma cells but rather interacts with an as yet unidentified “partner” that is more 
directly involved in DNA fragmentation and chromatin condensation. This is 
compatible with a recent report on a cross-talk between caspase-12 and AiF in the 
execution of apoptosis in a model of retinitis pigmentosa, a form of retinal 
degeneration in which programmed cell death of rod photoreceptors is linked to ER 
stress (Sanges et al., 2006). Since I observed that AiF is released into the cytosol in 
plasma cells undergoing programmed cell death, it would be interesting to determine if 
and how AiF and caspase-12 collaborate in the execution of plasma cell apoptosis. 
This could be addressed by testing how inhibition of caspase-12 affects the cellular 
localization of AiF.  
    Although the experiments performed in this study provide evidence that zATADfmk 
is a specific inhibitor of caspase-12 in the cellular systems that were used, one could 
argue that this does not entirely exclude unspecific effects on classical effector 
caspases. It would thus be interesting to study plasma cells deficient in caspase-12. In 
contrast to an earlier report that embryonic fibroblasts from caspase-12 knock-out 
mice are partly resistant to ER stress-induced apoptosis (Nakagawa et al., 2000), 
embryonic fibroblasts from another caspase-12 knock-out mouse were found to 
undergo ER stress-induced apoptosis at the same level as those from wild-type mice 
(Saleh et al., 2006). In both studies, plasma cells were not investigated, but Saleh and 
co-workers indicated that histological analyses of tissues from knock-down mice were 
not different from wild-type mice. The results of this study indicate that nuclear 
apoptotic events, but not plasma cell death itself as defined by loss of plasma 
membrane integrity and mitochondrial transmembrane potential, is regulated by 
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caspase-12. Since apoptotic cells with undigested nuclei are still engulfed by 
macrophages, and undegraded DNA only accumulates when DNase II in macrophagal 
lysosomes is dysfunctional (Danial and Korsmeyer, 2004; Nagata et al., 2003), one 
would not necessarily expect a change in the number of plasma cells or in the rate of 
plasma cell death in mice lacking caspase-12. On the other hand, observations made 
in mice with dysfunctional ICAD raise the possibility that in situations of substantial 
plasma cell apoptosis, such as at the end of an immune response, undigested plasma 
cell nuclei could exceed the digestive potential of macrophages and cause aberrant 
immune phenomena (McIlroy et al., 2000). Unfortunately, a collaboration request to 
Saleh and co-workers to investigate these questions was declined. The question could 
also be addressed by using siRNA-mediated gene-specific knock-down of caspase-12 
in I.29µ+ cells and LPS-stimulated primary B cells.  
 
8.5 Lack of active apoptotic effector caspases delays but does 
not prevent ER stress-induced apoptosis 
The hypothesis that key apoptotic effector caspases are not required for plasma cell 
apoptosis would predict that mice lacking these caspases have the same number of 
plasma cells and the same rate of plasma cell death as wild-type mice. However, the 
analysis of plasma cells from caspase-deficient mice is impossible for two reasons:  
inhibition or loss of only one major effector caspase (i.e. caspase-3) allows for largely 
unperturbed PCD through compensatory activation of other caspases (i.e.caspase-7), 
and single knock-out mice deficient in caspase-9 and double knock-out mice lacking 
both caspase-3 and caspase-7 are not viable (Kuida et al., 1998; Lakhani et al., 2006). 
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To test in a genetic model the hypothesis that lack of active effector caspases 
prolongs survival but does not prevent ER stress-induced PCD, the kinetics of ER 
stress-induced apoptosis were analysed in embryonic fibroblasts derived from mice 
lacking both caspase-3 and caspase-7, which have been shown to be largely resistant 
to apoptosis that is executed through the intrinsic pathway (Masud et al., 2007). 
Consistent with the findings of Masud and colleagues, most double-deficient 
fibroblasts survived apoptotic ER stress for some time. However, under conditions of 
prolonged ER stress, the caspase-deficient fibroblasts did ultimately undergo PCD. 
These observations provide proof in a genetic model that lack of active key apoptotic 
effector caspases can serve to prolong cellular survival under conditions of persistent 
ER stress. The results also show that ER stress-induced apoptosis does occur, albeit 
at a later time-point, when effector caspases cannot be activated. 
 
8.6 A proposed model for the regulation of plasma cell death by 
ER stress and inhibition of apoptotic caspases 
Based on the results of this study, I propose a model in which ER stress and inhibition 
of key apoptotic caspases regulate the timing of PCD in short-lived plasma cells 
(Figure 8.6). According to this model, intensified and prolonged secretion of 
immunoglobulins progressively aggravates ER stress in differentiated plasma cells 
until the continued ER stress responses fail to cope with the secretory load. This leads 
to accumulation of unfolded polypeptides and excessive levels of ER stress that 
initiate programmed cell death. I also propose that inhibition of key apoptotic 
caspases, which involves stabilization of caspase-3 in its inactive form, has evolved in 
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plasma cells as a strategy to delay programmed cell death under conditions of 
prolonged secretory challenge. When plasma cell apoptosis is eventually initiated by 
overwhelming ER stress, alternative signaling mechanisms including caspase-12, 
which mediates nuclear apoptotic events, execute death. This model implies that 
immunoglobulin secretion, which is the primary function of plasma cells, also 
constitutes the predominant cause of death in short-lived plasma cells, thereby 
providing an intrinsic “fuse” that limits the extent of the immediate immune response 
for a specific antibody. Thus, the operation of the two opposing forces of excessive ER 
stress and inhibition of apoptotic effector caspases in plasma cells provides a finely-
tuned system for calibrating the short-term humoral immune response. 
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Figure 8.6 Schematic model of programmed plasma cell death. In B cells, 
apoptotic insults cause MOMP and release of Cytochrome C. This leads to activation 
of caspase-9 and caspase-3, which results the rapid execution of apoptosis. In plasma 
cells, immunoglobulin secretion causes accumulation of misfolded proteins, leading to 
excessive levels of ER stress that cause MOMP and release of Cytochrome C. 
Inhibition of key effector caspases downstream of the mitochondria halts the execution 
of apoptosis to prolong survival and allow for optimal immunoglobulin secretion until 
persistent ER stress leads to delayed apoptosis via alternative mechanisms that may 
involve AiF and caspase-12. 
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Figure S1. B cell activation and interaction with T cells. Following antigen 
binding (a), the B-cell receptor (BCR) triggers a signal-transduction cascade (b), 
which leads to the transcriptional activation of genes associated with B-cell 
activation. The BCR is internalized (c) and either degraded (d) or trafficked to an 
intracellular compartment termed the MIIC (e), where newly synthesized major 
histocompatibility complex class II (MHC) molecules and peptides derived from 
the antigen bound to the BCR are formed into complexes. The peptide–MHC 
complexes are subsequently transported to the cell surface, where they are 
recognized by the T-cell receptor (TCR) of T-helper cells (f), leading to T-cell 
activation (g). The activated T cell provides 'help' to the B cell, leading to full B-
cell activation (h) through both secreted cytokines and cell–cell interactions. 
Reproduced, with permission, from Pierce, Nature Reviews Immunology (2002) 
© 2002 by Nature Publishing Group. 
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Figure S2. The apoptotic pathways to caspase activation. The extrinsic 
pathway is activated by triggering of cell surface death receptors of the tumour 
necrosis factor (TNF) receptor superfamily, including CD95 and TNF-related 
apoptosis-inducing ligand (TRAIL). This results in  activation of the initiator 
caspase 8 after its recruitment to a trimerized receptor-ligand complex (DISC) 
through the adaptor molecule Fas-associated death domain protein (FADD). In 
the intrinsic pathway, apoptosis results in perturbation of mitochondria and the 
ensuing release of proteins, such as cytochrome c, from the inter-mitochondrial 
membrane space, which is regulated in part by BCL2 family members. Cytosolic 
cytochrome c binds to apoptotic protease-activating factor 1 (Apaf1), which 
results in formation of the Apaf1–caspase 9 apoptosome complex and activation 
of the initiator caspase 9. This results in activation of the effector caspases 3, 6 
and 7, which are responsible for the cleavage of important cellular substrates 
resulting in the classical biochemical and morphological changes associated with 
the apoptotic phenotype. Reproduced, with permission, from MacFarlane and 
Williams, EMBO Reports (2004) © 2004 by Nature Publishing Group. 
 
